{"PMC7386780": [["IntroductionEarly reports of mysterious pneumonia caused by pathogen of unknown origin were reported in Wuhan city of China during late December 2019.", [["pneumonia", "DISEASE", 40, 49], ["mysterious pneumonia", "PROBLEM", 29, 49], ["mysterious", "OBSERVATION_MODIFIER", 29, 39], ["pneumonia", "OBSERVATION", 40, 49]]], ["The causative agent was later identified as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and disease caused was named as COVID-19 [1].", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 51, 89], ["COVID-19", "CHEMICAL", 137, 145], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 44, 103], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 44, 89], ["SARS-CoV", "TEST", 93, 101], ["disease", "PROBLEM", 109, 116], ["COVID", "TEST", 137, 142], ["Severe", "OBSERVATION_MODIFIER", 44, 50], ["Acute", "OBSERVATION_MODIFIER", 51, 56], ["Respiratory Syndrome", "OBSERVATION", 57, 77]]], ["The disease outbreak which started in china, has now spread to 203 countries of the world and as on July 13, 2020, a total of 12,768,307 cases and 566,654 deaths have been reported globally (https://covid19.who.int/).", [["deaths", "DISEASE", 155, 161], ["The disease outbreak", "PROBLEM", 0, 20], ["disease", "OBSERVATION", 4, 11]]], ["Before COVID-19, human coronaviruses (CoVs) have caused two more epidemics in last two decades, SARS in 2002/2003 and Middle east respiratory syndrome (MERS) in 2012.", [["SARS", "DISEASE", 96, 100], ["Middle east respiratory syndrome", "DISEASE", 118, 150], ["human", "ORGANISM", 17, 22], ["coronaviruses", "ORGANISM", 23, 36], ["CoVs", "CELL", 38, 42], ["human", "SPECIES", 17, 22], ["human coronaviruses", "SPECIES", 17, 36], ["COVID", "TEST", 7, 12], ["human coronaviruses (CoVs", "PROBLEM", 17, 42], ["SARS", "PROBLEM", 96, 100], ["Middle east respiratory syndrome", "PROBLEM", 118, 150], ["Middle", "ANATOMY_MODIFIER", 118, 124], ["respiratory syndrome", "OBSERVATION", 130, 150]]], ["The infectivity of SARS CoV-2 seems to be higher than that of SARS-CoV and MERS-CoV, the causative agents of SARS and MERS respectively as asymptomatic SARS-CoV-2 infected individuals can transmit the virus to healthy population.", [["SARS", "DISEASE", 19, 23], ["SARS", "DISEASE", 62, 66], ["SARS", "DISEASE", 109, 113], ["SARS-CoV-2 infected", "DISEASE", 152, 171], ["SARS CoV-2", "ORGANISM", 19, 29], ["SARS-CoV", "ORGANISM", 62, 70], ["MERS-CoV", "ORGANISM", 75, 83], ["SARS-CoV-2", "ORGANISM", 152, 162], ["individuals", "ORGANISM", 172, 183], ["CoV-", "SPECIES", 157, 161], ["SARS CoV", "SPECIES", 19, 27], ["SARS-CoV", "SPECIES", 62, 70], ["MERS-CoV", "SPECIES", 75, 83], ["SARS CoV", "TEST", 19, 27], ["SARS", "PROBLEM", 62, 66], ["CoV", "PROBLEM", 80, 83], ["SARS", "PROBLEM", 109, 113], ["asymptomatic SARS", "PROBLEM", 139, 156], ["infected individuals", "PROBLEM", 163, 183], ["infectivity", "OBSERVATION_MODIFIER", 4, 15], ["higher", "OBSERVATION_MODIFIER", 42, 48]]], ["On the other hand case fatality rate (CFR) of COVID-19 is higher than that of seasonal influenza but lower than SARS and MERS [2].", [["influenza", "DISEASE", 87, 96], ["SARS", "DISEASE", 112, 116], ["fatality rate", "TEST", 23, 36], ["CFR", "TEST", 38, 41], ["COVID", "TEST", 46, 51], ["seasonal influenza", "PROBLEM", 78, 96], ["influenza", "OBSERVATION", 87, 96]]], ["COVID-19 patients present common symptoms such as fever, dry cough, fatigue, headache, diarrhea and pneumonia whereas acute respiratory distress syndrome (ARDS) is observed in severe cases [3].IntroductionSARS-CoV-2 probably originated from bats and amplified in an intermediate host before reaching to the humans [4].", [["respiratory", "ANATOMY", 124, 135], ["fever", "DISEASE", 50, 55], ["dry cough", "DISEASE", 57, 66], ["fatigue", "DISEASE", 68, 75], ["headache", "DISEASE", 77, 85], ["diarrhea", "DISEASE", 87, 95], ["pneumonia", "DISEASE", 100, 109], ["acute respiratory distress syndrome", "DISEASE", 118, 153], ["ARDS", "DISEASE", 155, 159], ["patients", "ORGANISM", 9, 17], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 193, 215], ["humans", "ORGANISM", 307, 313], ["patients", "SPECIES", 9, 17], ["humans", "SPECIES", 307, 313], ["humans", "SPECIES", 307, 313], ["common symptoms", "PROBLEM", 26, 41], ["fever", "PROBLEM", 50, 55], ["dry cough", "PROBLEM", 57, 66], ["fatigue", "PROBLEM", 68, 75], ["headache", "PROBLEM", 77, 85], ["diarrhea", "PROBLEM", 87, 95], ["pneumonia", "PROBLEM", 100, 109], ["acute respiratory distress syndrome", "PROBLEM", 118, 153], ["ARDS", "PROBLEM", 155, 159], ["IntroductionSARS", "TEST", 193, 209], ["diarrhea", "OBSERVATION", 87, 95], ["pneumonia", "OBSERVATION", 100, 109], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["respiratory distress", "OBSERVATION", 124, 144]]], ["Like other human CoVs, SARS-CoV-2 is an enveloped beta coronavirus with positive sense, single stranded RNA as its genome [5], [6].", [["human", "ORGANISM", 11, 16], ["CoVs", "GENE_OR_GENE_PRODUCT", 17, 21], ["SARS-CoV-2", "ORGANISM", 23, 33], ["beta coronavirus", "ORGANISM", 50, 66], ["positive sense, single stranded RNA", "RNA", 72, 107], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["SARS-CoV-2", "SPECIES", 23, 33], ["beta coronavirus", "SPECIES", 50, 66], ["other human CoVs", "PROBLEM", 5, 21], ["an enveloped beta coronavirus", "PROBLEM", 37, 66], ["single stranded RNA", "PROBLEM", 88, 107]]], ["SARSCoV-2, has genome of size 29.9 kb [7] whereas SARS-CoV has 27.9 kb and MERS-CoV has 30.1 kb large genome [8].", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 50, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["SARSCoV-2", "DNA", 0, 9], ["SARS-CoV", "DNA", 50, 58], ["MERS-CoV", "DNA", 75, 83], ["SARS-CoV", "SPECIES", 50, 58], ["MERS-CoV", "SPECIES", 75, 83], ["SARSCoV", "TEST", 0, 7], ["SARS", "TEST", 50, 54], ["CoV", "TEST", 55, 58], ["kb", "TEST", 68, 70], ["MERS", "TEST", 75, 79], ["CoV", "TEST", 80, 83], ["kb large genome", "PROBLEM", 93, 108], ["size", "OBSERVATION_MODIFIER", 25, 29], ["genome", "OBSERVATION", 102, 108]]], ["SARS-CoV-2 genome contains 5\u2019 capping and 3\u2019 poly(A) tail allowing the expression of viral replicase encoded by nearly two third of genome.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2 genome", "DNA", 0, 17], ["poly(A) tail", "PROTEIN", 45, 57], ["viral replicase", "PROTEIN", 85, 100], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["5\u2019 capping", "TREATMENT", 27, 37], ["3\u2019 poly(A) tail", "TREATMENT", 42, 57], ["viral replicase", "PROBLEM", 85, 100], ["viral replicase", "OBSERVATION", 85, 100]]], ["Total four structural proteins such as spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are present in SARS-CoV-2 [9].", [["membrane", "ANATOMY", 50, 58], ["spike (S)", "GENE_OR_GENE_PRODUCT", 39, 48], ["membrane", "CELLULAR_COMPONENT", 50, 58], ["E", "GENE_OR_GENE_PRODUCT", 74, 75], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 82, 98], ["structural proteins", "PROTEIN", 11, 30], ["spike (S), membrane (M), envelope (E)", "PROTEIN", 39, 76], ["nucleocapsid (N) proteins", "PROTEIN", 82, 107], ["SARS-CoV", "SPECIES", 123, 131], ["Total four structural proteins", "TEST", 0, 30], ["spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins", "PROBLEM", 39, 107], ["CoV", "TEST", 128, 131]]], ["S protein, a class I fusion protein is expressed on viral the surface and mediates the viral attachment, fusion and entry into host cell by binding to angiotensin-converting enzyme 2 (ACE2) as its receptor [9], [10], [11].", [["surface", "ANATOMY", 62, 69], ["cell", "ANATOMY", 132, 136], ["angiotensin", "CHEMICAL", 151, 162], ["surface", "CELLULAR_COMPONENT", 62, 69], ["host cell", "CELL", 127, 136], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 151, 182], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["[10], [11]", "SIMPLE_CHEMICAL", 211, 221], ["S protein", "PROTEIN", 0, 9], ["class I fusion protein", "PROTEIN", 13, 35], ["host cell", "CELL_TYPE", 127, 136], ["angiotensin-converting enzyme 2", "PROTEIN", 151, 182], ["ACE2", "PROTEIN", 184, 188], ["S protein", "TEST", 0, 9], ["a class I fusion protein", "PROBLEM", 11, 35], ["the viral attachment", "PROBLEM", 83, 103], ["fusion", "TREATMENT", 105, 111], ["angiotensin", "TEST", 151, 162], ["enzyme", "TEST", 174, 180], ["viral attachment", "OBSERVATION", 87, 103], ["host cell", "OBSERVATION", 127, 136]]], ["S protein consists of two functional subunits, S1 for host receptor binding and S2 responsible for fusion of viral and host cell membrane [10] (Fig. 1).", [["cell membrane", "ANATOMY", 124, 137], ["S1", "GENE_OR_GENE_PRODUCT", 47, 49], ["S2", "GENE_OR_GENE_PRODUCT", 80, 82], ["cell membrane", "CELLULAR_COMPONENT", 124, 137], ["S protein", "PROTEIN", 0, 9], ["S1", "PROTEIN", 47, 49], ["S2", "PROTEIN", 80, 82], ["S protein", "TEST", 0, 9], ["host receptor binding", "TEST", 54, 75], ["fusion of viral and host cell membrane", "TREATMENT", 99, 137], ["host cell membrane", "OBSERVATION", 119, 137]]], ["Recently Alba et al predicted the B and T-cell epitopes of SARS-CoV-2 antigens using bioinformatics approach and revealed that S protein is the most immundominant antigen having maximum no of B and T-cell epitopes [12].", [["T-cell", "ANATOMY", 40, 46], ["T-cell", "ANATOMY", 198, 204], ["B", "CELL", 34, 35], ["T-cell", "CELL", 40, 46], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 59, 78], ["S protein", "GENE_OR_GENE_PRODUCT", 127, 136], ["B", "CELL", 192, 193], ["T-cell", "CELL", 198, 204], ["B and T-cell epitopes", "PROTEIN", 34, 55], ["SARS-CoV-2 antigens", "PROTEIN", 59, 78], ["S protein", "PROTEIN", 127, 136], ["immundominant antigen", "PROTEIN", 149, 170], ["B and T-cell epitopes", "PROTEIN", 192, 213], ["SARS", "PROBLEM", 59, 63], ["CoV", "TEST", 64, 67], ["bioinformatics approach", "TEST", 85, 108], ["S protein", "TEST", 127, 136]]], ["Immunogenicity of S protein makes it the most attractive vaccine target against SARS-CoV-2 infection and many groups are working to develop S protein based vaccine.IntroductionTill date, there is no approved treatment or vaccine available to control COVID-19 and researchers across the globe are racing against time to develop new therapeutic agents as well as vaccine against SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 80, 100], ["SARS-CoV-2 infection", "DISEASE", 377, 397], ["S protein", "GENE_OR_GENE_PRODUCT", 18, 27], ["SARS-CoV-2", "ORGANISM", 80, 90], ["globe", "ORGAN", 286, 291], ["SARS-CoV-2", "ORGANISM", 377, 387], ["S protein", "PROTEIN", 18, 27], ["S protein", "PROTEIN", 140, 149], ["CoV-2", "SPECIES", 85, 90], ["CoV-2", "SPECIES", 382, 387], ["SARS-CoV-2", "SPECIES", 80, 90], ["SARS-CoV-2", "SPECIES", 377, 387], ["Immunogenicity of S protein", "PROBLEM", 0, 27], ["SARS", "PROBLEM", 80, 84], ["CoV-2 infection", "PROBLEM", 85, 100], ["S protein based vaccine", "TREATMENT", 140, 163], ["treatment", "TREATMENT", 208, 217], ["vaccine", "TREATMENT", 221, 228], ["COVID", "TEST", 250, 255], ["new therapeutic agents", "TREATMENT", 327, 349], ["vaccine", "TREATMENT", 361, 368], ["SARS", "PROBLEM", 377, 381], ["CoV", "PROBLEM", 382, 385], ["2 infection", "PROBLEM", 386, 397], ["S protein", "OBSERVATION_MODIFIER", 18, 27], ["infection", "OBSERVATION", 91, 100], ["no", "UNCERTAINTY", 196, 198], ["globe", "ANATOMY", 286, 291], ["infection", "OBSERVATION", 388, 397]]], ["Several vaccine candidates including RNA, DNA, subunit vaccine targeting spike protein \u201cS\u201d, attenuated virus strains and inactivated viral particles; are in the developmental pipeline [5].Heterologous effects of BCG vaccination: implications in COVID-19 associated mortalityThe century old TB vaccine BCG, a live attenuated strain of Mycobacterium bovis is the most widely used vaccine across the world, which protects against disseminated TB in children including miliary TB and TB meningitis, however, in adults, the efficacy of BCG against pulmonary TB is limited [13].", [["pulmonary", "ANATOMY", 543, 552], ["TB", "DISEASE", 290, 292], ["Mycobacterium bovis", "DISEASE", 334, 353], ["TB", "DISEASE", 440, 442], ["miliary TB", "DISEASE", 465, 475], ["TB meningitis", "DISEASE", 480, 493], ["pulmonary TB", "DISEASE", 543, 555], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["Mycobacterium bovis", "ORGANISM", 334, 353], ["children", "ORGANISM", 446, 454], ["pulmonary", "ORGAN", 543, 552], ["spike protein", "PROTEIN", 73, 86], ["Mycobacterium bovis", "SPECIES", 334, 353], ["children", "SPECIES", 446, 454], ["Mycobacterium bovis", "SPECIES", 334, 353], ["Several vaccine candidates", "TREATMENT", 0, 26], ["RNA, DNA", "TREATMENT", 37, 45], ["subunit vaccine", "TREATMENT", 47, 62], ["spike protein", "TEST", 73, 86], ["attenuated virus strains", "PROBLEM", 92, 116], ["inactivated viral particles", "PROBLEM", 121, 148], ["BCG vaccination", "TREATMENT", 212, 227], ["COVID", "TEST", 245, 250], ["The century old TB vaccine BCG", "TREATMENT", 274, 304], ["Mycobacterium bovis", "PROBLEM", 334, 353], ["disseminated TB", "PROBLEM", 427, 442], ["miliary TB", "PROBLEM", 465, 475], ["TB meningitis", "PROBLEM", 480, 493], ["BCG", "TREATMENT", 531, 534], ["pulmonary TB", "PROBLEM", 543, 555], ["viral particles", "OBSERVATION", 133, 148], ["Mycobacterium bovis", "OBSERVATION", 334, 353], ["protects against", "UNCERTAINTY", 410, 426], ["disseminated", "OBSERVATION_MODIFIER", 427, 439], ["TB", "OBSERVATION", 440, 442], ["miliary", "OBSERVATION_MODIFIER", 465, 472], ["TB", "OBSERVATION", 473, 475], ["TB", "OBSERVATION_MODIFIER", 480, 482], ["meningitis", "OBSERVATION", 483, 493], ["pulmonary", "ANATOMY", 543, 552], ["TB", "OBSERVATION", 553, 555]]], ["Additionally, BCG offers off target protective effects against several non-mycobacterial infections [14] and many studies have reported BCG mediated reduction in infant mortality due to infection unrelated to tuberculosis [15].", [["non-mycobacterial infections", "DISEASE", 71, 99], ["infection", "DISEASE", 186, 195], ["tuberculosis", "DISEASE", 209, 221], ["BCG", "TREATMENT", 14, 17], ["target protective effects", "TREATMENT", 29, 54], ["several non-mycobacterial infections", "PROBLEM", 63, 99], ["many studies", "TEST", 109, 121], ["BCG mediated reduction", "TREATMENT", 136, 158], ["infection", "PROBLEM", 186, 195], ["tuberculosis", "PROBLEM", 209, 221], ["reduction", "OBSERVATION_MODIFIER", 149, 158], ["infection", "OBSERVATION", 186, 195], ["tuberculosis", "OBSERVATION", 209, 221]]], ["In 1927, Swedish physician Carl N\u00e4slund reported three fold lower mortality in BCG vaccinated infants compared to the unvaccinated babies during first year of their lives [16].", [["infants", "ORGANISM", 94, 101], ["babies", "ORGANISM", 131, 137], ["infants", "SPECIES", 94, 101]]], ["Besides, BCG vaccination was associated with lower child mortality due to malaria in Guinea-Bissau [17].", [["malaria", "DISEASE", 74, 81], ["BCG vaccination", "TREATMENT", 9, 24], ["lower child mortality", "PROBLEM", 45, 66], ["malaria", "PROBLEM", 74, 81], ["malaria", "OBSERVATION", 74, 81]]], ["The beneficial effects of BCG in infants have been confirmed in many randomized control trials (RCT) and may be attributed to the protection offered against respiratory infections and neonatal sepsis [18], [19].", [["respiratory", "ANATOMY", 157, 168], ["BCG", "CHEMICAL", 26, 29], ["respiratory infections", "DISEASE", 157, 179], ["sepsis", "DISEASE", 193, 199], ["BCG", "SIMPLE_CHEMICAL", 26, 29], ["infants", "ORGANISM", 33, 40], ["infants", "SPECIES", 33, 40], ["BCG", "TREATMENT", 26, 29], ["many randomized control trials", "TREATMENT", 64, 94], ["the protection", "TREATMENT", 126, 140], ["respiratory infections", "PROBLEM", 157, 179], ["neonatal sepsis", "PROBLEM", 184, 199], ["BCG", "OBSERVATION", 26, 29], ["sepsis", "OBSERVATION", 193, 199]]], ["Another case control study in Guinea- Bissau reported the reduction in the incidence of acute lower respiratory tract infection (ALRI) caused by respiratory syncytial virus (RSV) in BCG vaccinated infants as compared to infants without BCG vaccination, suggesting the heterologous effects of BCG [20].Heterologous effects of BCG vaccination: implications in COVID-19 associated mortalityMoreover, intravesical BCG has been used as non-specific immunotherapy for the treatment of bladder cancer and immunomodulatory effects exhibited by BCG treatment are attributed to the slowdown of tumor progression in the patients [21].", [["lower respiratory tract", "ANATOMY", 94, 117], ["bladder cancer", "ANATOMY", 479, 493], ["tumor", "ANATOMY", 584, 589], ["lower respiratory tract infection", "DISEASE", 94, 127], ["ALRI", "DISEASE", 129, 133], ["respiratory syncytial virus", "DISEASE", 145, 172], ["bladder cancer", "DISEASE", 479, 493], ["tumor", "DISEASE", 584, 589], ["lower", "ORGANISM_SUBDIVISION", 94, 99], ["respiratory tract", "ORGANISM_SUBDIVISION", 100, 117], ["respiratory syncytial virus", "ORGANISM", 145, 172], ["RSV", "ORGANISM", 174, 177], ["infants", "ORGANISM", 197, 204], ["infants", "ORGANISM", 220, 227], ["bladder cancer", "CANCER", 479, 493], ["tumor", "CANCER", 584, 589], ["patients", "ORGANISM", 609, 617], ["respiratory syncytial virus", "SPECIES", 145, 172], ["infants", "SPECIES", 197, 204], ["infants", "SPECIES", 220, 227], ["patients", "SPECIES", 609, 617], ["respiratory syncytial virus", "SPECIES", 145, 172], ["RSV", "SPECIES", 174, 177], ["Another case control study", "TEST", 0, 26], ["acute lower respiratory tract infection", "PROBLEM", 88, 127], ["respiratory syncytial virus", "PROBLEM", 145, 172], ["BCG vaccination", "TREATMENT", 236, 251], ["the heterologous effects of BCG", "TREATMENT", 264, 295], ["BCG vaccination", "TREATMENT", 325, 340], ["intravesical BCG", "TREATMENT", 397, 413], ["non-specific immunotherapy", "TREATMENT", 431, 457], ["the treatment", "TREATMENT", 462, 475], ["bladder cancer", "PROBLEM", 479, 493], ["immunomodulatory effects", "PROBLEM", 498, 522], ["BCG treatment", "TREATMENT", 536, 549], ["tumor progression", "PROBLEM", 584, 601], ["reduction", "OBSERVATION_MODIFIER", 58, 67], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["lower", "ANATOMY_MODIFIER", 94, 99], ["respiratory tract", "ANATOMY", 100, 117], ["infection", "OBSERVATION", 118, 127], ["respiratory", "ANATOMY", 145, 156], ["syncytial virus", "OBSERVATION", 157, 172], ["bladder", "ANATOMY", 479, 486], ["cancer", "OBSERVATION", 487, 493], ["slowdown", "OBSERVATION_MODIFIER", 572, 580], ["tumor", "OBSERVATION", 584, 589]]], ["In a recent randomized controlled trial (RCT) Arts et al reported that BCG vaccination offered protection against vaccine strain of yellow fever virus in adults through epigenetic reprograming in circulating monocytes.", [["monocytes", "ANATOMY", 208, 217], ["yellow fever", "DISEASE", 132, 144], ["yellow fever virus", "ORGANISM", 132, 150], ["monocytes", "CELL", 208, 217], ["circulating monocytes", "CELL_TYPE", 196, 217], ["yellow fever virus", "SPECIES", 132, 150], ["yellow fever virus", "SPECIES", 132, 150], ["a recent randomized controlled trial (RCT) Arts et al", "TREATMENT", 3, 56], ["BCG vaccination", "TREATMENT", 71, 86], ["protection", "TREATMENT", 95, 105], ["yellow fever virus", "PROBLEM", 132, 150], ["circulating monocytes", "OBSERVATION", 196, 217]]], ["This study further asserted that BCG vaccination led to the induction of trained immunity as indicated by upregulation of IL-1\u03b2 mediated responses which correlated with decrease in the viral load and consequent protection in vaccinated participants compared to placebo treated groups [14].", [["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 122, 127], ["IL-1\u03b2", "PROTEIN", 122, 127], ["participants", "SPECIES", 236, 248], ["This study", "TEST", 0, 10], ["BCG vaccination", "TREATMENT", 33, 48], ["IL", "TEST", 122, 124], ["the viral load", "PROBLEM", 181, 195], ["placebo treated groups", "TREATMENT", 261, 283], ["viral load", "OBSERVATION", 185, 195]]], ["Another RCT involving H1N1 influenza vaccine strain reported enhanced induction of functional antibody response against this strain if BCG vaccination was given prior to influenza vaccination [22].Heterologous effects of BCG vaccination: implications in COVID-19 associated mortalityFurthermore, a BCG vaccination diminished the risk of pneumonia in tuberculin negative elderly people in Japan [23].", [["pneumonia", "DISEASE", 337, 346], ["H1N1 influenza", "ORGANISM", 22, 36], ["people", "ORGANISM", 378, 384], ["H1N1 influenza vaccine", "SPECIES", 22, 44], ["people", "SPECIES", 378, 384], ["Another RCT", "TEST", 0, 11], ["H1N1 influenza vaccine", "TREATMENT", 22, 44], ["functional antibody response", "PROBLEM", 83, 111], ["this strain", "PROBLEM", 120, 131], ["BCG vaccination", "TREATMENT", 135, 150], ["influenza vaccination", "TREATMENT", 170, 191], ["BCG vaccination", "TREATMENT", 221, 236], ["a BCG vaccination", "TREATMENT", 296, 313], ["pneumonia", "PROBLEM", 337, 346], ["H1N1", "OBSERVATION", 22, 26], ["pneumonia", "OBSERVATION", 337, 346]]], ["A small study by Wardhana et al reported significant reduction in acute upper respiratory tract infections in elderly people after BCG vaccination which was given once a month for three consecutive months [24].", [["upper respiratory tract", "ANATOMY", 72, 95], ["upper respiratory tract infections", "DISEASE", 72, 106], ["upper respiratory", "ORGANISM_SUBDIVISION", 72, 89], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124], ["A small study", "TEST", 0, 13], ["significant reduction", "PROBLEM", 41, 62], ["acute upper respiratory tract infections", "PROBLEM", 66, 106], ["BCG vaccination", "TREATMENT", 131, 146], ["small", "OBSERVATION_MODIFIER", 2, 7], ["significant", "OBSERVATION_MODIFIER", 41, 52], ["reduction", "OBSERVATION_MODIFIER", 53, 62], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["upper", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95], ["infections", "OBSERVATION", 96, 106]]], ["A clinical study from South Africa investigating the effectiveness of BCG vaccination on MTB infections in adolescents reported a 73% decrease in respiratory tract infections compared to non-vaccinated population [25], [26].Heterologous effects of BCG vaccination: implications in COVID-19 associated mortalityThe ongoing COVID-19 pandemic has spread over 210 countries and territories till date.", [["respiratory tract", "ANATOMY", 146, 163], ["MTB infections", "DISEASE", 89, 103], ["respiratory tract infections", "DISEASE", 146, 174], ["respiratory tract", "ORGANISM_SUBDIVISION", 146, 163], ["adolescents", "SPECIES", 107, 118], ["A clinical study", "TEST", 0, 16], ["BCG vaccination", "TREATMENT", 70, 85], ["MTB infections", "PROBLEM", 89, 103], ["a 73% decrease in respiratory tract infections", "PROBLEM", 128, 174], ["BCG vaccination", "TREATMENT", 248, 263], ["COVID", "TEST", 281, 286], ["The ongoing COVID", "TEST", 310, 327], ["pandemic", "PROBLEM", 331, 339], ["respiratory tract", "ANATOMY", 146, 163]]], ["Significant differences in COVID-19 associated morbidity and mortality, are visible in different countries, which probably varies according to their population size, geography, socioeconomic status, and healthcare infrastructure of the respective country.", [["Significant differences in COVID-19 associated morbidity", "PROBLEM", 0, 56], ["visible", "OBSERVATION_MODIFIER", 76, 83], ["size", "OBSERVATION_MODIFIER", 160, 164]]], ["Interestingly, in a recent epidemiological study Aron et al attributed the country wise variation in COVID-19 related mortality and morbidity to BCG vaccination program in various countries.", [["a recent epidemiological study", "TEST", 18, 48], ["COVID", "TEST", 101, 106], ["morbidity to BCG vaccination program", "TREATMENT", 132, 168]]], ["This study revealed that countries with proper BCG vaccination program have reported lesser COVID-19 associated mortality as compared to the countries where BCG vaccination has been removed from their vaccination program, suggesting probable protection offered by BCG vaccine against COVID-19 [27].", [["COVID-19", "CHEMICAL", 284, 292], ["This study", "TEST", 0, 10], ["proper BCG vaccination program", "TREATMENT", 40, 70], ["lesser COVID-19 associated mortality", "PROBLEM", 85, 121], ["BCG vaccination", "TREATMENT", 157, 172], ["BCG vaccine", "TREATMENT", 264, 275], ["COVID", "TEST", 284, 289], ["lesser", "OBSERVATION_MODIFIER", 85, 91], ["suggesting probable", "UNCERTAINTY", 222, 241]]], ["The findings of this study might be error prone and limiting due to differences in the various factors prevalent in the respective country such as testing capabilities/rates, adequate reporting of the cases and mortality, medical care facilities, disease burden and stage of the disease transmission, hence randomized clinical trials are needed to determine the BCG mediated protection against COVID-19.", [["this study", "TEST", 16, 26], ["testing capabilities", "TEST", 147, 167], ["disease burden", "PROBLEM", 247, 261], ["the disease transmission", "PROBLEM", 275, 299], ["COVID", "TEST", 394, 399]]], ["Till date, 11 clinical trials using BCG vaccine and 3 trials using recombinant BCG vaccine VPM1002 have been initiated with aim to study the BCG mediated protective effects in health care workers handling COVID-19 patients and elderly population.Trained Immunity: Innate memory response ::: Mechanism underlying heterologous effects of BCGThe mechanism underlying the heterologous protective effects BCG is not yet fully understood however, evidences suggest that induction of memory in innate immune cells such as monocytes, natural killer cells and macrophages, independent of T and B cell response, which is also termed as \u2018trained immunity\u2019; plays a critical role in non-specific protection exhibited by BCG vaccination [13].", [["immune cells", "ANATOMY", 494, 506], ["monocytes", "ANATOMY", 515, 524], ["natural killer cells", "ANATOMY", 526, 546], ["macrophages", "ANATOMY", 551, 562], ["B cell", "ANATOMY", 585, 591], ["VPM1002", "CHEMICAL", 91, 98], ["VPM1002", "SIMPLE_CHEMICAL", 91, 98], ["patients", "ORGANISM", 214, 222], ["innate immune cells", "CELL", 487, 506], ["monocytes", "CELL", 515, 524], ["natural killer cells", "CELL", 526, 546], ["macrophages", "CELL", 551, 562], ["T", "CELL", 579, 580], ["B cell", "CELL", 585, 591], ["innate immune cells", "CELL_TYPE", 487, 506], ["monocytes", "CELL_TYPE", 515, 524], ["natural killer cells", "CELL_TYPE", 526, 546], ["macrophages", "CELL_TYPE", 551, 562], ["patients", "SPECIES", 214, 222], ["BCG vaccine", "TREATMENT", 36, 47], ["3 trials", "TREATMENT", 52, 60], ["recombinant BCG vaccine VPM1002", "TREATMENT", 67, 98], ["BCG", "TREATMENT", 336, 339], ["the heterologous protective effects BCG", "PROBLEM", 364, 403], ["memory in innate immune cells", "PROBLEM", 477, 506], ["monocytes", "TEST", 515, 524], ["macrophages", "PROBLEM", 551, 562], ["non-specific protection", "TREATMENT", 671, 694], ["natural killer cells", "OBSERVATION", 526, 546]]], ["In severe combined immunodeficiency (SCID) mice which lacks adaptive immunity, BCG vaccination protects from lethal systemic candidiasis by activation of NK cells, further confirming the role of innate immune cells in heterologous benefits of BCG [28].", [["NK cells", "ANATOMY", 154, 162], ["immune cells", "ANATOMY", 202, 214], ["immunodeficiency", "DISEASE", 19, 35], ["SCID", "DISEASE", 37, 41], ["candidiasis", "DISEASE", 125, 136], ["mice", "ORGANISM", 43, 47], ["candidiasis", "PATHOLOGICAL_FORMATION", 125, 136], ["NK cells", "CELL", 154, 162], ["innate immune cells", "CELL", 195, 214], ["NK cells", "CELL_TYPE", 154, 162], ["innate immune cells", "CELL_TYPE", 195, 214], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["severe combined immunodeficiency (SCID) mice", "PROBLEM", 3, 47], ["adaptive immunity", "TREATMENT", 60, 77], ["BCG vaccination", "TREATMENT", 79, 94], ["lethal systemic candidiasis", "PROBLEM", 109, 136], ["NK cells", "TREATMENT", 154, 162], ["innate immune cells", "TREATMENT", 195, 214], ["BCG", "TEST", 243, 246], ["severe", "OBSERVATION_MODIFIER", 3, 9], ["immunodeficiency", "OBSERVATION", 19, 35]]], ["In a recent study, peripheral blood mononuclear cells (PBMCs) isolated from healthy human volunteers three months post BCG vaccination, produced increased levels of pro-inflammatory cytokines IL-1\u03b2 and TNF-\u03b1, when stimulated with unrelated pathogens in vitro.", [["peripheral blood mononuclear cells", "ANATOMY", 19, 53], ["PBMCs", "ANATOMY", 55, 60], ["peripheral blood mononuclear cells", "CELL", 19, 53], ["PBMCs", "CELL", 55, 60], ["human", "ORGANISM", 84, 89], ["volunteers", "ORGANISM", 90, 100], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 192, 197], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 202, 207], ["peripheral blood mononuclear cells", "CELL_TYPE", 19, 53], ["PBMCs", "CELL_TYPE", 55, 60], ["pro-inflammatory cytokines", "PROTEIN", 165, 191], ["IL-1\u03b2", "PROTEIN", 192, 197], ["TNF-\u03b1", "PROTEIN", 202, 207], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["a recent study", "TEST", 3, 17], ["peripheral blood mononuclear cells", "PROBLEM", 19, 53], ["PBMCs", "TEST", 55, 60], ["BCG vaccination", "TREATMENT", 119, 134], ["pro-inflammatory cytokines IL", "TREATMENT", 165, 194], ["TNF", "TEST", 202, 205], ["peripheral", "ANATOMY_MODIFIER", 19, 29], ["blood", "ANATOMY", 30, 35], ["mononuclear cells", "OBSERVATION", 36, 53], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["pro-inflammatory cytokines", "OBSERVATION", 165, 191]]], ["Further, upregulation in the expression of CD14, CD11b and TLR4 was observed along with increased epigenetic modifications at the promoter sequences of the genes of pro-inflammatory cytokines in human PBMCs, which suggests that increased cytokine production may be responsible for the better protection during secondary infection with non-mycobacterial pathogen [29].Trained Immunity: Innate memory response ::: Mechanism underlying heterologous effects of BCGTrained innate immune cells exhibit rapid, stronger and qualitatively different transcriptional responses when exposed to pathogens as compared to untrained cells.", [["PBMCs", "ANATOMY", 201, 206], ["immune cells", "ANATOMY", 475, 487], ["cells", "ANATOMY", 617, 622], ["infection", "DISEASE", 320, 329], ["CD14", "GENE_OR_GENE_PRODUCT", 43, 47], ["CD11b", "GENE_OR_GENE_PRODUCT", 49, 54], ["TLR4", "GENE_OR_GENE_PRODUCT", 59, 63], ["human", "ORGANISM", 195, 200], ["PBMCs", "CELL", 201, 206], ["BCGTrained innate immune cells", "CELL", 457, 487], ["cells", "CELL", 617, 622], ["CD14", "PROTEIN", 43, 47], ["CD11b", "PROTEIN", 49, 54], ["TLR4", "PROTEIN", 59, 63], ["promoter sequences", "DNA", 130, 148], ["pro-inflammatory cytokines", "PROTEIN", 165, 191], ["human PBMCs", "CELL_TYPE", 195, 206], ["cytokine", "PROTEIN", 238, 246], ["BCGTrained innate immune cells", "CELL_TYPE", 457, 487], ["untrained cells", "CELL_TYPE", 607, 622], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 195, 200], ["CD14", "TEST", 43, 47], ["CD11b", "TEST", 49, 54], ["TLR4", "TEST", 59, 63], ["increased epigenetic modifications", "PROBLEM", 88, 122], ["pro-inflammatory cytokines in human PBMCs", "PROBLEM", 165, 206], ["increased cytokine production", "PROBLEM", 228, 257], ["secondary infection", "PROBLEM", 310, 329], ["non-mycobacterial pathogen", "PROBLEM", 335, 361], ["heterologous effects", "PROBLEM", 433, 453], ["BCGTrained innate immune cells", "PROBLEM", 457, 487], ["pathogens", "PROBLEM", 582, 591], ["pro-inflammatory cytokines", "OBSERVATION", 165, 191], ["increased", "OBSERVATION_MODIFIER", 228, 237], ["cytokine production", "OBSERVATION", 238, 257], ["heterologous effects", "OBSERVATION", 433, 453]]], ["The underlying molecular mechanism is poorly understood however; evidences suggest the involvement of several regulatory mechanisms including epigenetic reprogramming and chromatin reorganization in immune cells during the generation of trained immunity by primary stimulus.", [["chromatin", "ANATOMY", 171, 180], ["immune cells", "ANATOMY", 199, 211], ["chromatin", "CELLULAR_COMPONENT", 171, 180], ["immune cells", "CELL", 199, 211], ["chromatin", "DNA", 171, 180], ["immune cells", "CELL_TYPE", 199, 211], ["several regulatory mechanisms", "PROBLEM", 102, 131], ["epigenetic reprogramming", "PROBLEM", 142, 166], ["chromatin reorganization", "TREATMENT", 171, 195], ["immune cells", "TREATMENT", 199, 211], ["molecular mechanism", "OBSERVATION", 15, 34], ["chromatin reorganization", "OBSERVATION", 171, 195], ["immune cells", "OBSERVATION", 199, 211]]], ["[30], [31]", [["[31]", "SIMPLE_CHEMICAL", 6, 10]]]], "97b3af92db88bc049aa4c271b5adbe40d93a9499": [["IntroductionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the pathogen responsible for coronavirus disease that is behind a major ongoing pandemic (1) (2) (3) .", [["acute respiratory syndrome coronavirus", "DISEASE", 19, 57], ["coronavirus disease", "DISEASE", 105, 124], ["IntroductionSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 59], ["SARS-CoV-2", "ORGANISM", 61, 71], ["coronavirus", "ORGANISM", 105, 116], ["coronavirus", "SPECIES", 105, 116], ["IntroductionSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 57], ["SARS-CoV-2", "SPECIES", 61, 71], ["acute respiratory syndrome coronavirus", "PROBLEM", 19, 57], ["SARS-CoV", "TEST", 61, 69], ["the pathogen", "PROBLEM", 76, 88], ["coronavirus disease", "PROBLEM", 105, 124], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["responsible for", "UNCERTAINTY", 89, 104], ["coronavirus disease", "OBSERVATION", 105, 124]]], ["Virus entry into host cells is dependent on the S1 spike glycoprotein that forms homotrimers on the surface of the virion and interacts with the ACE2 receptor in susceptible cells (4) (5) (6) .IntroductionMany studies on clinical characteristics and mortality resulting from SARS-CoV-2 infection have highlighted the need for a detailed understanding of immune responses against this pathogen (7) .", [["cells", "ANATOMY", 22, 27], ["surface", "ANATOMY", 100, 107], ["virion", "ANATOMY", 115, 121], ["cells", "ANATOMY", 174, 179], ["SARS", "DISEASE", 275, 279], ["infection", "DISEASE", 286, 295], ["Virus", "ORGANISM", 0, 5], ["host cells", "CELL", 17, 27], ["homotrimers", "GENE_OR_GENE_PRODUCT", 81, 92], ["surface", "CELLULAR_COMPONENT", 100, 107], ["virion", "CELLULAR_COMPONENT", 115, 121], ["ACE2", "GENE_OR_GENE_PRODUCT", 145, 149], ["cells", "CELL", 174, 179], ["SARS-CoV-2", "ORGANISM", 275, 285], ["host cells", "CELL_TYPE", 17, 27], ["S1 spike glycoprotein", "PROTEIN", 48, 69], ["homotrimers", "PROTEIN", 81, 92], ["ACE2 receptor", "PROTEIN", 145, 158], ["CoV-2", "SPECIES", 280, 285], ["SARS-CoV", "SPECIES", 275, 283], ["Virus entry into host cells", "PROBLEM", 0, 27], ["the S1 spike glycoprotein", "PROBLEM", 44, 69], ["SARS", "PROBLEM", 275, 279], ["CoV-2 infection", "PROBLEM", 280, 295], ["this pathogen", "PROBLEM", 379, 392], ["host cells", "OBSERVATION", 17, 27], ["dependent", "OBSERVATION_MODIFIER", 31, 40], ["virion", "ANATOMY", 115, 121]]], ["While appropriate innate and adaptive immune responses are necessary for recovery from infection, aberrant immune responses can be a major contributing factor to mortality (8, 9) .", [["infection", "DISEASE", 87, 96], ["infection", "PROBLEM", 87, 96], ["aberrant immune responses", "PROBLEM", 98, 123], ["infection", "OBSERVATION", 87, 96]]], ["In parallel, understanding immune recognition of SARS-CoV-2 is crucial to the ongoing massive global effort into developing an effecting vaccine against this pathogen (10) .", [["SARS", "DISEASE", 49, 53], ["SARS-CoV-2", "ORGANISM", 49, 59], ["SARS-CoV", "SPECIES", 49, 57], ["SARS", "PROBLEM", 49, 53], ["an effecting vaccine", "TREATMENT", 124, 144], ["this pathogen", "PROBLEM", 153, 166]]], ["Although early analyses have focused on the development of neutralizing antibodies, cellular immune responses are emerging of vital importance (11) both for understanding normal immune response against this pathogen and for designing and optimizing vaccines (12) .", [["cellular", "ANATOMY", 84, 92], ["cellular", "CELL", 84, 92], ["neutralizing antibodies", "PROTEIN", 59, 82], ["neutralizing antibodies", "PROBLEM", 59, 82], ["this pathogen", "PROBLEM", 202, 215], ["optimizing vaccines", "TREATMENT", 238, 257]]], ["In particular T-cell mediated immunity appears to be important for both viral clearance and for long-term immunity (11) .", [["T-cell", "ANATOMY", 14, 20], ["T-cell", "CELL", 14, 20]]], ["Thus, analysis of antigenic epitopes from SARS-CoV-2 should be a priority for the design of vaccines that induce effective and longlasting cellular immune responses (13) .IntroductionCytotoxic T-cell responses against virus-infected cells hinge on the presentation of small peptidic fragments of viral proteins, called antigenic peptides, by specialized proteins on the cell surface that belong to the Major Histocompatibility Class I complex (MHCI, also called Human Leukocyte Antigens, HLA, in humans).", [["cellular", "ANATOMY", 139, 147], ["Cytotoxic T-cell", "ANATOMY", 183, 199], ["cells", "ANATOMY", 233, 238], ["cell surface", "ANATOMY", 370, 382], ["SARS", "DISEASE", 42, 46], ["SARS-CoV-2", "ORGANISM", 42, 52], ["cellular", "CELL", 139, 147], ["Cytotoxic T-cell", "CELL", 183, 199], ["cells", "CELL", 233, 238], ["cell surface", "CELLULAR_COMPONENT", 370, 382], ["Major Histocompatibility Class I", "GENE_OR_GENE_PRODUCT", 402, 434], ["MHCI", "GENE_OR_GENE_PRODUCT", 444, 448], ["Human", "ORGANISM", 462, 467], ["Leukocyte Antigens", "GENE_OR_GENE_PRODUCT", 468, 486], ["HLA", "GENE_OR_GENE_PRODUCT", 488, 491], ["humans", "ORGANISM", 496, 502], ["antigenic epitopes", "PROTEIN", 18, 36], ["virus-infected cells", "CELL_TYPE", 218, 238], ["viral proteins", "PROTEIN", 296, 310], ["Major Histocompatibility Class I complex", "PROTEIN", 402, 442], ["MHCI", "PROTEIN", 444, 448], ["Human Leukocyte Antigens", "PROTEIN", 462, 486], ["HLA", "PROTEIN", 488, 491], ["Human", "SPECIES", 462, 467], ["humans", "SPECIES", 496, 502], ["SARS-CoV", "SPECIES", 42, 50], ["humans", "SPECIES", 496, 502], ["antigenic epitopes", "PROBLEM", 18, 36], ["SARS", "PROBLEM", 42, 46], ["vaccines", "TREATMENT", 92, 100], ["virus", "PROBLEM", 218, 223], ["infected cells hinge", "PROBLEM", 224, 244], ["small peptidic fragments", "PROBLEM", 268, 292], ["viral proteins", "PROBLEM", 296, 310], ["antigenic peptides", "PROBLEM", 319, 337], ["Human Leukocyte Antigens", "TEST", 462, 486], ["HLA", "TEST", 488, 491], ["infected cells hinge", "OBSERVATION", 224, 244], ["small", "OBSERVATION_MODIFIER", 268, 273], ["peptidic fragments", "OBSERVATION", 274, 292], ["viral proteins", "OBSERVATION", 296, 310]]], ["Antigenic peptides are derived from viral proteins that are proteolytically degraded by complex proteolytic cascades (14) .", [["viral proteins", "PROTEIN", 36, 50], ["Antigenic peptides", "PROBLEM", 0, 18], ["viral proteins", "PROBLEM", 36, 50], ["complex proteolytic cascades", "PROBLEM", 88, 116], ["viral proteins", "OBSERVATION", 36, 50], ["complex", "OBSERVATION_MODIFIER", 88, 95], ["proteolytic cascades", "OBSERVATION", 96, 116]]], ["Intracellular aminopeptidases, ER aminopeptidase 1 (ERAP1), ER aminopeptidase 2 (ERAP2) and insulinregulated aminopeptidase (IRAP) play important roles in producing antigenic peptides, by down-sizing longer peptides to the correct length for binding onto MHCI (15) .", [["Intracellular", "ANATOMY", 0, 13], ["ER aminopeptidase 1", "GENE_OR_GENE_PRODUCT", 31, 50], ["ERAP1", "GENE_OR_GENE_PRODUCT", 52, 57], ["ER aminopeptidase 2", "GENE_OR_GENE_PRODUCT", 60, 79], ["ERAP2", "GENE_OR_GENE_PRODUCT", 81, 86], ["insulinregulated aminopeptidase", "GENE_OR_GENE_PRODUCT", 92, 123], ["IRAP", "GENE_OR_GENE_PRODUCT", 125, 129], ["MHCI", "GENE_OR_GENE_PRODUCT", 255, 259], ["aminopeptidases", "PROTEIN", 14, 29], ["ER aminopeptidase 1", "PROTEIN", 31, 50], ["ERAP1", "PROTEIN", 52, 57], ["ER aminopeptidase 2", "PROTEIN", 60, 79], ["ERAP2", "PROTEIN", 81, 86], ["insulinregulated aminopeptidase", "PROTEIN", 92, 123], ["IRAP", "PROTEIN", 125, 129], ["MHCI", "PROTEIN", 255, 259], ["Intracellular aminopeptidases", "TREATMENT", 0, 29], ["ER aminopeptidase", "TREATMENT", 31, 48], ["ER aminopeptidase 2 (ERAP2)", "TREATMENT", 60, 87], ["insulinregulated aminopeptidase (IRAP)", "TREATMENT", 92, 130]]], ["Appropriate processing of pathogen antigens by these enzymes can determine the generation of cytotoxic immune responses and aberrant processing can lead to immune evasion (16) .", [["pathogen antigens", "PROTEIN", 26, 43], ["enzymes", "PROTEIN", 53, 60], ["pathogen antigens", "PROBLEM", 26, 43], ["these enzymes", "TEST", 47, 60], ["cytotoxic immune responses", "PROBLEM", 93, 119], ["aberrant processing", "PROBLEM", 124, 143], ["immune evasion", "PROBLEM", 156, 170]]], ["Thus, it is important to understand how these enzymes process SARS-CoV-2 antigens, so as to gain insight into the efficacy of antiviral cytotoxic responses and reveal possible avenues to enhance them.IntroductionIn this study, we utilized a novel approach to analyze antigen trimming by intracellular aminopeptidases ERAP1, ERAP2 and IRAP, focusing on the largest antigen of SARS-CoV-2, namely S1 spike glycoprotein.", [["intracellular", "ANATOMY", 287, 300], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 62, 81], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 287, 300], ["ERAP1", "GENE_OR_GENE_PRODUCT", 317, 322], ["ERAP2", "GENE_OR_GENE_PRODUCT", 324, 329], ["IRAP", "GENE_OR_GENE_PRODUCT", 334, 338], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 375, 385], ["S1 spike glycoprotein", "GENE_OR_GENE_PRODUCT", 394, 415], ["enzymes", "PROTEIN", 46, 53], ["SARS-CoV-2 antigens", "PROTEIN", 62, 81], ["intracellular aminopeptidases", "PROTEIN", 287, 316], ["ERAP1", "PROTEIN", 317, 322], ["ERAP2", "PROTEIN", 324, 329], ["IRAP", "PROTEIN", 334, 338], ["SARS-CoV-2", "PROTEIN", 375, 385], ["S1 spike glycoprotein", "PROTEIN", 394, 415], ["SARS", "TEST", 62, 66], ["antiviral cytotoxic responses", "TREATMENT", 126, 155], ["this study", "TEST", 215, 225], ["a novel approach", "TREATMENT", 239, 255], ["analyze antigen trimming", "TREATMENT", 259, 283], ["intracellular aminopeptidases ERAP1", "TREATMENT", 287, 322], ["ERAP2", "TEST", 324, 329], ["IRAP", "TEST", 334, 338], ["SARS", "TEST", 375, 379], ["CoV", "TEST", 380, 383], ["namely S1 spike glycoprotein", "PROBLEM", 387, 415]]], ["By using tandem LC-MS/MS analysis, we were able to follow trimming in parallel of a large ensemble of peptides derived from the full length of S1 protein.IntroductionThis approach was inspired by two established observations: i) that these enzymes are expected to normally encounter a very large number of potential substrates concurrently in the cell and ii) accommodation of peptides inside a large cavity of each enzyme can lead to complex interactions between substrates that have to compete for the same space in the cavity (17) (18) (19) .", [["cell", "ANATOMY", 347, 351], ["S1", "GENE_OR_GENE_PRODUCT", 143, 145], ["cell", "CELL", 347, 351], ["S1 protein", "PROTEIN", 143, 153], ["enzymes", "PROTEIN", 240, 247], ["enzyme", "PROTEIN", 416, 422], ["MS/MS analysis", "TEST", 19, 33], ["a large ensemble of peptides", "PROBLEM", 82, 110], ["these enzymes", "TEST", 234, 247], ["accommodation of peptides", "PROBLEM", 360, 385], ["a large cavity of each enzyme", "PROBLEM", 393, 422], ["complex interactions between substrates", "PROBLEM", 435, 474], ["large", "OBSERVATION_MODIFIER", 395, 400], ["cavity", "OBSERVATION", 401, 407], ["cavity", "ANATOMY", 522, 528]]], ["Our analysis provides novel insight into the differences in specificity between the three enzymes and provides a potential filter of traditional bioinformatic approaches that aim to predict antigenic epitopes.", [["enzymes", "PROTEIN", 90, 97], ["antigenic epitopes", "PROTEIN", 190, 208], ["Our analysis", "TEST", 0, 12], ["the three enzymes", "TEST", 80, 97], ["a potential filter", "TREATMENT", 111, 129], ["traditional bioinformatic approaches", "TREATMENT", 133, 169], ["antigenic epitopes", "PROBLEM", 190, 208]]], ["Finally, we propose a limited list of peptides that are potential ligands for common HLA alleles and could be prioritized for further immunological analyses and vaccine design efforts.Enzyme expression and purificationRecombinant ERAP1, ERAP2 and IRAP were expressed and purified as described previously.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 230, 235], ["ERAP2", "GENE_OR_GENE_PRODUCT", 237, 242], ["IRAP", "GENE_OR_GENE_PRODUCT", 247, 251], ["HLA alleles", "DNA", 85, 96], ["ERAP1", "PROTEIN", 230, 235], ["ERAP2", "PROTEIN", 237, 242], ["IRAP", "PROTEIN", 247, 251], ["common HLA alleles", "PROBLEM", 78, 96], ["further immunological analyses", "TEST", 126, 156], ["vaccine design efforts", "TREATMENT", 161, 183], ["Enzyme expression", "TEST", 184, 201], ["purificationRecombinant ERAP1", "TEST", 206, 235], ["ERAP2", "TEST", 237, 242], ["IRAP", "TEST", 247, 251], ["purificationRecombinant ERAP1", "OBSERVATION", 206, 235]]], ["Briefly, ERAP1 and ERAP2 were expressed by Hi5 insect cells in culture after infection with baculovirus carrying the appropriate gene and purified by affinity chromatography using a C-terminal his tag (20, 21) .", [["Hi5 insect cells", "ANATOMY", 43, 59], ["C", "CHEMICAL", 182, 183], ["ERAP1", "GENE_OR_GENE_PRODUCT", 9, 14], ["ERAP2", "GENE_OR_GENE_PRODUCT", 19, 24], ["Hi5 insect cells", "CELL", 43, 59], ["baculovirus", "ORGANISM", 92, 103], ["ERAP1", "PROTEIN", 9, 14], ["ERAP2", "PROTEIN", 19, 24], ["Hi5 insect cells", "CELL_LINE", 43, 59], ["C-terminal his tag", "DNA", 182, 200], ["baculovirus", "SPECIES", 92, 103], ["ERAP2", "TREATMENT", 19, 24], ["Hi5 insect cells", "PROBLEM", 43, 59], ["culture", "TEST", 63, 70], ["infection", "PROBLEM", 77, 86], ["baculovirus", "TREATMENT", 92, 103], ["affinity chromatography", "TEST", 150, 173], ["a C-terminal his tag", "TREATMENT", 180, 200]]], ["The enzymatic extracellular domain of IRAP was expressed by stably transfected HEK 293S GnTI (-) cells and purified by affinity chromatography using a C-terminal Rhodopsin 1D4 tag (22) .", [["extracellular", "ANATOMY", 14, 27], ["HEK 293S GnTI (-) cells", "ANATOMY", 79, 102], ["C", "CHEMICAL", 151, 152], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["IRAP", "GENE_OR_GENE_PRODUCT", 38, 42], ["HEK 293S GnTI (-) cells", "CELL", 79, 102], ["enzymatic extracellular domain", "PROTEIN", 4, 34], ["IRAP", "PROTEIN", 38, 42], ["HEK 293S GnTI (-) cells", "CELL_LINE", 79, 102], ["C-terminal Rhodopsin 1D4 tag", "DNA", 151, 179], ["The enzymatic extracellular domain of IRAP", "TEST", 0, 42], ["GnTI", "TEST", 88, 92], ["affinity chromatography", "TEST", 119, 142], ["a C-terminal Rhodopsin 1D4 tag", "TREATMENT", 149, 179]]], ["Enzymes were stored with 10% glycerol in aliquots at -80\uf0b0C until needed.PeptidesThe PepMix SARS-CoV-2 peptide mixture was purchased by JBT Peptide Technologies GmbH.", [["glycerol", "CHEMICAL", 29, 37], ["SARS-CoV-2 peptide", "CHEMICAL", 91, 109], ["glycerol", "CHEMICAL", 29, 37], ["glycerol", "SIMPLE_CHEMICAL", 29, 37], ["Enzymes", "TEST", 0, 7], ["Peptides", "TEST", 72, 80], ["The PepMix SARS", "TEST", 80, 95], ["CoV-2 peptide mixture", "TREATMENT", 96, 117]]], ["Peptide pools were dissolved in DMSO.", [["DMSO", "CHEMICAL", 32, 36], ["DMSO", "CHEMICAL", 32, 36], ["DMSO", "SIMPLE_CHEMICAL", 32, 36], ["Peptide pools", "PROBLEM", 0, 13], ["dissolved", "OBSERVATION_MODIFIER", 19, 28]]], ["Prior to reactions the two peptide collections (158 and 157 peptides respectively) were mixed at equimolar concentrations and diluted in buffer containing 10mM Hepes pH 7, 100mM NaCl to a final concentration of 48\u03bcM.Enzymatic reactionsEnzymatic reactions were performed in triplicate in a total volume of 50\u03bcL in 10mM Hepes pH 7, 100mM NaCl.", [["NaCl", "CHEMICAL", 178, 182], ["NaCl", "CHEMICAL", 336, 340], ["NaCl", "CHEMICAL", 178, 182], ["NaCl", "CHEMICAL", 336, 340], ["the two peptide collections", "PROBLEM", 19, 46], ["mixed at equimolar concentrations", "TREATMENT", 88, 121], ["10mM Hepes pH", "TREATMENT", 155, 168], ["Enzymatic reactions", "PROBLEM", 216, 235], ["Enzymatic reactions", "PROBLEM", 235, 254], ["a total volume", "TEST", 287, 301], ["Hepes pH", "TEST", 318, 326], ["collections", "OBSERVATION", 35, 46]]], ["Freshly thawed enzyme stocks were added to each reaction to a final concentration of 50nM.", [["Freshly thawed enzyme stocks", "TREATMENT", 0, 28], ["enzyme stocks", "OBSERVATION", 15, 28]]], ["Reactions were incubated at 37\uf0b0C for 2 hours, stopped by the addition of 7.5\u03bcL of a 10% TFA solution, flash frozen in liquid nitrogen and stored at -80\uf0b0C until analysis.LC-MS/MS analysisThe sample was preconcentrated on a pepmap LC trapping column (0.3X5mm) at a rate of 30uL of Buffer A (0.1% Formic acid in water) in 5min.", [["sample", "ANATOMY", 190, 196], ["Formic acid", "CHEMICAL", 294, 305], ["TFA", "CHEMICAL", 88, 91], ["nitrogen", "CHEMICAL", 125, 133], ["Formic acid", "CHEMICAL", 294, 305], ["TFA", "SIMPLE_CHEMICAL", 88, 91], ["Formic acid", "SIMPLE_CHEMICAL", 294, 305], ["a 10% TFA solution", "TREATMENT", 82, 100], ["flash frozen in liquid nitrogen", "TREATMENT", 102, 133], ["analysis", "TEST", 160, 168], ["LC", "TEST", 169, 171], ["MS analysis", "TEST", 175, 186], ["The sample", "TEST", 186, 196], ["a pepmap LC trapping column", "TREATMENT", 220, 247], ["Buffer A", "TREATMENT", 279, 287], ["Formic acid in water)", "TREATMENT", 294, 315], ["column", "OBSERVATION_MODIFIER", 241, 247]]], ["The LC gradient used was 5% Buffer B (0.1% Formic acid in Acetonitrile) to 25% in 36 min followed by an increase to 36% in 5 min and a second increase to 80% in 0.5min and then was kept constant for 2min.", [["Formic acid", "CHEMICAL", 43, 54], ["Acetonitrile", "CHEMICAL", 58, 70], ["Acetonitrile", "CHEMICAL", 58, 70], ["Formic acid", "SIMPLE_CHEMICAL", 43, 54], ["Acetonitrile", "SIMPLE_CHEMICAL", 58, 70], ["The LC gradient", "TREATMENT", 0, 15], ["Formic acid in Acetonitrile)", "TREATMENT", 43, 71], ["LC", "OBSERVATION_MODIFIER", 4, 6], ["gradient", "OBSERVATION_MODIFIER", 7, 15], ["increase", "OBSERVATION_MODIFIER", 104, 112]]], ["The column was equilibrated for 15 min prior to the next injection.", [["the next injection", "TREATMENT", 48, 66], ["column", "ANATOMY", 4, 10]]], ["A full MS was acquired with a Q Exactive HF-X Hybrid Quadropole-Orbitrap mass spectrometer, in the scan range of 350-1400m/z using 60K resolving power with an AGC of 3x 10 6 and max IT of 45ms, followed by MS/MS scans of the 12 most abundant ions, using 15K resolving power with an AGC of 1x 10 5 and max IT of 22ms and an NCE of 28.", [["a Q Exactive HF", "PROBLEM", 28, 43], ["Orbitrap mass spectrometer", "TEST", 64, 90], ["an AGC", "TEST", 156, 162], ["max IT", "TEST", 178, 184], ["MS/MS scans", "TEST", 206, 217], ["an AGC", "TEST", 279, 285], ["max IT", "TEST", 301, 307], ["an NCE", "TEST", 320, 326]]], ["The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (23) partner repository with the dataset identifier PXD019901.Database SearchWe employed the MaxQuant computational proteomics platform version 1.6.14.0 to search the peak lists against the Spike glycoprotein SARS2 FASTA file (Swissprot accession number P0DTC2) and a file containing 247 frequently observed contaminants.", [["Spike glycoprotein", "PROTEIN", 296, 314], ["SARS2", "PROTEIN", 315, 320], ["The mass spectrometry proteomics", "TEST", 0, 32], ["mass", "OBSERVATION", 4, 8]]], ["N-terminal acetylation (42.010565 Da) and methionine oxidation (15.", [["methionine", "CHEMICAL", 42, 52], ["N", "CHEMICAL", 0, 1], ["methionine", "CHEMICAL", 42, 52], ["methionine", "SIMPLE_CHEMICAL", 42, 52], ["terminal acetylation", "TREATMENT", 2, 22], ["methionine oxidation", "TREATMENT", 42, 62]]], ["The false discovery rate (FDR) were set to of 0.01 both for peptide.", [["The false discovery rate", "TEST", 0, 24]]], ["The enzyme specificity was set as unspecific.", [["The enzyme specificity", "TEST", 0, 22]]], ["The minimum peptide length was set to 6 amino acids.", [["amino acids", "CHEMICAL", 40, 51], ["amino acids", "CHEMICAL", 40, 51], ["amino acids", "AMINO_ACID", 40, 51], ["The minimum peptide length", "TEST", 0, 26], ["amino acids", "TEST", 40, 51], ["length", "OBSERVATION_MODIFIER", 20, 26]]], ["The initial allowed mass deviation of the precursor ion was set to 4.5 ppm and the maximum fragment mass deviation was set to 20 ppm.Results and discussionTo investigate the trimming of antigenic epitope precursors by intracellular aminopeptidases that generate antigenic peptides, we used a mixture of 315 synthetic peptides derived from the sequence of the SARS-CoV-2 S1 spike glycoprotein.", [["intracellular", "ANATOMY", 218, 231], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 218, 231], ["SARS-CoV-2 S1", "GENE_OR_GENE_PRODUCT", 359, 372], ["intracellular aminopeptidases", "PROTEIN", 218, 247], ["SARS-CoV-2 S1 spike glycoprotein", "PROTEIN", 359, 391], ["the maximum fragment mass deviation", "PROBLEM", 79, 114], ["antigenic epitope precursors", "TREATMENT", 186, 214], ["intracellular aminopeptidases", "TREATMENT", 218, 247], ["antigenic peptides", "TREATMENT", 262, 280], ["a mixture of 315 synthetic peptides", "TREATMENT", 290, 325], ["the SARS", "TEST", 355, 363], ["CoV", "TEST", 364, 367], ["mass deviation", "OBSERVATION", 20, 34], ["4.5 ppm", "OBSERVATION_MODIFIER", 67, 74], ["maximum", "OBSERVATION_MODIFIER", 83, 90], ["fragment", "OBSERVATION_MODIFIER", 91, 99], ["mass deviation", "OBSERVATION", 100, 114], ["20 ppm", "OBSERVATION_MODIFIER", 126, 132]]], ["All peptides were 15 residues long and spanned the entire sequence of the protein with an 11 residue overlap between adjacent peptides.", [["an 11 residue overlap between adjacent peptides", "PROBLEM", 87, 134]]], ["The peptide mixture was incubated with either ERAP1, ERAP2, IRAP or an equimolar mixture of ERAP1 and ERAP2 at a substrate to enzyme ratio of 1000:1 and the digestion products analyzed by LC-MS/MS using a custom search database generated by in silico digestions of the full S1 protein sequence (UniProt ID: P0DTC2).", [["ERAP1", "GENE_OR_GENE_PRODUCT", 46, 51], ["ERAP2", "GENE_OR_GENE_PRODUCT", 53, 58], ["IRAP", "GENE_OR_GENE_PRODUCT", 60, 64], ["ERAP1", "GENE_OR_GENE_PRODUCT", 92, 97], ["ERAP2", "GENE_OR_GENE_PRODUCT", 102, 107], ["ERAP1", "PROTEIN", 46, 51], ["ERAP2", "PROTEIN", 53, 58], ["IRAP", "PROTEIN", 60, 64], ["ERAP1", "PROTEIN", 92, 97], ["ERAP2", "PROTEIN", 102, 107], ["digestion products", "PROTEIN", 157, 175], ["S1 protein sequence", "PROTEIN", 274, 293], ["P0DTC2", "PROTEIN", 307, 313], ["The peptide mixture", "TREATMENT", 0, 19], ["ERAP2", "TEST", 53, 58], ["IRAP", "TEST", 60, 64], ["ERAP1", "PROBLEM", 92, 97], ["ERAP2", "TEST", 102, 107], ["enzyme ratio", "TEST", 126, 138], ["the digestion products", "TREATMENT", 153, 175], ["MS", "PROBLEM", 194, 196], ["a custom search database", "TEST", 203, 227]]], ["All analyses were performed on three biological replicates for each reaction, as well as a control reaction that was performed in the absence of enzyme.", [["enzyme", "PROTEIN", 145, 151], ["All analyses", "TEST", 0, 12], ["each reaction", "PROBLEM", 63, 76], ["a control reaction", "PROBLEM", 89, 107], ["enzyme", "TEST", 145, 151]]], ["An additional technical replicate for the control sample was also analyzed.", [["the control sample", "TEST", 38, 56]]], ["For statistical robustness, we performed a t-test between the control sample and each reaction and selected for further analysis only the peptides for which the quantification value changed by a statistically significant degree (p-value<0.05).Results and discussionThe relative abundance of each peptide before and after the reaction was compared by label-free-quantification.", [["a t-test", "TEST", 41, 49], ["further analysis", "TEST", 112, 128], ["the quantification value", "TEST", 157, 181], ["p-value", "TEST", 229, 236], ["the reaction", "PROBLEM", 321, 333], ["abundance", "OBSERVATION_MODIFIER", 278, 287]]], ["Analysis identified 263 unique 15mers in the samples out of the total 315 in the mixture.", [["Analysis", "TEST", 0, 8], ["the samples", "TEST", 41, 52]]], ["This represents an 83% coverage of included peptides which may be due to poor ionization and detection for some peptide sequences.", [["peptides", "PROBLEM", 44, 52], ["poor ionization", "PROBLEM", 73, 88], ["some peptide sequences", "TEST", 107, 129], ["may be due to", "UNCERTAINTY", 59, 72], ["poor ionization", "OBSERVATION", 73, 88]]], ["As a result, further analysis was limited to the peptides detectable by our experimental setup.", [["further analysis", "TEST", 13, 29]]], ["On average, incubation with enzyme reduced the relative abundance of the 15mer peptides indicating successful digestion ( Figure 1A , B).", [["enzyme", "TEST", 28, 34], ["successful digestion", "PROBLEM", 99, 119]]], ["This reduction was much more evident for ERAP1 and ERAP2 (and their mixture) than for IRAP.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 41, 46], ["ERAP2", "GENE_OR_GENE_PRODUCT", 51, 56], ["IRAP", "GENE_OR_GENE_PRODUCT", 86, 90], ["ERAP1", "PROTEIN", 41, 46], ["ERAP2", "PROTEIN", 51, 56], ["IRAP", "PROTEIN", 86, 90], ["This reduction", "TREATMENT", 0, 14], ["ERAP1 and ERAP2", "TREATMENT", 41, 56], ["IRAP", "PROBLEM", 86, 90]]], ["Each enzyme featured a unique digestion fingerprint, suggesting different selectivity, as suggested in previous studies (24) .", [["Each enzyme", "TEST", 0, 11], ["a unique digestion fingerprint", "PROBLEM", 21, 51], ["previous studies", "TEST", 103, 119], ["digestion fingerprint", "OBSERVATION", 30, 51], ["different selectivity", "OBSERVATION", 64, 85]]], ["Since the majority of peptides presented by HLA are 8-11 residues long, we analyzed the comparative abundance of 8-11mers generated from each reaction ( Figure 1C, D) .", [["HLA", "GENE_OR_GENE_PRODUCT", 44, 47], ["the comparative abundance", "TEST", 84, 109]]], ["Of the three enzymes, ERAP1 was the most efficient in generating peptides within this length range, consistent with previous reports on the mechanism of action of this enzyme (17, 25) .", [["ERAP1", "GENE_OR_GENE_PRODUCT", 22, 27], ["enzymes", "PROTEIN", 13, 20], ["ERAP1", "PROTEIN", 22, 27], ["the three enzymes", "TEST", 3, 20], ["ERAP1", "TEST", 22, 27], ["this enzyme", "TEST", 163, 174], ["consistent with", "UNCERTAINTY", 100, 115]]], ["ERAP2 and the ERAP1/ERAP2 mixture followed, while IRAP was the least efficient.", [["ERAP2", "GENE_OR_GENE_PRODUCT", 0, 5], ["ERAP1", "GENE_OR_GENE_PRODUCT", 14, 19], ["ERAP2", "GENE_OR_GENE_PRODUCT", 20, 25], ["IRAP", "GENE_OR_GENE_PRODUCT", 50, 54], ["ERAP2", "PROTEIN", 0, 5], ["ERAP1", "PROTEIN", 14, 19], ["ERAP2", "PROTEIN", 20, 25], ["IRAP", "PROTEIN", 50, 54], ["ERAP2", "TEST", 0, 5], ["the ERAP1/ERAP2 mixture", "TREATMENT", 10, 33]]], ["Similar to the trimming of 15mers, the generation of 8-11mers followed a unique fingerprint for each enzyme.", [["enzyme", "PROTEIN", 101, 107], ["each enzyme", "TEST", 96, 107]]], ["This is consistent with the previous hypotheses that each of these enzymes accommodate peptides in a large internal cavity and selectivity is driven by interactions with the whole sequence of the peptide (17, 21, 22) .", [["enzymes", "PROTEIN", 67, 74], ["these enzymes", "TEST", 61, 74], ["consistent with", "UNCERTAINTY", 8, 23], ["large", "OBSERVATION_MODIFIER", 101, 106], ["internal cavity", "ANATOMY", 107, 122], ["selectivity", "OBSERVATION_MODIFIER", 127, 138]]], ["Indeed, comparing the peptide sequences generated by each enzyme, out of 1184 peptides identified, 142 were common between all three enzymes, 244 between ERAP1 and ERAP2 and 220 between ERAP1 and IRAP ( Figure 2A) .", [["ERAP1", "GENE_OR_GENE_PRODUCT", 154, 159], ["ERAP2", "GENE_OR_GENE_PRODUCT", 164, 169], ["ERAP1", "GENE_OR_GENE_PRODUCT", 186, 191], ["IRAP", "GENE_OR_GENE_PRODUCT", 196, 200], ["enzyme", "PROTEIN", 58, 64], ["enzymes", "PROTEIN", 133, 140], ["ERAP1", "PROTEIN", 154, 159], ["ERAP2", "PROTEIN", 164, 169], ["ERAP1", "PROTEIN", 186, 191], ["IRAP", "PROTEIN", 196, 200], ["Figure 2A", "PROTEIN", 203, 212], ["the peptide sequences", "TEST", 18, 39], ["each enzyme", "TEST", 53, 64], ["ERAP1", "TEST", 154, 159], ["ERAP2", "TEST", 164, 169], ["ERAP1", "TEST", 186, 191], ["IRAP", "TEST", 196, 200]]], ["Furthermore, 169 peptides were unique for ERAP1, 234 for ERAP2 and 303 for IRAP.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 42, 47], ["ERAP2", "GENE_OR_GENE_PRODUCT", 57, 62], ["IRAP", "GENE_OR_GENE_PRODUCT", 75, 79], ["ERAP1", "PROTEIN", 42, 47], ["ERAP2", "PROTEIN", 57, 62], ["IRAP", "PROTEIN", 75, 79], ["ERAP1", "TEST", 42, 47], ["ERAP2", "TEST", 57, 62], ["IRAP", "TEST", 75, 79]]], ["A similar situation was evident for 8-11mer peptides ( Figure 2B) .", [["A similar situation", "PROBLEM", 0, 19]]], ["Strikingly, the mixture of ERAP1 with ERAP2 generated the fewest number of distinct sequences of 8-11mers ( Figure 2C ).", [["ERAP1", "GENE_OR_GENE_PRODUCT", 27, 32], ["ERAP2", "GENE_OR_GENE_PRODUCT", 38, 43], ["ERAP1", "PROTEIN", 27, 32], ["ERAP2", "PROTEIN", 38, 43], ["distinct sequences", "TEST", 75, 93], ["fewest", "OBSERVATION_MODIFIER", 58, 64]]], ["This was in contrast to the finding that the ERAP1/ERAP2 mixture generated about the same average signal intensity as ERAP2 ( Figure 1D ).", [["ERAP1", "GENE_OR_GENE_PRODUCT", 45, 50], ["ERAP2", "GENE_OR_GENE_PRODUCT", 51, 56], ["ERAP1", "PROTEIN", 45, 50], ["ERAP2", "PROTEIN", 51, 56], ["ERAP2", "PROTEIN", 118, 123], ["the ERAP1/ERAP2 mixture", "TREATMENT", 41, 64], ["intensity", "OBSERVATION_MODIFIER", 105, 114]]], ["This was due to ERAP1/ERAP2 mixture generating fewer, in terms of sequence, distinct peptides, which were however relatively abundant.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 16, 21], ["ERAP2", "GENE_OR_GENE_PRODUCT", 22, 27], ["ERAP1", "PROTEIN", 16, 21], ["ERAP2", "PROTEIN", 22, 27], ["ERAP1/ERAP2 mixture", "TREATMENT", 16, 35]]], ["This finding is consistent with the proposed synergism of ERAP1 and ERAP2 (26) and suggests that the combination of these two enzymes is more efficient in trimming variable sequences and can thus over-trim peptides to lengths below 7 residues that are not detectable in our experimental setup and should not be able to stably bind onto MHCI ( Figure 2C ).", [["ERAP1", "GENE_OR_GENE_PRODUCT", 58, 63], ["ERAP2 (26)", "GENE_OR_GENE_PRODUCT", 68, 78], ["MHCI", "GENE_OR_GENE_PRODUCT", 336, 340], ["ERAP1", "PROTEIN", 58, 63], ["ERAP2 (26)", "PROTEIN", 68, 78], ["enzymes", "PROTEIN", 126, 133], ["MHCI", "PROTEIN", 336, 340], ["Figure 2C", "PROTEIN", 343, 352], ["ERAP2", "TEST", 68, 73], ["these two enzymes", "TEST", 116, 133], ["consistent with", "UNCERTAINTY", 16, 31], ["synergism", "OBSERVATION", 45, 54]]], ["As a result, incubation with ERAP1/ERAP2 mixture, accumulates only peptides that are resistant to degradation by both enzymes.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 29, 34], ["ERAP2", "GENE_OR_GENE_PRODUCT", 35, 40], ["ERAP1", "PROTEIN", 29, 34], ["ERAP2", "PROTEIN", 35, 40], ["enzymes", "PROTEIN", 118, 125], ["ERAP1/ERAP2 mixture", "TREATMENT", 29, 48], ["both enzymes", "TEST", 113, 125]]], ["Since epitope length is a key parameter for binding onto MHCI (the majority of presented peptides are 9mers) we analyzed the distribution of lengths of peptides generated by each enzymatic reaction ( Figure 3 ).", [["MHCI", "GENE_OR_GENE_PRODUCT", 57, 61], ["MHCI", "PROTEIN", 57, 61], ["each enzymatic reaction", "PROBLEM", 174, 197]]], ["ERAP1 was very efficient in trimming the 15mer substrates and generated primarily 9mer peptides, consistent with its proposed property as a \"molecular ruler\" (25) .", [["ERAP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["ERAP1", "PROTEIN", 0, 5], ["15mer substrates", "PROTEIN", 41, 57], ["consistent with", "UNCERTAINTY", 97, 112]]], ["Neither ERAP2 nor IRAP were able to accumulate 9mers preferably, but still generated significant numbers.", [["ERAP2", "GENE_OR_GENE_PRODUCT", 8, 13], ["IRAP", "GENE_OR_GENE_PRODUCT", 18, 22], ["ERAP2", "PROTEIN", 8, 13], ["IRAP", "PROTEIN", 18, 22], ["IRAP", "PROBLEM", 18, 22]]], ["The mixture of ERAP1 and ERAP2 showed a similar fractional distribution of peptide lengths ( Figure 3B ), but produced a much lower number of distinct peptide sequences ( Figure 3A ), presumably due to over-trimming to smaller lengths or even single amino acids.", [["amino acids", "CHEMICAL", 250, 261], ["amino acids", "CHEMICAL", 250, 261], ["ERAP1", "GENE_OR_GENE_PRODUCT", 15, 20], ["ERAP2", "GENE_OR_GENE_PRODUCT", 25, 30], ["amino acids", "AMINO_ACID", 250, 261], ["ERAP1", "PROTEIN", 15, 20], ["ERAP2", "PROTEIN", 25, 30], ["ERAP1", "TEST", 15, 20], ["ERAP2", "TEST", 25, 30], ["a similar fractional distribution of peptide lengths", "PROBLEM", 38, 90], ["single amino acids", "TREATMENT", 243, 261], ["peptide lengths", "OBSERVATION", 75, 90]]], ["For each peptide we selected the best scoring HLA-allele and plotted the calculated percentile rank of the predicted score for each enzymatic reaction ( Figure 4A ).", [["HLA-allele", "DNA", 46, 56], ["each enzymatic reaction", "PROBLEM", 127, 150]]], ["The geometric mean of the predicted affinity was lowest for ERAP1 (indicating that the ERAP1 generated peptides had the highest average affinity for HLA), followed by IRAP and then ERAP2.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 60, 65], ["ERAP1", "GENE_OR_GENE_PRODUCT", 87, 92], ["HLA", "GENE_OR_GENE_PRODUCT", 149, 152], ["IRAP", "GENE_OR_GENE_PRODUCT", 167, 171], ["ERAP2", "GENE_OR_GENE_PRODUCT", 181, 186], ["ERAP1", "PROTEIN", 60, 65], ["ERAP1", "PROTEIN", 87, 92], ["HLA", "PROTEIN", 149, 152], ["IRAP", "PROTEIN", 167, 171], ["ERAP2", "PROTEIN", 181, 186], ["ERAP1", "PROBLEM", 60, 65], ["the ERAP1 generated peptides", "PROBLEM", 83, 111]]], ["Only a subset of generated peptides was predicted to bind with sufficient affinity onto at least one HLA: 23% for ERAP1, 22% for ERAP2, 6% for ERAP1/ERAP2 mixture and 21% for IRAP (peptide sequences are listed in Table 1a ).", [["ERAP1", "GENE_OR_GENE_PRODUCT", 114, 119], ["ERAP2", "GENE_OR_GENE_PRODUCT", 129, 134], ["ERAP1", "GENE_OR_GENE_PRODUCT", 143, 148], ["ERAP2", "GENE_OR_GENE_PRODUCT", 149, 154], ["IRAP", "GENE_OR_GENE_PRODUCT", 175, 179], ["ERAP1", "PROTEIN", 114, 119], ["ERAP2", "PROTEIN", 129, 134], ["ERAP1", "PROTEIN", 143, 148], ["ERAP2", "PROTEIN", 149, 154], ["IRAP", "PROTEIN", 175, 179], ["ERAP1", "TEST", 114, 119], ["ERAP2", "TEST", 129, 134], ["ERAP1/ERAP2 mixture", "TREATMENT", 143, 162], ["IRAP (peptide sequences", "TEST", 175, 198]]], ["These peptides spanned the whole sequence of the S1 spike glycoprotein, although each enzyme presented a unique signature onto this sequence ( Figure 4B ).Figure 4: Panel A, scatter plotshowing the predicted affinity of produced peptides for common HLA alleles as calculated by HLAthena.", [["S1 spike glycoprotein", "PROTEIN", 49, 70], ["HLA alleles", "DNA", 249, 260], ["These peptides", "TEST", 0, 14], ["the S1 spike glycoprotein", "PROBLEM", 45, 70], ["each enzyme", "TEST", 81, 92], ["this sequence", "TEST", 127, 140], ["common HLA alleles", "PROBLEM", 242, 260]]], ["Color region encompasses peptides that are predicted to bind to at least one of the common HLA alleles used in the analysis.", [["HLA alleles", "DNA", 91, 102], ["Color region encompasses peptides", "PROBLEM", 0, 33], ["the analysis", "TEST", 111, 123], ["peptides", "OBSERVATION", 25, 33], ["common HLA", "ANATOMY", 84, 94]]], ["Panel B, schematic representation of relative locations in the S1 protein sequence where the generated peptides are found.", [["S1 protein sequence", "DNA", 63, 82], ["the S1 protein sequence", "TEST", 59, 82]]], ["Panel C, Venn diagrams depicting overlap between peptides of S1 protein predicted to bind to common HLA alleles and peptides produced experimentally by ERAP1, ERAP2, IRAP or ERAP1/ERAP2 mixture.", [["S1", "GENE_OR_GENE_PRODUCT", 61, 63], ["ERAP1", "GENE_OR_GENE_PRODUCT", 152, 157], ["ERAP2", "GENE_OR_GENE_PRODUCT", 159, 164], ["IRAP", "GENE_OR_GENE_PRODUCT", 166, 170], ["ERAP1", "GENE_OR_GENE_PRODUCT", 174, 179], ["ERAP2", "GENE_OR_GENE_PRODUCT", 180, 185], ["S1 protein", "PROTEIN", 61, 71], ["HLA alleles", "DNA", 100, 111], ["ERAP1", "PROTEIN", 152, 157], ["ERAP2", "PROTEIN", 159, 164], ["IRAP", "PROTEIN", 166, 170], ["ERAP1", "PROTEIN", 174, 179], ["ERAP2", "PROTEIN", 180, 185], ["Panel C", "TEST", 0, 7], ["Venn diagrams", "TEST", 9, 22], ["S1 protein", "PROBLEM", 61, 71], ["common HLA alleles and peptides", "PROBLEM", 93, 124], ["ERAP1/ERAP2 mixture", "TREATMENT", 174, 193], ["common HLA", "ANATOMY", 93, 103]]], ["Numerals indicate number of peptides in each separate segment.Figure 4: Panel A, scatter plotIn a recent publication, the authors proposed that different HLA alleles can have significant variability in their ability to present SARS-CoV-2 epitopes, with HLA-B46:01 having the capability to present the fewest and HLA-B15:03 being able to present the most (29) .", [["SARS", "DISEASE", 227, 231], ["HLA", "GENE_OR_GENE_PRODUCT", 154, 157], ["HLA-B46:01", "GENE_OR_GENE_PRODUCT", 253, 263], ["HLA-B15:03", "GENE_OR_GENE_PRODUCT", 312, 322], ["HLA alleles", "DNA", 154, 165], ["SARS-CoV-2 epitopes", "PROTEIN", 227, 246], ["different HLA alleles", "PROBLEM", 144, 165], ["significant variability", "PROBLEM", 175, 198], ["HLA", "TEST", 253, 256], ["HLA", "TEST", 312, 315], ["number", "OBSERVATION_MODIFIER", 18, 24], ["peptides", "OBSERVATION", 28, 36], ["separate segment", "ANATOMY_MODIFIER", 45, 61]]], ["We thus used HLAthena to analyze the propensity of the experimentally produced peptides to bind onto these two alleles (Supplemental Table 2 ).", [["HLAthena", "TREATMENT", 13, 21]]], ["ERAP1 was found to produce 15 potential ligands for HLA-B15:03 but only 6 for HLA-B46:01, consistent with the proposed trend.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 0, 5], ["HLA-B15:03", "GENE_OR_GENE_PRODUCT", 52, 62], ["HLA-B46:01", "GENE_OR_GENE_PRODUCT", 78, 88], ["ERAP1", "PROTEIN", 0, 5], ["HLA", "TEST", 52, 55], ["HLA", "TEST", 78, 81], ["consistent with", "UNCERTAINTY", 90, 105]]], ["In contrast, ERAP2 produced 8 potential ligands for both alleles and IRAP produced 6 for HLA-B15:03 and 4 for HLA-B46:01.", [["ERAP2", "GENE_OR_GENE_PRODUCT", 13, 18], ["IRAP", "GENE_OR_GENE_PRODUCT", 69, 73], ["HLA-B15:03", "GENE_OR_GENE_PRODUCT", 89, 99], ["HLA-B46:01", "GENE_OR_GENE_PRODUCT", 110, 120], ["ERAP2", "PROTEIN", 13, 18], ["alleles", "DNA", 57, 64], ["IRAP", "PROTEIN", 69, 73], ["HLA-B46:01", "DNA", 110, 120], ["HLA", "TEST", 89, 92], ["HLA", "TEST", 110, 113]]], ["Strikingly, the mixture of ERAP1 with ERAP2 produced 4 peptides that could bind onto HLA-B15:03, but no peptides predicted to bind onto HLA-B46:01 (Table 1b) .", [["ERAP1", "GENE_OR_GENE_PRODUCT", 27, 32], ["ERAP2", "GENE_OR_GENE_PRODUCT", 38, 43], ["HLA-B15:03", "GENE_OR_GENE_PRODUCT", 85, 95], ["HLA-B46:01", "GENE_OR_GENE_PRODUCT", 136, 146], ["Table 1b", "GENE_OR_GENE_PRODUCT", 148, 156], ["ERAP1", "PROTEIN", 27, 32], ["ERAP2", "PROTEIN", 38, 43], ["HLA", "PROTEIN", 85, 88], ["B15:03", "PROTEIN", 89, 95], ["HLA", "PROTEIN", 136, 139], ["B46:01", "PROTEIN", 140, 146], ["HLA", "TEST", 85, 88], ["HLA", "TEST", 136, 139]]], ["Thus, our findings appear to validate the hypothesis that HLA-B15:03 is likely to present more SARS-CoV-2 epitopes than HLA-B46:01, but only for ERAP1, which however is considered the dominant aminopeptidase activity in the cell for generating antigenic peptides.Figure 4: Panel A, scatter plotBioinformatic epitope predictions based on antigen sequence are often used as a tool to study the potential antigenicity of a particular epitope or pathogen.", [["cell", "ANATOMY", 224, 228], ["HLA-B15:03", "GENE_OR_GENE_PRODUCT", 58, 68], ["HLA-B46:01", "GENE_OR_GENE_PRODUCT", 120, 130], ["ERAP1", "GENE_OR_GENE_PRODUCT", 145, 150], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 193, 207], ["cell", "CELL", 224, 228], ["HLA-B15:03", "PROTEIN", 58, 68], ["SARS-CoV-2 epitopes", "PROTEIN", 95, 114], ["HLA", "PROTEIN", 120, 123], ["B46:01", "PROTEIN", 124, 130], ["ERAP1", "PROTEIN", 145, 150], ["aminopeptidase", "PROTEIN", 193, 207], ["HLA", "TEST", 58, 61], ["CoV", "TEST", 100, 103], ["HLA", "TEST", 120, 123], ["ERAP1", "TEST", 145, 150], ["generating antigenic peptides", "TREATMENT", 233, 262], ["scatter plotBioinformatic epitope predictions", "PROBLEM", 282, 327], ["antigen sequence", "TEST", 337, 353], ["pathogen", "PROBLEM", 442, 450], ["likely to", "UNCERTAINTY", 72, 81], ["dominant", "OBSERVATION_MODIFIER", 184, 192], ["aminopeptidase activity", "OBSERVATION", 193, 216], ["pathogen", "OBSERVATION", 442, 450]]], ["The power of those predictions is constantly evolving and primarily relies on predictions of binding affinity on HLA.", [["HLA", "GENE_OR_GENE_PRODUCT", 113, 116], ["power", "OBSERVATION_MODIFIER", 4, 9]]], ["To compare such predictions to our experimentally generated peptides, we used the full sequence of the S1 spike glycoprotein and the NetMHCpan 4.1 server (30) to predict potential epitopes that could be presented by the common HLA alleles indicated in the previous paragraph.", [["S1 spike glycoprotein", "PROTEIN", 103, 124], ["NetMHCpan", "PROTEIN", 133, 142], ["HLA alleles", "DNA", 227, 238], ["potential epitopes", "PROBLEM", 170, 188]]], ["Of those potential epitopes however, less than 7% were found to be produced experimentally by one of the enzymes tested and more specifically 58 by ERAP1, 52 by ERAP2, 4 for the ERAP1/2 mixture and 53 by IRAP ( Figure 4C ).", [["ERAP1", "GENE_OR_GENE_PRODUCT", 148, 153], ["ERAP2", "GENE_OR_GENE_PRODUCT", 161, 166], ["ERAP1", "GENE_OR_GENE_PRODUCT", 178, 183], ["epitopes", "PROTEIN", 19, 27], ["enzymes", "PROTEIN", 105, 112], ["ERAP1", "PROTEIN", 148, 153], ["ERAP2", "PROTEIN", 161, 166], ["ERAP1", "PROTEIN", 178, 183], ["IRAP", "PROTEIN", 204, 208], ["the enzymes", "TEST", 101, 112], ["ERAP1", "TEST", 148, 153], ["ERAP2", "TEST", 161, 166], ["the ERAP1/2 mixture", "TEST", 174, 193], ["IRAP", "TEST", 204, 208]]], ["While our experimental approach has limitations as discussed below, this finding suggests that intracellular antigen processing by aminopeptidases may constitute a major filter in determining which peptides will be presented by MHCI.", [["intracellular", "ANATOMY", 95, 108], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["antigen", "GENE_OR_GENE_PRODUCT", 109, 116], ["aminopeptidases", "GENE_OR_GENE_PRODUCT", 131, 146], ["MHCI", "GENE_OR_GENE_PRODUCT", 228, 232], ["aminopeptidases", "PROTEIN", 131, 146], ["MHCI", "PROTEIN", 228, 232], ["intracellular antigen processing", "PROBLEM", 95, 127], ["a major filter", "TREATMENT", 162, 176], ["filter", "OBSERVATION", 170, 176]]], ["Indeed, it has been recently proposed that the main function of ERAP1 is to limit the peptide pool available for MHCI (31) .", [["ERAP1", "GENE_OR_GENE_PRODUCT", 64, 69], ["MHCI", "GENE_OR_GENE_PRODUCT", 113, 117], ["ERAP1", "PROTEIN", 64, 69], ["MHCI", "PROTEIN", 113, 117]]], ["In this context, this experimental approach could be useful in optimizing bioinformatic predictions.Figure 4: Panel A, scatter plotOur findings provide new information on both the general biological functions of intracellular aminopeptidases that generate antigenic peptides as well as on specific processing of a key antigen from SARS-CoV-2.", [["intracellular", "ANATOMY", 212, 225], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 212, 225], ["SARS-CoV-2", "ORGANISM", 331, 341], ["intracellular aminopeptidases", "PROTEIN", 212, 241], ["SARS-CoV", "SPECIES", 331, 339], ["this experimental approach", "TREATMENT", 17, 43], ["scatter plot", "TEST", 119, 131], ["intracellular aminopeptidases", "TREATMENT", 212, 241], ["antigenic peptides", "TREATMENT", 256, 274], ["CoV", "TEST", 336, 339]]], ["Specifically, our results highlight that each enzyme bears a unique trimming fingerprint to antigen processing.", [["antigen", "GENE_OR_GENE_PRODUCT", 92, 99], ["enzyme", "PROTEIN", 46, 52], ["each enzyme", "TEST", 41, 52]]], ["Although this has been suggested before based on differences in specificity towards specific peptide substrates (26, (32) (33) (34) , it has not been observed in the context of peptide ensembles.", [["specific peptide substrates", "TEST", 84, 111]]], ["This is potentially important since competition of different peptides for the cavity in these enzymes could result in complex substrate interactions.", [["enzymes", "PROTEIN", 94, 101], ["different peptides", "TREATMENT", 51, 69], ["these enzymes", "TEST", 88, 101], ["cavity", "OBSERVATION", 78, 84], ["complex", "OBSERVATION_MODIFIER", 118, 125], ["substrate interactions", "OBSERVATION", 126, 148]]], ["At first glance, major differences in trimming fingerprints between each or the three enzymes, may appear to impose an unnecessary complication to antigenic peptide generation.", [["enzymes", "PROTEIN", 86, 93], ["an unnecessary complication", "PROBLEM", 116, 143], ["antigenic peptide generation", "TREATMENT", 147, 175]]], ["It is conceivable, however, that this trimming variability is desirable for the immune system, since it can expand the breadth of possible antigenic peptides detected in different immunological settings and cell types.", [["immune system", "ANATOMY", 80, 93], ["cell", "ANATOMY", 207, 211], ["cell", "CELL", 207, 211], ["this trimming variability", "PROBLEM", 33, 58], ["antigenic peptides", "PROBLEM", 139, 157], ["possible", "UNCERTAINTY", 130, 138], ["antigenic peptides", "OBSERVATION", 139, 157], ["cell types", "OBSERVATION", 207, 217]]], ["Our results also highlight a previously proposed property of ERAP1: the specialization in trimming large peptides and producing peptides that have the ideal length for MHCI binding -most of the ERAP1 products fall well within that range (25) .", [["ERAP1", "GENE_OR_GENE_PRODUCT", 61, 66], ["MHCI", "GENE_OR_GENE_PRODUCT", 168, 172], ["ERAP1", "GENE_OR_GENE_PRODUCT", 194, 199], ["ERAP1", "PROTEIN", 61, 66], ["MHCI", "PROTEIN", 168, 172], ["ERAP1 products", "PROTEIN", 194, 208], ["the specialization in trimming large peptides", "TREATMENT", 68, 113], ["MHCI binding", "PROBLEM", 168, 180]]], ["In contrast, both ERAP2 and IRAP appear to be less optimized for length selection.", [["ERAP2", "GENE_OR_GENE_PRODUCT", 18, 23], ["IRAP", "GENE_OR_GENE_PRODUCT", 28, 32], ["ERAP2", "PROTEIN", 18, 23], ["IRAP", "PROTEIN", 28, 32], ["length selection", "TREATMENT", 65, 81]]], ["However, they are still able to produce many peptides that are potential cargo for MHCI, casting some doubt on whether the unique trimming properties of ERAP1 are absolutely necessary for this basic function.", [["MHCI", "GENE_OR_GENE_PRODUCT", 83, 87], ["ERAP1", "GENE_OR_GENE_PRODUCT", 153, 158], ["MHCI", "PROTEIN", 83, 87], ["ERAP1", "PROTEIN", 153, 158], ["this basic function", "TEST", 188, 207]]], ["Furthermore, the combination of ERAP1 with ERAP2 appears to provide significant synergism in trimming, to the point of over-trimming peptides and limiting available sequences.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 32, 37], ["ERAP2", "GENE_OR_GENE_PRODUCT", 43, 48], ["ERAP1", "PROTEIN", 32, 37], ["ERAP2", "PROTEIN", 43, 48], ["ERAP1 with ERAP2", "TREATMENT", 32, 48], ["significant synergism in trimming", "PROBLEM", 68, 101], ["significant", "OBSERVATION_MODIFIER", 68, 79], ["synergism", "OBSERVATION", 80, 89]]], ["Synergism between ERAP1 and ERAP2 has been demonstrated before in trimming isolated peptides and these two enzymes have been proposed to also form functional dimers (33, 35) .", [["ERAP1", "GENE_OR_GENE_PRODUCT", 18, 23], ["ERAP2", "GENE_OR_GENE_PRODUCT", 28, 33], ["ERAP1", "PROTEIN", 18, 23], ["ERAP2", "PROTEIN", 28, 33], ["enzymes", "PROTEIN", 107, 114], ["Synergism between ERAP1", "TREATMENT", 0, 23], ["ERAP2", "TREATMENT", 28, 33], ["these two enzymes", "TEST", 97, 114]]], ["While the biological repercussions of this are not fully clear yet, it is conceivable that the strong associations between ERAP2 activity and predisposition to autoimmunity may be related to this effect (36) .Figure 4: Panel A, scatter plotDespite the current importance in understanding immune reactions in COVID- 19, very little is known about the cellular adaptive immune responses against SARS-CoV-2.", [["cellular", "ANATOMY", 350, 358], ["autoimmunity", "DISEASE", 160, 172], ["ERAP2", "GENE_OR_GENE_PRODUCT", 123, 128], ["COVID- 19", "CELL", 308, 317], ["cellular", "CELL", 350, 358], ["SARS-CoV-2", "ORGANISM", 393, 403], ["ERAP2", "PROTEIN", 123, 128], ["SARS-CoV", "SPECIES", 393, 401], ["autoimmunity", "PROBLEM", 160, 172], ["immune reactions", "PROBLEM", 288, 304], ["COVID", "TEST", 308, 313], ["SARS", "PROBLEM", 393, 397]]], ["Cellular immune responses are emerging as a central player in clearing the infection and as targets for vaccine efforts (37, 38) .", [["Cellular", "ANATOMY", 0, 8], ["infection", "DISEASE", 75, 84], ["the infection", "PROBLEM", 71, 84], ["vaccine efforts", "TREATMENT", 104, 119], ["infection", "OBSERVATION", 75, 84]]], ["Furthermore, HLA polymorphic variation has been suggested to underlie the large variability in virus clearance that has been observed amongst individuals (39) .", [["HLA", "GENE_OR_GENE_PRODUCT", 13, 16], ["HLA polymorphic variation", "PROBLEM", 13, 38], ["the large variability in virus clearance", "PROBLEM", 70, 110], ["large", "OBSERVATION_MODIFIER", 74, 79], ["variability", "OBSERVATION_MODIFIER", 80, 91], ["virus clearance", "OBSERVATION", 95, 110]]], ["Our analysis of the largest antigen of SARS-CoV-2, S1 spike glycoprotein, suggests that aminopeptidase trimming can be a significant filter that helps shape which peptides will be presented by HLA.", [["SARS-CoV-2", "ORGANISM", 39, 49], ["S1 spike glycoprotein", "GENE_OR_GENE_PRODUCT", 51, 72], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 88, 102], ["HLA", "GENE_OR_GENE_PRODUCT", 193, 196], ["SARS-CoV-2, S1 spike glycoprotein", "PROTEIN", 39, 72], ["aminopeptidase", "PROTEIN", 88, 102], ["SARS-CoV", "SPECIES", 39, 47], ["Our analysis", "TEST", 0, 12], ["SARS", "TEST", 39, 43], ["CoV", "TEST", 44, 47], ["S1 spike glycoprotein", "TREATMENT", 51, 72], ["aminopeptidase trimming", "TREATMENT", 88, 111], ["a significant filter", "TREATMENT", 119, 139], ["largest", "OBSERVATION_MODIFIER", 20, 27], ["significant", "OBSERVATION_MODIFIER", 121, 132], ["filter", "OBSERVATION", 133, 139]]], ["Thus, we propose a short list of candidate peptides that could be prioritized in downstream antigenic analysis as well as in vaccine design and efficacy studies.Figure 4: Panel A, scatter plotWhile the functions of ERAP1, ERAP2 and IRAP have been studied in both in vitro and in vivo contexts during the last decade, their relative functional differences have only been compared in processing specific substrates at a time.", [["ERAP1", "GENE_OR_GENE_PRODUCT", 215, 220], ["ERAP2", "GENE_OR_GENE_PRODUCT", 222, 227], ["IRAP", "GENE_OR_GENE_PRODUCT", 232, 236], ["ERAP1", "PROTEIN", 215, 220], ["ERAP2", "PROTEIN", 222, 227], ["IRAP", "PROTEIN", 232, 236], ["candidate peptides", "TREATMENT", 33, 51], ["downstream antigenic analysis", "TEST", 81, 110], ["efficacy studies", "TEST", 144, 160], ["ERAP1", "TEST", 215, 220], ["ERAP2", "TEST", 222, 227], ["IRAP", "TEST", 232, 236]]], ["However, all these enzymes have a broad substrate specificity and can normally encounter thousands of different peptides in the ER or endosomal compartments.", [["ER", "ANATOMY", 128, 130], ["endosomal compartments", "ANATOMY", 134, 156], ["ER", "GENE_OR_GENE_PRODUCT", 128, 130], ["endosomal compartments", "CELLULAR_COMPONENT", 134, 156], ["enzymes", "PROTEIN", 19, 26], ["ER", "PROTEIN", 128, 130], ["all these enzymes", "TEST", 9, 26], ["different", "OBSERVATION_MODIFIER", 102, 111], ["peptides", "OBSERVATION", 112, 120], ["endosomal compartments", "OBSERVATION", 134, 156]]], ["On the other hand, studies focusing on the presented immunopeptidome have revealed effects attributed to ERAP1 and ERAP2 trimming, but direct comparisons have been difficult because of the dominant effect of MHCI affinity on presentation (40).", [["ERAP1", "GENE_OR_GENE_PRODUCT", 105, 110], ["ERAP2", "GENE_OR_GENE_PRODUCT", 115, 120], ["MHCI", "GENE_OR_GENE_PRODUCT", 208, 212], ["ERAP1", "PROTEIN", 105, 110], ["ERAP2", "PROTEIN", 115, 120], ["MHCI", "PROTEIN", 208, 212], ["studies", "TEST", 19, 26], ["ERAP1 and ERAP2 trimming", "TREATMENT", 105, 129], ["MHCI affinity", "PROBLEM", 208, 221], ["dominant", "OBSERVATION_MODIFIER", 189, 197], ["MHCI affinity", "OBSERVATION", 208, 221]]], ["Our approach stands in-between these two types of studies.", [["studies", "TEST", 50, 57]]], ["It mimics the multiple-substrate situation that is likely normal in vivo but focuses on antigenic peptide precursor trimming.", [["antigenic peptide precursor trimming", "TREATMENT", 88, 124], ["multiple", "OBSERVATION_MODIFIER", 14, 22], ["likely", "UNCERTAINTY", 51, 57], ["normal", "OBSERVATION", 58, 64]]], ["In this context, our approach may have broader application for the quick prediction of potential antigenic epitopes as an additional filter on bioinformatic predictions.Figure 4: Panel A, scatter plotIndeed, bioinformatic predictions result in many candidate peptides, very few of which will provoke an immune response; adding more filters can increase the usefulness of these rapid approaches.", [["antigenic epitopes", "PROTEIN", 97, 115], ["potential antigenic epitopes", "PROBLEM", 87, 115], ["an additional filter", "TREATMENT", 119, 139], ["bioinformatic predictions", "TEST", 208, 233], ["more filters", "TREATMENT", 327, 339], ["these rapid approaches", "TREATMENT", 371, 393]]], ["Due to differences in ionization and detection by the LC-MS/MS some peptides may not be detected or may be under-represented compared to other sequences, making comparisons between different peptides less reliable.", [["ionization", "TEST", 22, 32], ["detection", "TEST", 37, 46], ["the LC", "TEST", 50, 56], ["MS some peptides", "PROBLEM", 60, 76]]], ["Furthermore, it is an in vitro approach that is limited to the peptide pool used and cannot take into account the dynamics of MHCI binding that can protect peptides from further aminopeptidase degradation (41) or peptide proofreading by chaperone components or the peptide loading complex (42) .", [["MHCI", "GENE_OR_GENE_PRODUCT", 126, 130], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 178, 192], ["MHCI", "PROTEIN", 126, 130], ["aminopeptidase", "PROTEIN", 178, 192], ["chaperone components", "PROTEIN", 237, 257], ["peptide loading complex", "PROTEIN", 265, 288], ["further aminopeptidase degradation", "PROBLEM", 170, 204], ["the peptide loading complex", "PROBLEM", 261, 288]]], ["Due to those limitations, we restricted our analysis to statistical comparisons and avoided drawing conclusions regarding particular peptide sequences.Figure 4: Panel A, scatter plotIn summary, we analyzed the trimming of a peptide ensemble spanning the sequence of the S1 spike glycoprotein of SARS-CoV-2, the pathogen responsible for the recent COVID-19 pandemic.", [["SARS-CoV-2", "ORGANISM", 295, 305], ["S1 spike glycoprotein", "PROTEIN", 270, 291], ["SARS-CoV", "SPECIES", 295, 303], ["our analysis", "TEST", 40, 52], ["particular peptide sequences", "TEST", 122, 150], ["SARS", "PROBLEM", 295, 299], ["CoV", "TEST", 300, 303], ["the pathogen", "PROBLEM", 307, 319], ["the recent COVID", "TEST", 336, 352], ["pandemic", "PROBLEM", 356, 364]]], ["Our analysis provided novel insight into the function of antigen trimming enzymes and suggested that aminopeptidase trimming may be a significant filter in determining which peptides can be presented by MHCI.", [["antigen trimming enzymes", "GENE_OR_GENE_PRODUCT", 57, 81], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 101, 115], ["MHCI", "GENE_OR_GENE_PRODUCT", 203, 207], ["antigen trimming enzymes", "PROTEIN", 57, 81], ["aminopeptidase", "PROTEIN", 101, 115], ["MHCI", "PROTEIN", 203, 207], ["Our analysis", "TEST", 0, 12], ["antigen trimming enzymes", "TEST", 57, 81], ["aminopeptidase trimming", "TREATMENT", 101, 124], ["a significant filter", "TREATMENT", 132, 152], ["significant", "OBSERVATION_MODIFIER", 134, 145], ["filter", "OBSERVATION", 146, 152]]], ["Furthermore, we have identified a limited set of peptides that were experimentally produced by elongated precursors which could be prioritized in future studies aiming to investigate the antigenicity of SARS-CoV-2 infected cells and assist in the design of highly effective vaccines that aim to produce adaptive cytotoxic responses.", [["cells", "ANATOMY", 223, 228], ["SARS", "DISEASE", 203, 207], ["SARS-CoV-2", "ORGANISM", 203, 213], ["cells", "CELL", 223, 228], ["SARS-CoV-2 infected cells", "CELL_LINE", 203, 228], ["SARS-CoV", "SPECIES", 203, 211], ["a limited set of peptides", "PROBLEM", 32, 57], ["elongated precursors", "PROBLEM", 95, 115], ["future studies", "TEST", 146, 160], ["SARS", "PROBLEM", 203, 207], ["CoV", "TEST", 208, 211], ["2 infected cells", "PROBLEM", 212, 228], ["highly effective vaccines", "TREATMENT", 257, 282], ["elongated", "OBSERVATION_MODIFIER", 95, 104]]], ["We propose that our experimental approach may also be useful as a general tool for enhancing bioinformatic predictions of antigenic epitopes.", [["antigenic epitopes", "PROTEIN", 122, 140], ["our experimental approach", "TREATMENT", 16, 41], ["antigenic epitopes", "PROBLEM", 122, 140]]]], "PMC6346470": [["History of Biological StandardizationThe concept of biological standardization and the use of biological reference materials has existed since the turn of the 20th century after simultaneous discovery of diphtheria antitoxin by von Behring and Roux (3,4).", [["diphtheria antitoxin", "GENE_OR_GENE_PRODUCT", 204, 224], ["diphtheria antitoxin", "PROTEIN", 204, 224], ["Biological Standardization", "TEST", 11, 37], ["biological standardization", "TEST", 52, 78], ["diphtheria antitoxin", "TREATMENT", 204, 224], ["Roux", "ANATOMY", 244, 248]]], ["Attempts to recreate production of antitoxin in horses were successful in France, but yielded an ineffective product in England.", [["horses", "ORGANISM", 48, 54], ["antitoxin", "PROTEIN", 35, 44], ["antitoxin", "TREATMENT", 35, 44], ["ineffective", "OBSERVATION", 97, 108]]], ["This failure was attributed to weak serum and led Ehrlich to propose use of a standard antitoxin preparation, measured in units, with which to calibrate future batches and ensure potency (5).", [["serum", "ANATOMY", 36, 41], ["Ehrlich", "ANATOMY", 50, 57], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["Ehrlich", "CANCER", 50, 57], ["This failure", "PROBLEM", 0, 12], ["weak serum", "PROBLEM", 31, 41], ["a standard antitoxin preparation", "TREATMENT", 76, 108], ["failure", "OBSERVATION", 5, 12]]], ["This concept was applied by Dale in the 1920s to other biological products, such as insulin, but the need for international oversight was recognized (6).History of Biological StandardizationIn the 1920s, the League of Nations initiated the provision of IRPs under the Commission on Biological Standardization, and biological standardization was subsequently incorporated into the constitution of the World Health Organization (WHO) upon its creation in 1946 (7).", [["insulin", "GENE_OR_GENE_PRODUCT", 84, 91], ["insulin", "PROTEIN", 84, 91], ["biological products", "TREATMENT", 55, 74], ["insulin", "TREATMENT", 84, 91], ["Biological Standardization", "TEST", 282, 308]]], ["The Expert Committee on Biological Standardization meets annually to establish detailed recommendations and guidelines for manufacturing, licensing, and control of complex biological materials, including blood products, vaccines, and related in vitro diagnostic tests, and to maintain a catalog of IRPs to be distributed globally as required.", [["blood", "ANATOMY", 204, 209], ["blood", "ORGANISM_SUBSTANCE", 204, 209], ["IRPs", "GENE_OR_GENE_PRODUCT", 298, 302], ["IRPs", "PROTEIN", 298, 302], ["manufacturing", "TREATMENT", 123, 136], ["blood products", "TREATMENT", 204, 218], ["vaccines", "TREATMENT", 220, 228], ["vitro diagnostic tests", "TEST", 245, 267]]], ["These WHO IRPs, composed of international reference standards and other reference materials (Table 1), provide a common set of reagents that are used to ensure the quality of biological assays and medicines globally.", [["reagents", "TREATMENT", 127, 135], ["biological assays", "TEST", 175, 192], ["medicines", "TREATMENT", 197, 206]]], ["These IRPs are considered to be the standard against which regional, national, and international laboratories and manufacturers should calibrate their own working standards.", [["IRPs", "GENE_OR_GENE_PRODUCT", 6, 10], ["international laboratories", "TEST", 83, 109]]], ["Reference materials only become WHO-endorsed IRPs after extensive collaborative studies involving multiple laboratories internationally.", [["extensive collaborative studies", "TEST", 56, 87]]], ["This process enables materials to be ascribed defined units of biological activity, most commonly international units.History of Biological StandardizationAlthough several hundred centers contribute to WHO collaborative studies, only 3 centers produce and hold IRPs.", [["IRPs", "GENE_OR_GENE_PRODUCT", 261, 265], ["biological activity", "TREATMENT", 63, 82], ["collaborative studies", "TEST", 206, 227]]], ["These centers are the National Institute for Biological Standards and Control in England, the Center for Biologics Evaluation and Research in the United States, and the Paul-Ehrlich Institute in Germany.", [["Biological Standards", "TREATMENT", 45, 65], ["Biologics Evaluation", "TEST", 105, 125]]], ["The role of these institutions is to produce, store, and distribute IRPs and differs from those that distribute repository materials, such as the US Centers for Disease Control and Prevention, the International Reagent Resource, and the National Institute of Allergy and Infectious Diseases Biodefense and Emerging Infections research resources repository.Utility of IRPs for WHO Research and Development Blueprint DiseasesIn the aftermath of the 2014 West Africa Ebola virus disease (EVD) outbreak, there has been considerable focus on expediting research and development to ensure we are better prepared for future disease outbreaks.", [["Infectious Diseases Biodefense", "DISEASE", 271, 301], ["Infections", "DISEASE", 315, 325], ["Ebola virus disease", "DISEASE", 464, 483], ["EVD", "DISEASE", 485, 488], ["West Africa Ebola virus", "ORGANISM", 452, 475], ["Ebola virus disease", "SPECIES", 464, 483], ["West Africa Ebola virus", "SPECIES", 452, 475], ["Disease Control", "TREATMENT", 161, 176], ["Africa Ebola virus disease (EVD) outbreak", "PROBLEM", 457, 498], ["future disease outbreaks", "PROBLEM", 610, 634], ["Infectious", "OBSERVATION_MODIFIER", 271, 281], ["Diseases", "OBSERVATION", 415, 423], ["considerable", "OBSERVATION_MODIFIER", 515, 527], ["focus", "OBSERVATION_MODIFIER", 528, 533]]], ["In 2015, WHO launched the Research and Development Blueprint for Action to Prevent Epidemics, a global strategy and preparedness plan that seeks to build upon the successes and address the gaps identified during the 2014 EVD outbreak by focusing on severe, emerging diseases with the potential to create a public health emergency and for which inadequate treatment and preventive options are currently available (8,9).", [["Epidemics", "PROBLEM", 83, 92], ["a global strategy", "TREATMENT", 94, 111], ["the gaps", "PROBLEM", 185, 193], ["emerging diseases", "PROBLEM", 257, 274], ["inadequate treatment", "TREATMENT", 344, 364], ["preventive options", "TREATMENT", 369, 387]]], ["Furthermore, the second cluster, which focused on accelerating research and development processes, is subdivided into 3 distinct areas of work: 1) assessing epidemic threats and defining priority pathogens; 2) developing research and development roadmaps to accelerate evaluation of diagnostics, therapeutics, and vaccines; and 3) outlining appropriate regulatory and ethical pathways.Utility of IRPs for WHO Research and Development Blueprint DiseasesCentral to the research and development blueprint is a list of priority diseases, first published in November 2015, with subsequent revision through a tailored prioritization method in 2017 and 2018 (Table 2) (10,11).", [["accelerate evaluation", "TEST", 258, 279], ["diagnostics", "TEST", 283, 294], ["therapeutics", "TREATMENT", 296, 308], ["vaccines", "TREATMENT", 314, 322], ["subsequent revision", "TREATMENT", 573, 592], ["Diseases", "OBSERVATION", 444, 452], ["revision", "OBSERVATION", 584, 592]]], ["For each priority disease on the list, a research and development roadmap is to be produced that encompasses diagnostics, vaccines, and therapeutics.", [["vaccines", "TREATMENT", 122, 130], ["therapeutics", "TREATMENT", 136, 148]]], ["The first research and development roadmap to have been developed and published is for Middle East respiratory syndrome coronavirus (MERS-CoV) (12), which serves to inform the roadmap generation process for other diseases on the priority pathogen list.", [["respiratory syndrome coronavirus", "DISEASE", 99, 131], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 87, 131], ["MERS-CoV", "ORGANISM", 133, 141], ["Middle East respiratory syndrome coronavirus", "SPECIES", 87, 131], ["MERS-CoV", "SPECIES", 133, 141], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 87, 131], ["other diseases", "PROBLEM", 207, 221], ["respiratory syndrome", "OBSERVATION", 99, 119]]], ["Within the MERS-CoV roadmap, development of reference reagents has been identified as a priority, but the major operational and ethical issues associated with sourcing and obtaining bulk starting material for such reagents have not been discussed.", [["MERS-CoV", "SPECIES", 11, 19], ["bulk starting material", "TREATMENT", 182, 204], ["such reagents", "TREATMENT", 209, 222]]], ["An allied initiative is the Coalition for Epidemic Preparedness and Innovation (CEPI), whose aim is to accelerate development of vaccines for high-threat pathogens (13).", [["high-threat pathogens", "DISEASE", 142, 163], ["Innovation (CEPI)", "TREATMENT", 68, 85], ["vaccines", "TREATMENT", 129, 137], ["high-threat pathogens", "PROBLEM", 142, 163]]], ["The necessity for reference materials in development and evaluation of new diagnostics, vaccines, and biotherapeutics has been recognized by CEPI by the formation of a Working Group on Standards and Assays, but they are not explicitly considered in the WHO research and development blueprint.Utility of IRPs for WHO Research and Development Blueprint DiseasesBefore the 2014 EVD epidemic, no IRPs existed for any diseases on the research and development bueprint.", [["evaluation", "TEST", 57, 67], ["new diagnostics", "TEST", 71, 86], ["vaccines", "TREATMENT", 88, 96], ["biotherapeutics", "TREATMENT", 102, 117], ["Assays", "TEST", 199, 205], ["EVD epidemic", "PROBLEM", 375, 387], ["IRPs", "PROBLEM", 392, 396], ["any diseases", "PROBLEM", 409, 421], ["diseases", "OBSERVATION", 413, 421]]], ["Expedited development led to production of an interim Ebola antibody reference reagent in October 2015, and the first international standard was endorsed in October 2017 (14,15).", [["Ebola", "DISEASE", 54, 59], ["Ebola", "ORGANISM", 54, 59]]], ["Although this accelerated production represents an impressive collaborative feat, the lack of availability of PCR, antigen, and antibody IRPs at the start of this EVD outbreak, and for subsequent outbreaks of infection with MERS-CoV and Zika virus, likely hampered development of accurate diagnostics and vaccines (16).", [["infection", "DISEASE", 209, 218], ["antibody IRPs", "GENE_OR_GENE_PRODUCT", 128, 141], ["MERS-CoV", "ORGANISM", 224, 232], ["Zika virus", "ORGANISM", 237, 247], ["antibody IRPs", "PROTEIN", 128, 141], ["MERS-CoV", "SPECIES", 224, 232], ["Zika virus", "SPECIES", 237, 247], ["this accelerated production", "PROBLEM", 9, 36], ["PCR", "TEST", 110, 113], ["antigen", "TEST", 115, 122], ["antibody IRPs", "PROBLEM", 128, 141], ["this EVD outbreak", "TREATMENT", 158, 175], ["infection", "PROBLEM", 209, 218], ["MERS", "PROBLEM", 224, 228], ["CoV", "PROBLEM", 229, 232], ["Zika virus", "PROBLEM", 237, 247], ["vaccines", "TREATMENT", 305, 313], ["impressive", "OBSERVATION_MODIFIER", 51, 61], ["infection", "OBSERVATION", 209, 218]]], ["In addition, the exceptional circumstances and unprecedented duration of the 2014 EVD epidemic enabled a major proportion of IRP development to occur while the outbreak was ongoing.Utility of IRPs for WHO Research and Development Blueprint DiseasesDevelopment of IRPs from sample acquisition to WHO endorsement usually takes 2\u20133 years, which is considerably longer than most outbreaks of diseases on the research and development blueprint.", [["diseases", "PROBLEM", 388, 396], ["diseases", "OBSERVATION", 388, 396]]], ["The availability of IRPs for often rare and sporadic diseases with epidemic potential before, or soon after, occurrence of outbreaks would facilitate diagnostics and research activities, such as seroepidemiologic studies and immunogenicity assessment of experimental vaccines.", [["sporadic diseases", "PROBLEM", 44, 61], ["seroepidemiologic studies", "TEST", 195, 220], ["immunogenicity assessment", "TEST", 225, 250], ["experimental vaccines", "TREATMENT", 254, 275]]], ["At the present time, with the exception of Zaire Ebolavirus antibody, antigen, and nucleic acid IRPs and a WHO-endorsed Zika virus RNA and antibody standards, no IRPs exist for any other disease on the research and development blueprint.", [["nucleic acid", "CHEMICAL", 83, 95], ["antigen", "GENE_OR_GENE_PRODUCT", 70, 77], ["Zika virus", "ORGANISM", 120, 130], ["Zaire Ebolavirus antibody", "PROTEIN", 43, 68], ["nucleic acid IRPs", "PROTEIN", 83, 100], ["Zika virus RNA", "RNA", 120, 134], ["IRPs", "PROTEIN", 162, 166], ["Zaire Ebolavirus", "SPECIES", 43, 59], ["Zika virus", "SPECIES", 120, 130], ["Zaire Ebolavirus antibody", "PROBLEM", 43, 68], ["antigen", "TEST", 70, 77], ["nucleic acid IRPs", "PROBLEM", 83, 100], ["Zika virus RNA", "PROBLEM", 120, 134], ["antibody standards", "TEST", 139, 157], ["any other disease", "PROBLEM", 177, 194], ["Ebolavirus", "OBSERVATION", 49, 59], ["disease", "OBSERVATION", 187, 194]]], ["The availability of IRPs for these diseases would facilitate development of essential tools in epidemic preparedness, including diagnostics, vaccines, and therapeutics.DiagnosticsAccurate and accessible diagnostic tools are vital in limiting the public health effect of disease outbreaks, in addition to providing reliable data for clinical and epidemiologic studies.", [["IRPs", "TREATMENT", 20, 24], ["these diseases", "PROBLEM", 29, 43], ["diagnostics", "TEST", 128, 139], ["vaccines", "TREATMENT", 141, 149], ["therapeutics", "TREATMENT", 155, 167], ["disease outbreaks", "PROBLEM", 270, 287], ["clinical and epidemiologic studies", "TEST", 332, 366], ["disease", "OBSERVATION", 270, 277]]], ["A coordinated diagnostic product development effort for epidemic disease threats has been initiated by the Foundation for Innovative New Diagnostics under the auspices of CEPI (17).", [["epidemic disease threats", "PROBLEM", 56, 80], ["CEPI", "TREATMENT", 171, 175]]], ["WHO states that IRPs are major resources for ensuring the reliability of in vitro biological diagnostic procedures used for diagnosis of diseases (18).", [["diseases", "PROBLEM", 137, 145]]], ["The recent epidemics caused by MERS-CoV, Ebola virus, and Zika virus have highlighted complexities in prompt development of sensitive and specific assays, particularly those that would be accessible in resource constrained settings (19\u201321).", [["Ebola virus", "DISEASE", 41, 52], ["MERS-CoV", "ORGANISM", 31, 39], ["Ebola virus", "ORGANISM", 41, 52], ["Zika virus", "ORGANISM", 58, 68], ["Ebola virus", "SPECIES", 41, 52], ["Zika virus", "SPECIES", 58, 68], ["MERS-CoV", "SPECIES", 31, 39], ["Ebola virus", "SPECIES", 41, 52], ["Zika virus", "SPECIES", 58, 68], ["The recent epidemics", "PROBLEM", 0, 20], ["Ebola virus", "PROBLEM", 41, 52], ["Zika virus", "PROBLEM", 58, 68], ["specific assays", "TEST", 138, 153]]], ["Availability of international reference standards that encompass genetic material, antigens, and antibodies would enable harmonization and calibration of tests.", [["antigens", "PROTEIN", 83, 91], ["antibodies", "PROTEIN", 97, 107], ["calibration of tests", "TEST", 139, 159]]], ["These standards would facilitate development and validation of diagnostic assays, which include nucleic acid amplification tests, serologic assays, and antigen-based point-of-care tests.Development of Vaccines and TherapeuticsNo vaccine or therapeutic is currently licensed by regulators in Europe or the United States for use for any disease on the research and development blueprint.", [["diagnostic assays", "TEST", 63, 80], ["nucleic acid amplification tests", "TEST", 96, 128], ["serologic assays", "TEST", 130, 146], ["antigen", "TEST", 152, 159], ["Vaccines", "TREATMENT", 201, 209], ["Therapeutics", "TREATMENT", 214, 226], ["vaccine", "TREATMENT", 229, 236], ["any disease", "PROBLEM", 331, 342]]], ["On August 8, 2014, WHO declared the Ebola outbreak in West Africa to be a public health emergency of international concern.", [["Ebola", "DISEASE", 36, 41], ["Ebola", "OBSERVATION", 36, 41]]], ["This declaration led to subsequent concerted efforts from the international scientific community to accelerate development of Ebola vaccines, with funding, regulatory and ethical review, expert advice, and manufacturing support being initiated at extraordinary speed (22).", [["Ebola", "DISEASE", 126, 131], ["Ebola", "ORGANISM", 126, 131], ["Ebola", "SPECIES", 126, 131], ["Ebola vaccines", "TREATMENT", 126, 140], ["manufacturing support", "TREATMENT", 206, 227], ["Ebola", "OBSERVATION", 126, 131]]], ["Although vaccine development was considered to be a relatively successful component of the Ebola research and development efforts, and the recombinant vesicular stomatitis virus\u2013Zaire Ebola virus showed high efficacy in a ring vaccination trial (23), this development came too late to have any major effect on the course of the West Africa epidemic.", [["Ebola", "DISEASE", 91, 96], ["vesicular stomatitis", "DISEASE", 151, 171], ["Ebola", "ORGANISM", 91, 96], ["recombinant", "ORGANISM", 139, 150], ["vesicular stomatitis virus", "ORGANISM", 151, 177], ["Zaire Ebola virus", "ORGANISM", 178, 195], ["Zaire Ebola virus", "SPECIES", 178, 195], ["Zaire Ebola virus", "SPECIES", 178, 195], ["vaccine", "TREATMENT", 9, 16], ["the recombinant vesicular stomatitis virus", "PROBLEM", 135, 177], ["Zaire Ebola virus", "PROBLEM", 178, 195], ["a ring vaccination trial", "TREATMENT", 220, 244], ["Ebola", "OBSERVATION", 91, 96], ["vesicular stomatitis", "OBSERVATION", 151, 171], ["high", "OBSERVATION_MODIFIER", 203, 207], ["efficacy", "OBSERVATION_MODIFIER", 208, 216]]], ["Other candidate vaccines also underwent clinical evaluation, and encouraging safety and immunogenicity data were generated from phase 1 and 2 trials of several candidates.", [["clinical evaluation", "TEST", 40, 59], ["immunogenicity data", "TEST", 88, 107]]], ["However, studies were performed by different groups with a variety of immunogenicity assays and reference reagents being used, making comparison of immunogenicity results complicated (24\u201328).", [["studies", "TEST", 9, 16], ["immunogenicity assays", "TEST", 70, 91], ["reference reagents", "TREATMENT", 96, 114]]], ["A set of biological standards that are common to all assays would enable calibration and harmonization of assay data between trials, and could prove vital in determining correlates of protection and clinical outcomes.", [["assay data", "TEST", 106, 116], ["trials", "TREATMENT", 125, 131]]], ["These standards would also enable better selection of candidate vaccines to transition from the preclinical stage to clinical evaluation.Development of Vaccines and TherapeuticsThere has been considerable interest in biological therapies for emerging epidemic threats (29).", [["candidate vaccines", "TREATMENT", 54, 72], ["clinical evaluation", "TEST", 117, 136], ["Vaccines", "TREATMENT", 152, 160], ["Therapeutics", "TREATMENT", 165, 177], ["biological therapies", "TREATMENT", 217, 237], ["considerable", "OBSERVATION_MODIFIER", 192, 204], ["interest", "OBSERVATION_MODIFIER", 205, 213]]], ["Convalescent-phase plasma and monoclonal antibodies have been evaluated as treatment for Ebola (30,31) and have been considered as therapies for Zika virus (32) and MERS-CoV (33,34), forming a key focus of the MERS-CoV research and development blueprint roadmap (12).", [["plasma", "ANATOMY", 19, 25], ["Ebola", "DISEASE", 89, 94], ["plasma", "ORGANISM_SUBSTANCE", 19, 25], ["Ebola", "ORGANISM", 89, 94], ["Zika virus", "ORGANISM", 145, 155], ["MERS-CoV", "ORGANISM", 165, 173], ["Convalescent-phase plasma", "PROTEIN", 0, 25], ["monoclonal antibodies", "PROTEIN", 30, 51], ["Zika virus", "SPECIES", 145, 155], ["MERS-CoV", "SPECIES", 165, 173], ["MERS-CoV", "SPECIES", 210, 218], ["Convalescent-phase plasma", "TEST", 0, 25], ["monoclonal antibodies", "TEST", 30, 51], ["Ebola", "PROBLEM", 89, 94], ["Zika virus", "PROBLEM", 145, 155], ["MERS-CoV", "TEST", 165, 173]]], ["Availability of IRPs would enable characterization of the potency, purity, and identity of complex biological materials, such as antibodies, which would facilitate not only research of immunotherapies but also the standardization of preparations postlicensure.Challenges in Development of Standards for Research and Development Blueprint DiseasesAntigen and nucleic acid reference materials can be synthesized through recombinant techniques as long as necessary genomic sequence data are available (35\u201337), but for some newly emerging pathogens, acquisition of live pathogens might be required.", [["nucleic acid", "CHEMICAL", 358, 370], ["IRPs", "SIMPLE_CHEMICAL", 16, 20], ["nucleic acid", "SIMPLE_CHEMICAL", 358, 370], ["antibodies", "PROTEIN", 129, 139], ["complex biological materials", "PROBLEM", 91, 119], ["immunotherapies", "TREATMENT", 185, 200], ["Research", "TREATMENT", 303, 311], ["Blueprint DiseasesAntigen", "PROBLEM", 328, 353], ["nucleic acid reference materials", "TREATMENT", 358, 390], ["recombinant techniques", "TREATMENT", 418, 440], ["genomic sequence data", "TEST", 462, 483], ["some newly emerging pathogens", "PROBLEM", 515, 544], ["live pathogens", "PROBLEM", 561, 575]]], ["Simple blood draws can complicate field operations in the midst of an epidemic, and logistical issues regarding processing and storage of acute, potentially infectious samples can also present many obstacles.", [["blood", "ANATOMY", 7, 12], ["samples", "ANATOMY", 168, 175], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["Simple blood draws", "TREATMENT", 0, 18], ["field operations", "TREATMENT", 34, 50], ["acute, potentially infectious samples", "PROBLEM", 138, 175], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["infectious", "OBSERVATION", 157, 167]]], ["However, the ideal starting material for production of antibody-based reference preparations is serum or plasma from convalescent-phase patients.Challenges in Development of Standards for Research and Development Blueprint DiseasesNovel methods for generating fully human immunoglobulin for use as reference materials have been explored when human plasma is not readily available, such as inoculation of transchromosomal cattle and subsequent isolation of antibodies (35,38,39).", [["serum", "ANATOMY", 96, 101], ["plasma", "ANATOMY", 105, 111], ["plasma", "ANATOMY", 348, 354], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["plasma", "ORGANISM_SUBSTANCE", 105, 111], ["patients", "ORGANISM", 136, 144], ["human", "ORGANISM", 266, 271], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 272, 286], ["human", "ORGANISM", 342, 347], ["plasma", "ORGANISM_SUBSTANCE", 348, 354], ["transchromosomal cattle", "ORGANISM", 404, 427], ["antibody", "PROTEIN", 55, 63], ["human immunoglobulin", "PROTEIN", 266, 286], ["antibodies", "PROTEIN", 456, 466], ["patients", "SPECIES", 136, 144], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 342, 347], ["cattle", "SPECIES", 421, 427], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 342, 347], ["cattle", "SPECIES", 421, 427], ["antibody", "TEST", 55, 63], ["generating fully human immunoglobulin", "TREATMENT", 249, 286], ["human plasma", "TEST", 342, 354], ["transchromosomal cattle", "TREATMENT", 404, 427], ["subsequent isolation of antibodies", "TREATMENT", 432, 466]]], ["However, this technology is still relatively new, and convalescent-phase serum is considered superior because it will most closely represent a clinical sample and has a polyclonal range of antibody specificities that can be further optimized by pooling samples.", [["serum", "ANATOMY", 73, 78], ["samples", "ANATOMY", 253, 260], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["convalescent-phase serum", "TEST", 54, 78], ["a polyclonal range of antibody specificities", "PROBLEM", 167, 211], ["pooling samples", "TEST", 245, 260], ["new", "OBSERVATION_MODIFIER", 45, 48]]], ["Although many previous clinical studies of the research and development blueprint priority diseases have resulted in collection and storage of plasma from convalescent patients, several obstacles would largely preclude these samples being repurposed to generate reference materials.", [["plasma", "ANATOMY", 143, 149], ["samples", "ANATOMY", 225, 232], ["plasma", "ORGANISM_SUBSTANCE", 143, 149], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["collection", "PROBLEM", 117, 127]]], ["These issues include sample volume, receipt of appropriate consent, appropriate records, documentation of sample provenance, and willingness of researchers to share samples.", [["sample", "ANATOMY", 21, 27]]], ["A more suitable alternative to repurposing old samples would be to initiate clinical studies with objectives that include acquisition of blood samples for production of reference materials for each of the research and development blueprint priority diseases.", [["blood samples", "ANATOMY", 137, 150], ["blood samples", "ORGANISM_SUBSTANCE", 137, 150], ["clinical studies", "TEST", 76, 92], ["blood samples", "TEST", 137, 150], ["production of reference materials", "TREATMENT", 155, 188]]], ["However, such studies would have several challenges.Challenge in Identifying Suitable Patients to Donate MaterialMany pathogens on the WHO priority pathogens list cause outbreaks that are difficult to anticipate temporally and geographically, and outbreaks are often limited in numbers of cases and duration.", [["Patients", "ORGANISM", 86, 94], ["Patients", "SPECIES", 86, 94], ["such studies", "TEST", 9, 21], ["outbreaks", "PROBLEM", 169, 178]]], ["In addition, these pathogens most commonly cause outbreaks in resource-constrained environments, where poor healthcare infrastructure, limited diagnostic capability, and suboptimal disease reporting systems would limit retrospective identification of suitable patients (40).", [["patients", "ORGANISM", 260, 268], ["patients", "SPECIES", 260, 268], ["these pathogens", "PROBLEM", 13, 28], ["suboptimal disease reporting systems", "PROBLEM", 170, 206]]], ["For development of Ebola antibody IRPs, plasma was obtained either from recovered EVD patients in Sierra Leone who were enrolled in a convalescent-phase plasma trial or as donations from countries not directly involved in the outbreak (Italy, Norway, the United Kingdom, and the United States) (14,15).", [["plasma", "ANATOMY", 40, 46], ["plasma", "ANATOMY", 153, 159], ["Ebola", "ORGANISM", 19, 24], ["plasma", "ORGANISM_SUBSTANCE", 40, 46], ["patients", "ORGANISM", 86, 94], ["plasma", "ORGANISM_SUBSTANCE", 153, 159], ["Ebola antibody IRPs", "PROTEIN", 19, 38], ["patients", "SPECIES", 86, 94], ["Ebola", "SPECIES", 19, 24], ["Ebola antibody IRPs", "TEST", 19, 38], ["a convalescent-phase plasma trial", "TREATMENT", 132, 165], ["Ebola antibody", "OBSERVATION", 19, 33]]], ["However, it would be inappropriate to use this example as a model for sample acquisition because it required occurrence of a large and devastating outbreak for a concerted international response to be successful.Challenge in Identifying Suitable Patients to Donate MaterialFocused efforts to obtain material for the generation of IRPs should be made for high-threat epidemic diseases, and methods to identify and sample patients from previous outbreaks should be explored.", [["Patients", "ORGANISM", 246, 254], ["patients", "ORGANISM", 420, 428], ["Patients", "SPECIES", 246, 254], ["patients", "SPECIES", 420, 428], ["sample acquisition", "TEST", 70, 88], ["a large and devastating outbreak", "PROBLEM", 123, 155], ["IRPs", "TREATMENT", 330, 334], ["high-threat epidemic diseases", "PROBLEM", 354, 383], ["large", "OBSERVATION_MODIFIER", 125, 130], ["devastating", "OBSERVATION_MODIFIER", 135, 146]]], ["In addition, preparation for promptly identifying and sampling patients prospectively given a diagnosis in future outbreaks should be made.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71]]], ["This preparation would optimize the likelihood of obtaining high-quality samples for rare and sporadic disease pathogens, such as Nipah virus or Rift Valley fever virus, but would require a systematic and coordinated approach that brings together local investigators with international partners in a transparent and equitable framework.", [["Nipah virus", "DISEASE", 130, 141], ["Rift Valley fever", "DISEASE", 145, 162], ["Nipah virus", "ORGANISM", 130, 141], ["Rift Valley fever virus", "ORGANISM", 145, 168], ["Nipah virus", "SPECIES", 130, 141], ["Rift Valley fever virus", "SPECIES", 145, 168], ["Nipah virus", "SPECIES", 130, 141], ["Rift Valley fever virus", "SPECIES", 145, 168], ["sporadic disease pathogens", "PROBLEM", 94, 120], ["Nipah virus", "PROBLEM", 130, 141], ["Rift Valley fever virus", "PROBLEM", 145, 168]]], ["Global initiatives, such as the International Severe Acute Respiratory and Emerging Infections Consortium, exist to facilitate the rapid response to emerging infectious disease and epidemic threats by aiding the sharing of clinical research tools, such as open-access clinical study protocols.", [["Respiratory and Emerging Infections", "DISEASE", 59, 94], ["infectious disease", "DISEASE", 158, 176], ["Global initiatives", "PROBLEM", 0, 18], ["the International Severe Acute Respiratory and Emerging Infections Consortium", "PROBLEM", 28, 105], ["emerging infectious disease", "PROBLEM", 149, 176], ["clinical study protocols", "TEST", 268, 292], ["Severe", "OBSERVATION_MODIFIER", 46, 52], ["Acute", "OBSERVATION_MODIFIER", 53, 58], ["Respiratory", "ANATOMY", 59, 70], ["Infections", "OBSERVATION", 84, 94], ["infectious", "OBSERVATION", 158, 168]]], ["Preemptive identification of study sites and preparation of study documents, including template protocols and clinical agreements detailing methods for identifying and recruiting potential donors, sample collection, and processing, and roles and responsibilities would optimize the likelihood of success in this regard.Ethics ConsiderationsIn situations in which access to existing samples and appropriate consent for use in reference preparations are unavailable, the process of acquiring new samples for development of reference materials should be registered as a unique study for each prioritized epidemic disease.", [["donors", "ORGANISM", 189, 195], ["study sites", "TEST", 29, 40], ["preparation of study", "TEST", 45, 65], ["template protocols", "TREATMENT", 87, 105], ["sample collection", "TEST", 197, 214], ["a unique study", "TEST", 565, 579], ["each prioritized epidemic disease", "PROBLEM", 584, 617]]], ["This process would require ethics approval being sought through appropriate channels, thus enabling appropriate scrutiny by relevant ethics and regulatory bodies in countries coordinating activities in disease-endemic countries where samples are to be collected, and in the countries of international partners.", [["samples", "CANCER", 234, 241], ["ethics approval", "TREATMENT", 27, 42]]], ["These studies would involve minimal risk to participants because they would not involve administration of an investigational medicinal product and in most instances, only a single venesection would be required.ConsentSerum, plasma, and plasma-derived products contain insufficient genetic material to be universally considered as human tissue under legislation.", [["plasma", "ANATOMY", 224, 230], ["plasma", "ANATOMY", 236, 242], ["tissue", "ANATOMY", 336, 342], ["ConsentSerum", "SIMPLE_CHEMICAL", 210, 222], ["plasma", "ORGANISM_SUBSTANCE", 224, 230], ["plasma", "ORGANISM_SUBSTANCE", 236, 242], ["human", "ORGANISM", 330, 335], ["tissue", "TISSUE", 336, 342], ["participants", "SPECIES", 44, 56], ["human", "SPECIES", 330, 335], ["human", "SPECIES", 330, 335], ["These studies", "TEST", 0, 13], ["an investigational medicinal product", "TREATMENT", 106, 142], ["a single venesection", "TREATMENT", 171, 191], ["plasma-derived products", "TREATMENT", 236, 259], ["insufficient genetic material", "PROBLEM", 268, 297]]], ["However, they must be considered human biological material.", [["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38]]], ["The donor should receive information concerning all aspects of the study, with emphasis placed on the fact that participation is entirely voluntary.", [["the study", "TEST", 63, 72]]], ["The intended use of the blood components for the generation, storage, and international distribution of reference materials must be explained, in addition to the potential beneficiaries and the procedures involved.", [["blood", "ANATOMY", 24, 29], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["the blood components", "TREATMENT", 20, 40], ["the procedures", "TREATMENT", 190, 204]]], ["Consent processes should consist of all participants signing and dating an informed consent form before any study-specific procedures are performed.", [["participants", "SPECIES", 40, 52], ["any study", "TEST", 104, 113], ["specific procedures", "TEST", 114, 133]]], ["A collaborative international framework could include template participant information sheets and informed consent forms that could be readily adapted for disease- and country-specific studies when appropriate.Ownership and Equitable Benefit SharingSharing of biological materials is a necessity for rapid research progress, but recent experiences during epidemics have highlighted that concerted efforts to establish acceptable processes for obtaining and sharing reference materials are needed.", [["disease", "PROBLEM", 155, 162], ["specific studies", "TEST", 176, 192]]], ["At the present time, only a small number of institutions manufacture and provide reference materials to WHO for use as IRPs.", [["small", "OBSERVATION_MODIFIER", 28, 33]]], ["Therefore, export of samples to these institutions is an essential step in the production of IRPs for epidemic diseases.", [["IRPs", "GENE_OR_GENE_PRODUCT", 93, 97], ["epidemic diseases", "PROBLEM", 102, 119]]], ["Initiatives exist to facilitate sharing of benefits arising from the use of, and access to, human and nonhuman genetic material.", [["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97]]], ["An example of such an initiative is the Pandemic Influenza Preparedness (PIP) framework launched by WHO in 2011.", [["Influenza", "DISEASE", 49, 58]]], ["The PIP framework seeks to address concerns of low- and middle-income countries that sharing of influenza virus specimens with WHO was not matched with assurances that benefits derived from such sharing would be equitably distributed (41).", [["influenza", "DISEASE", 96, 105], ["influenza virus", "SPECIES", 96, 111], ["The PIP framework", "TREATMENT", 0, 17], ["influenza virus specimens", "PROBLEM", 96, 121]]], ["Concerns about inequitable sharing of benefits were further exacerbated during the 2009 influenza A(H1N1) pandemic because of unequal access to vaccines (42).", [["influenza A(H1N1) pandemic", "DISEASE", 88, 114], ["2009 influenza A(H1N1", "ORGANISM", 83, 104], ["influenza A(H1N1", "SPECIES", 88, 104], ["H1N1", "PROBLEM", 100, 104], ["pandemic", "PROBLEM", 106, 114], ["unequal access to vaccines", "TREATMENT", 126, 152]]], ["Despite the example set by the PIP framework, more recent epidemics of other infectious diseases have continued to raise issues with regard to sample sharing.", [["infectious diseases", "DISEASE", 77, 96], ["the PIP framework", "TEST", 27, 44], ["other infectious diseases", "PROBLEM", 71, 96]]], ["For example, local export restrictions in Brazil prevented sharing of well-characterized samples during the recent Zika virus epidemic, thereby presenting an obstacle to rapid development and assessment of diagnostics (43,44).Ownership and Equitable Benefit SharingFurther generalized guidance on fair and equitable sharing of benefits arising out of use of genetic biological resources is in the Nagoya Protocol (45).", [["samples", "ANATOMY", 89, 96], ["samples", "CANCER", 89, 96], ["Zika virus", "ORGANISM", 115, 125], ["Zika virus", "SPECIES", 115, 125], ["the recent Zika virus epidemic", "PROBLEM", 104, 134], ["assessment of diagnostics", "TEST", 192, 217]]], ["This protocol is a supplementary agreement to the Convention on Biological Diversity and contains detailed guidance divided into the following objectives: access obligations, benefit sharing obligations, and compliance obligations.", [["access obligations", "TREATMENT", 155, 173]]], ["No similar guidance exists for plasma-derived products, such as antibody reference materials.", [["plasma", "ANATOMY", 31, 37], ["plasma", "ORGANISM_SUBSTANCE", 31, 37], ["plasma-derived products", "TREATMENT", 31, 54]]], ["However, many facets of the Nagoya Protocol would remain pertinent to plasma-derived products and could be adapted to inform procedures.Ownership and Equitable Benefit SharingAcceptance that human-derived products should not be an object of commercialization or source of profit is enshrined in several key documents (46,47) that would continue to apply to development of IRPs.", [["plasma", "ANATOMY", 70, 76], ["IRPs", "DISEASE", 372, 376], ["plasma", "ORGANISM_SUBSTANCE", 70, 76], ["human", "ORGANISM", 191, 196], ["IRPs", "CANCER", 372, 376], ["human", "SPECIES", 191, 196], ["human", "SPECIES", 191, 196], ["the Nagoya Protocol", "TREATMENT", 24, 43], ["human-derived products", "TREATMENT", 191, 213]]], ["WHO distributes IRPs either free of charge to National Control Laboratories or with small handling charges and shipping costs to other organizations.", [["small handling charges", "PROBLEM", 84, 106], ["small", "OBSERVATION_MODIFIER", 84, 89], ["handling charges", "OBSERVATION", 90, 106]]], ["Negotiations between relevant parties and preemptive interaction between researchers and donor country authorities could lead to clearly defined, mutually agreed upon processes for acquisition and export of samples.", [["samples", "ANATOMY", 207, 214]]], ["These processes could subsequently be specified in legally binding clinical study agreements, and thus ensure compliance with principles of equitable benefit sharing and provide solutions to complex issues, such as intellectual property, product ownership, and access rights to IRPs.Operational ConsiderationsMost diseases on the research and development blueprint priority disease list are caused by category A pathogens, and handling of potentially infectious materials often requires Biosafety Level 4 laboratories.", [["IRPs", "DISEASE", 278, 282], ["category A pathogens", "PROBLEM", 401, 421], ["potentially infectious materials", "PROBLEM", 439, 471], ["pathogens", "OBSERVATION", 412, 421], ["infectious", "OBSERVATION_MODIFIER", 451, 461]]], ["In recent years, the threat of bioterrorism has resulted in strict rules and requirements, such as US Federal Select Agent regulations, which can result in increased cost, limited research, and reduced collaboration between institutions (48).", [["bioterrorism", "PROBLEM", 31, 43], ["bioterrorism", "OBSERVATION", 31, 43], ["increased", "OBSERVATION_MODIFIER", 156, 165], ["cost", "OBSERVATION", 166, 170]]], ["However, there is an encouraging increase in the number of Biosafety Level 4 laboratories globally, and initiatives now exist that seek to harmonize practices and facilitate collaboration between laboratories with the ultimate goal of positively contributing to global health (49,50).", [["encouraging", "OBSERVATION_MODIFIER", 21, 32], ["increase", "OBSERVATION_MODIFIER", 33, 41]]], ["The safe acquisition, processing, exporting, and importing of samples from recovered emerging high-threat disease patients would require careful planning.", [["high-threat disease", "DISEASE", 94, 113], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["careful planning", "TREATMENT", 137, 153]]], ["Requirements would be based on natural history of a specific disease, study site, and patient characteristics, such as period of convalescence since the acute illness.", [["acute illness", "DISEASE", 153, 166], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["a specific disease", "PROBLEM", 50, 68], ["study site", "TEST", 70, 80], ["the acute illness", "PROBLEM", 149, 166], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["illness", "OBSERVATION", 159, 166]]], ["Liaison with national authorities in donor and recipient countries with regard to exportation and importation regulations and requirements would be necessary.", [["exportation", "TREATMENT", 82, 93]]], ["In addition, most of these diseases occur primarily in low- and middle-income countries and often in remote or rural settings, where access to accurate medical records and diagnostic tools will be limited.", [["these diseases", "PROBLEM", 21, 35], ["diagnostic tools", "TEST", 172, 188], ["diseases", "OBSERVATION", 27, 35], ["low", "OBSERVATION_MODIFIER", 55, 58], ["middle", "ANATOMY_MODIFIER", 64, 70]]], ["Clear specifications regarding method of diagnosis, patient clinical details and disease course, sample collection date, and storage details would be required.ConclusionsBiological IRPs for infectious diseases with epidemic potential are a major global asset that will support timely and efficient development of vaccines, therapeutics, and diagnostics.", [["infectious diseases", "DISEASE", 190, 209], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["sample collection date", "TEST", 97, 119], ["infectious diseases", "PROBLEM", 190, 209], ["vaccines", "TREATMENT", 313, 321], ["therapeutics", "TREATMENT", 323, 335], ["diagnostics", "TEST", 341, 352]]], ["A critical barrier to development of reference materials for epidemic infections is acquisition of suitable source material.", [["infections", "DISEASE", 70, 80], ["A critical barrier", "TREATMENT", 0, 18], ["reference materials", "TREATMENT", 37, 56], ["epidemic infections", "PROBLEM", 61, 80]]], ["Work should begin to develop and agree to such a framework and to generate IRPs for these diseases so that drugs, diagnostics, and vaccines are available for future outbreaks.", [["these diseases", "PROBLEM", 84, 98], ["drugs", "TREATMENT", 107, 112], ["vaccines", "TREATMENT", 131, 139]]]], "bec8cbd6bb0b274338fbaf5ce5f5f302dadb7e82": [["INTRODUCTIONZoonotic pathogensdisease agents such as the SARS coronavirus, Lyme disease spirochete or West Nile virus, which are transmitted to humans from non-human animalsare significant burdens on global public health (Jones et al. 2008 ).", [["SARS coronavirus", "DISEASE", 57, 73], ["Lyme disease spirochete", "DISEASE", 75, 98], ["SARS coronavirus", "ORGANISM", 57, 73], ["Lyme disease spirochete", "ORGANISM", 75, 98], ["West Nile virus", "ORGANISM", 102, 117], ["humans", "ORGANISM", 144, 150], ["coronavirus", "SPECIES", 62, 73], ["West Nile virus", "SPECIES", 102, 117], ["humans", "SPECIES", 144, 150], ["SARS coronavirus", "SPECIES", 57, 73], ["West Nile virus", "SPECIES", 102, 117], ["humans", "SPECIES", 144, 150], ["INTRODUCTIONZoonotic pathogensdisease agents", "TREATMENT", 0, 44], ["the SARS coronavirus", "PROBLEM", 53, 73], ["Lyme disease spirochete", "PROBLEM", 75, 98], ["West Nile virus", "PROBLEM", 102, 117]]], ["Zoonotic transmission is inherently a multi-species phenomenon, often also involving vector intermediaries, making an understanding of underlying ecological processes essential for management and control.", [["management and control", "TREATMENT", 181, 203]]], ["Indeed, a key question in disease ecology and epidemiology is how to mitigate or ameliorate pathogen transmission from wildlife reservoirs to human populations.", [["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147]]], ["The 'dilution effect' hypothesis, which suggests that disease risk will decrease as a result of increased species diversity, offers an intriguing possibility of harnessing conservation initiatives in order to reduce disease risk to human populations (Pongsiri et al. 2009; Keesing et al. 2010 ).", [["human", "ORGANISM", 232, 237], ["human", "SPECIES", 232, 237], ["human", "SPECIES", 232, 237], ["The 'dilution effect' hypothesis", "PROBLEM", 0, 32], ["disease risk", "PROBLEM", 54, 66], ["increased species diversity", "PROBLEM", 96, 123], ["harnessing conservation initiatives", "TREATMENT", 161, 196], ["disease risk", "PROBLEM", 216, 228], ["disease", "OBSERVATION", 54, 61], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["species diversity", "OBSERVATION", 106, 123]]], ["Here, we use the inclusive definition of the dilution effect which describes the net effect of species diversity reducing disease risk by any of a variety of mechanisms (Keesing et al. 2006) .", [["the dilution effect", "TREATMENT", 41, 60], ["species diversity reducing disease risk", "PROBLEM", 95, 134]]], ["For example, Borrelia burgdorferi, the bacterium that causes Lyme disease, is transmitted by ticks (Ixodes spp.), but persists in vertebrate hosts (e.g. white-footed mice, Peromyscus leucopus, Sorex shrews and other species), which differ in the degree to which they can infect ticks (i.e. reservoir competence) (LoGiudice et al. 2003; Brisson et al. 2008) .", [["Borrelia burgdorferi", "DISEASE", 13, 33], ["Lyme disease", "DISEASE", 61, 73], ["Borrelia burgdorferi", "ORGANISM", 13, 33], ["Ixodes spp.", "ORGANISM", 100, 111], ["white-footed mice", "ORGANISM", 153, 170], ["Peromyscus leucopus", "ORGANISM", 172, 191], ["Sorex shrews", "ORGANISM", 193, 205], ["Borrelia burgdorferi", "SPECIES", 13, 33], ["Ixodes spp.", "SPECIES", 100, 111], ["mice", "SPECIES", 166, 170], ["Peromyscus leucopus", "SPECIES", 172, 191], ["Sorex shrews", "SPECIES", 193, 205], ["Borrelia burgdorferi", "SPECIES", 13, 33], ["Ixodes spp.", "SPECIES", 100, 111], ["white-footed mice", "SPECIES", 153, 170], ["Peromyscus leucopus", "SPECIES", 172, 191], ["Sorex shrews", "SPECIES", 193, 205], ["Borrelia burgdorferi", "PROBLEM", 13, 33], ["the bacterium", "PROBLEM", 35, 48], ["Lyme disease", "PROBLEM", 61, 73], ["white-footed mice", "PROBLEM", 153, 170], ["Peromyscus leucopus", "PROBLEM", 172, 191], ["Lyme disease", "OBSERVATION", 61, 73]]], ["The risk of human exposure to Lyme disease is therefore strongly influenced by the local abundance and interactions of tick hosts, Borrelia reservoir hosts, and Ixodes ticks.", [["Lyme disease", "DISEASE", 30, 42], ["human", "ORGANISM", 12, 17], ["tick hosts", "ORGANISM", 119, 129], ["Borrelia reservoir hosts", "ORGANISM", 131, 155], ["Ixodes ticks", "ORGANISM", 161, 173], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["Ixodes ticks", "SPECIES", 161, 173], ["Lyme disease", "PROBLEM", 30, 42], ["tick hosts", "TREATMENT", 119, 129], ["Borrelia reservoir hosts", "TREATMENT", 131, 155], ["Lyme disease", "OBSERVATION", 30, 42]]], ["LoGiudice et al. (2003 LoGiudice et al. ( , 2008 have hypothesised that a higher diversity of hosts for ticks could reduce the risk of Lyme disease.", [["Lyme disease", "DISEASE", 135, 147], ["ticks", "PROBLEM", 104, 109], ["Lyme disease", "PROBLEM", 135, 147], ["Lyme disease", "OBSERVATION", 135, 147]]], ["Similarly, reservoir competence of mosquito-borne West Nile virus (WNV) varies widely among avian species (Komar et al. 2003) , and higher avian biodiversity (species richness and evenness) has been postulated to reduce WNV risk (e.g. Ezenwa et al. 2006; Swaddle & Calos 2008; Allan et al. 2009 ).", [["WNV", "DISEASE", 220, 223], ["mosquito-borne", "ORGANISM", 35, 49], ["West Nile virus", "ORGANISM", 50, 65], ["WNV", "ORGANISM", 67, 70], ["WNV", "ORGANISM", 220, 223], ["West Nile virus", "SPECIES", 50, 65], ["West Nile virus", "SPECIES", 50, 65], ["WNV", "SPECIES", 67, 70], ["WNV", "SPECIES", 220, 223]]], ["Unlike WNV and B. burgdorferi, hantaviruses are generally associated with only a single species of rodent host, and transmission does not involve vectors, but a negative association between host diversity and hantavirus prevalence has nevertheless been proposed via mechanisms such as a higher biodiversity suppressing the encounter rate within a reservoir species, and therefore dampening intraspecific disease transmission (Clay et al. 2009; Dizney & Ruedas 2009; Carver et al. 2011) .INTRODUCTIONIf higher biodiversity reduces the risk of infectious diseases, then the dilution effect hypothesis has an obvious appeal as both conservation and public health agendas can be united in a common purpose: protect biodiversity, while simultaneously reducing deleterious health impacts of zoonotic and wildlife diseases (Pongsiri et al. 2009; Keesing et al. 2010) .", [["WNV and B. burgdorferi", "DISEASE", 7, 29], ["hantavirus", "DISEASE", 209, 219], ["intraspecific disease transmission", "DISEASE", 390, 424], ["infectious diseases", "DISEASE", 542, 561], ["zoonotic and wildlife diseases", "DISEASE", 785, 815], ["WNV", "ORGANISM", 7, 10], ["B. burgdorferi", "ORGANISM", 15, 29], ["hantaviruses", "ORGANISM", 31, 43], ["B. burgdorferi", "SPECIES", 15, 29], ["rodent", "SPECIES", 99, 105], ["WNV", "SPECIES", 7, 10], ["B. burgdorferi", "SPECIES", 15, 29], ["WNV", "PROBLEM", 7, 10], ["B. burgdorferi", "PROBLEM", 15, 29], ["hantaviruses", "PROBLEM", 31, 43], ["hantavirus prevalence", "PROBLEM", 209, 230], ["dampening intraspecific disease transmission", "PROBLEM", 380, 424], ["infectious diseases", "PROBLEM", 542, 561], ["the dilution effect hypothesis", "PROBLEM", 568, 598], ["WNV", "OBSERVATION", 7, 10], ["hantaviruses", "OBSERVATION", 31, 43], ["hantavirus", "OBSERVATION", 209, 219], ["reservoir species", "OBSERVATION", 347, 364], ["dampening", "OBSERVATION_MODIFIER", 380, 389], ["intraspecific", "OBSERVATION_MODIFIER", 390, 403], ["infectious", "OBSERVATION", 542, 552]]], ["Indeed, a recent review concluded that 'overall, despite many remaining questions, preserving intact ecosystems and their endemic biodiversity should generally reduce the prevalence of infectious diseases' (Keesing et al. 2010) .INTRODUCTIONHowever, emerging zoonoses involve multi-trophic level interactions that can be complex and variable and will often depend on the local idiosyncrasies of pathogen, host, vector and human ecology, which suggests that the dilution effect may not be a general phenomenon (e.g. LoGiudice et al. 2008; Ogden & Tsao 2009; These conflicting results about the relationship between biodiversity and disease risk suggest that consequences of conservation programmes for human health may be unpredictable and variable depending on the spatial scale and the ecological particulars of the system in question.", [["infectious diseases", "DISEASE", 185, 204], ["zoonoses", "DISEASE", 259, 267], ["human", "ORGANISM", 422, 427], ["human", "ORGANISM", 701, 706], ["human", "SPECIES", 422, 427], ["human", "SPECIES", 701, 706], ["human", "SPECIES", 422, 427], ["human", "SPECIES", 701, 706], ["infectious diseases'", "PROBLEM", 185, 205], ["multi-trophic level interactions", "PROBLEM", 276, 308], ["the dilution effect", "PROBLEM", 457, 476], ["a general phenomenon", "PROBLEM", 488, 508], ["disease risk", "PROBLEM", 631, 643], ["infectious", "OBSERVATION", 185, 195]]], ["If there is an argument to be made for redirecting scarce public health or conservation resources, it is critical to understand whether the relationship between biodiversity and disease risk is as generalisable as has been suggested.", [["disease risk", "PROBLEM", 178, 190]]], ["However, we are unaware of any formal assessment of the generality of the dilution effect.INTRODUCTIONHere, we analyse existing literature in a meta-analysis that examines the relationship between biodiversity and zoonotic disease risk.", [["zoonotic disease", "DISEASE", 214, 230], ["formal assessment", "TEST", 31, 48], ["the dilution effect", "PROBLEM", 70, 89], ["zoonotic disease risk", "PROBLEM", 214, 235], ["zoonotic disease", "OBSERVATION", 214, 230]]], ["We investigate whether the inclusive definition of the dilution effect that biodiversity is protective against disease riskis generally supported and can be regarded as a useful tool in public health approaches to zoonoses.", [["zoonoses", "DISEASE", 214, 222], ["the dilution effect", "TREATMENT", 51, 70], ["disease riskis", "PROBLEM", 111, 125]]], ["If there is no straightforward relationship between biodiversity and risk of zoonotic disease, then integrated approaches to disease control may require more detailed understanding of the transmission ecology of specific pathogen, vector and host species.METHODSWe aimed to collect and analyse all studies that evaluated links between host biodiversity and disease risk for disease agents that infect humans.", [["zoonotic disease", "DISEASE", 77, 93], ["humans", "ORGANISM", 401, 407], ["humans", "SPECIES", 401, 407], ["humans", "SPECIES", 401, 407], ["zoonotic disease", "PROBLEM", 77, 93], ["disease control", "TREATMENT", 125, 140], ["all studies", "TEST", 294, 305], ["disease agents", "TREATMENT", 374, 388], ["no", "UNCERTAINTY", 12, 14], ["zoonotic disease", "OBSERVATION", 77, 93], ["host species", "OBSERVATION", 242, 254]]], ["There are other studies that ask related questions for non-human diseases, but our primary interest was the possible relationship between public health and wildlife biodiversity.", [["non-human diseases", "DISEASE", 55, 73], ["non-human", "ORGANISM", 55, 64], ["other studies", "TEST", 10, 23], ["non-human diseases", "PROBLEM", 55, 73]]], ["Studies were only selected if they simultaneously provided field-based measures of disease risk (e.g. prevalence of infection in animal, human or vector populations; density of infected animals, humans or vectors) and measures of wildlife biodiversity [e.g. species richness (number of species present) or a diversity index (Shannon's index, Simpson's index, etc.)].", [["infection", "DISEASE", 116, 125], ["human", "ORGANISM", 137, 142], ["humans", "ORGANISM", 195, 201], ["human", "SPECIES", 137, 142], ["humans", "SPECIES", 195, 201], ["human", "SPECIES", 137, 142], ["humans", "SPECIES", 195, 201], ["Studies", "TEST", 0, 7], ["disease risk", "PROBLEM", 83, 95], ["infection", "PROBLEM", 116, 125], ["infected animals", "PROBLEM", 177, 193], ["wildlife biodiversity", "TREATMENT", 230, 251], ["species richness", "PROBLEM", 258, 274], ["a diversity index", "TEST", 306, 323], ["Shannon's index", "TEST", 325, 340], ["infection", "OBSERVATION", 116, 125], ["infected", "OBSERVATION", 177, 185]]], ["Studies most frequently involved multiple sites across which biodiversity varied, but we also included one study that examined disease prevalence in the presence and absence of a particular species (voles) over time (Carver et al. 2011) , and one study where non-reservoirs were removed (Suz an et al. 2009) .", [["Studies", "TEST", 0, 7], ["one study", "TEST", 103, 112], ["disease prevalence", "PROBLEM", 127, 145], ["a particular species", "PROBLEM", 177, 197], ["one study", "TEST", 243, 252], ["biodiversity varied", "OBSERVATION", 61, 80]]], ["Where studies presented data on different subsets of biodiversity, we used the most complete representations of species richness, as this criterion can be applied consistently across all studies.", [["biodiversity", "TREATMENT", 53, 65], ["species richness", "PROBLEM", 112, 128], ["all studies", "TEST", 183, 194], ["species richness", "OBSERVATION", 112, 128]]], ["For example, all bird species combined, rather than separate analyses of passerines or non-passerines (Ezenwa et al. 2006) ; or the 'whole model' rather than separate analyses of small mammals, large mammals or birds (LoGiudice et al. 2008) .", [["all bird species", "PROBLEM", 13, 29], ["small mammals", "PROBLEM", 179, 192], ["small mammals", "OBSERVATION", 179, 192], ["large", "OBSERVATION_MODIFIER", 194, 199], ["mammals", "OBSERVATION_MODIFIER", 200, 207]]], ["For studies that examined multiple measures of disease risk [e.g. seroprevalence and abundance of seropositive animals (Piudo et al. 2011)] , we chose the disease risk measure most consistently used across the study system [e.g. seroprevalence was used in most other hantavirus studies, so seroprevalence was adopted from Piudo et al. (2011) ].METHODSWe did not include studies where a proxy was used for biodiversity (e.g. forest fragmentation) or where disease risk was simply inferred (e.g. greater abundance of a particular reservoir host but without direct measures of disease).", [["hantavirus", "DISEASE", 267, 277], ["studies", "TEST", 4, 11], ["disease risk", "PROBLEM", 47, 59], ["seropositive animals", "PROBLEM", 98, 118], ["the disease risk", "PROBLEM", 151, 167], ["the study system", "TEST", 206, 222], ["biodiversity (e.g. forest fragmentation", "TREATMENT", 405, 444], ["disease risk", "PROBLEM", 455, 467], ["a particular reservoir host", "TREATMENT", 515, 542], ["disease", "PROBLEM", 574, 581]]], ["We did not incorporate studies that relied on county-level health data, because infection dynamics can operate at fine spatial scales and therefore data at coarse county or region levels may not be indicative of local pathogen transmission patterns, and because regional measures of biodiversity are sensitive to sampling effort, so that larger areas tend to report more species that smaller areas, making it difficult to obtain an accurate measure of diversity (Loss et al. 2009; Hamer et al. 2011) .METHODSStudies were identified through a comprehensive search on Web of Science \u00e2 , using search strings examining disease and biodiversity, with a particular focus on West Nile virus, hantaviruses and Lyme disease risk.", [["infection", "DISEASE", 80, 89], ["hantaviruses", "DISEASE", 686, 698], ["Lyme disease", "DISEASE", 703, 715], ["West Nile virus", "ORGANISM", 669, 684], ["hantaviruses", "ORGANISM", 686, 698], ["Nile virus", "SPECIES", 674, 684], ["West Nile virus", "SPECIES", 669, 684], ["studies", "TEST", 23, 30], ["infection dynamics", "PROBLEM", 80, 98], ["region levels", "TEST", 173, 186], ["local pathogen transmission patterns", "PROBLEM", 212, 248], ["sampling effort", "TEST", 313, 328], ["disease", "PROBLEM", 616, 623], ["West Nile virus", "PROBLEM", 669, 684], ["Lyme disease risk", "PROBLEM", 703, 720], ["may not be indicative of", "UNCERTAINTY", 187, 211], ["local", "OBSERVATION_MODIFIER", 212, 217], ["pathogen", "OBSERVATION", 218, 226], ["larger", "OBSERVATION_MODIFIER", 338, 344], ["more species", "OBSERVATION_MODIFIER", 366, 378], ["smaller", "OBSERVATION_MODIFIER", 384, 391], ["Lyme disease", "OBSERVATION", 703, 715]]], ["These pathogens were chosen because they infect humans and are cited in recent reviews as good examples of disease systems linking changes in biodiversity to adverse impacts upon human health (e.g. Pongsiri et al. 2009; Keesing et al. 2010) .", [["humans", "ORGANISM", 48, 54], ["human", "ORGANISM", 179, 184], ["humans", "SPECIES", 48, 54], ["human", "SPECIES", 179, 184], ["humans", "SPECIES", 48, 54], ["human", "SPECIES", 179, 184], ["These pathogens", "PROBLEM", 0, 15], ["disease systems", "PROBLEM", 107, 122]]], ["Unpublished data on Sin Nombre virus seroprevalence in California small mammals were provided by California Department of Public Health (see Table 1 ).", [["Sin Nombre virus", "ORGANISM", 20, 36], ["Sin Nombre virus", "SPECIES", 20, 36], ["Unpublished data", "TEST", 0, 16]]], ["Also included are two studies of the tick-borne disease agent, Anaplasma phagocytophilum (Foley et al. 2009; unpublished data from Nieto et al. 2007) , and unpublished data on plague (Yersinia pestis) in Colorado prairie dog populations from Stapp 2007 (Table 1 ).METHODSAn important finding of our meta-analysis is that the investigations of relationships between biodiversity and zoonotic disease risk is still in its infancy; a systematic literature search revealed only 13 published studies documenting relationships of wildlife biodiversity and zoonotic disease risk (following our criteria), and we were able to augment this with three unpublished data sets.", [["tick-borne disease", "DISEASE", 37, 55], ["Anaplasma phagocytophilum", "DISEASE", 63, 88], ["Yersinia pestis", "DISEASE", 184, 199], ["zoonotic disease", "DISEASE", 382, 398], ["zoonotic disease", "DISEASE", 550, 566], ["Anaplasma phagocytophilum", "ORGANISM", 63, 88], ["Yersinia pestis", "ORGANISM", 184, 199], ["dog", "ORGANISM", 221, 224], ["Anaplasma phagocytophilum", "SPECIES", 63, 88], ["Yersinia pestis", "SPECIES", 184, 199], ["dog", "SPECIES", 221, 224], ["Anaplasma phagocytophilum", "SPECIES", 63, 88], ["Yersinia pestis", "SPECIES", 184, 199], ["two studies", "TEST", 18, 29], ["Anaplasma phagocytophilum", "PROBLEM", 63, 88], ["zoonotic disease risk", "PROBLEM", 382, 403], ["a systematic literature search", "TEST", 429, 459], ["wildlife biodiversity", "TREATMENT", 524, 545], ["zoonotic disease risk", "PROBLEM", 550, 571], ["zoonotic disease", "OBSERVATION", 382, 398], ["wildlife biodiversity", "OBSERVATION", 524, 545], ["zoonotic", "OBSERVATION_MODIFIER", 550, 558]]], ["Furthermore, our criteria for inclusion in the meta-analysis resulted in a small sample size and consequent low analytical power.", [["the meta-analysis", "TEST", 43, 60], ["a small sample size", "PROBLEM", 73, 92], ["small", "OBSERVATION_MODIFIER", 75, 80], ["sample", "OBSERVATION_MODIFIER", 81, 87], ["size", "OBSERVATION_MODIFIER", 88, 92], ["low analytical power", "OBSERVATION_MODIFIER", 108, 128]]], ["Different selection criteria for the inclusion of studies may result in different conclusions.METHODSMeta-analysis depends on a standardised measure of effect size (Rosenthal & DiMatteo 2001) .", [["the inclusion of studies", "TEST", 33, 57]]], ["This measure is essentially a correlation between a factor (e.g. biodiversity) and a response (e.g. infection prevalence).", [["infection", "DISEASE", 100, 109], ["a response (e.g. infection prevalence)", "PROBLEM", 83, 121]]], ["Most studies do not publish raw numbers but most (though not all) publish values of test statistics (e.g. F, v 2 , t, or r 2 ).", [["Most studies", "TEST", 0, 12], ["test statistics", "TEST", 84, 99]]], ["For each study, we converted the test statistic for the relationships between biodiversity and disease risk to a standardised correlation-based effect size r (see Rosenthal & DiMatteo 2001) .", [["each study", "TEST", 4, 14], ["the test statistic", "TEST", 29, 47], ["a standardised correlation", "TEST", 111, 137]]], ["Where these results were not readily apparent in the published papers, we contacted authors and requested either the raw data or a derived effect size statistic, for example, via simplification of data to a contingency table.METHODSThe correlation measure of effect size, r, is heteroscedastic and is frequently transformed using Fisher's Z transformation to equalise variances (Rosenthal & DiMatteo 2001; Chaplin-Kramer et al. 2011) .", [["size", "OBSERVATION_MODIFIER", 266, 270]]], ["For effect-size measure r, Fisher's Z is calculated as follows:METHODSStudies where disease risk was lower in treatments of higher biodiversity were assigned a negative value.METHODSWe adopted a random-effects model, for which each study is taken to be a sample of a large population of possible studies (Cooper et al. 2009 ).", [["Fisher's Z", "TEST", 27, 37], ["disease risk", "PROBLEM", 84, 96], ["each study", "TEST", 227, 237], ["size", "OBSERVATION_MODIFIER", 11, 15], ["large", "OBSERVATION_MODIFIER", 267, 272]]], ["The variance in random-effects specification includes both the error term common to the fixed-effects model but also a term that accounts for between-study heterogeneity.", [["The variance in random-effects specification", "PROBLEM", 0, 44]]], ["The null hypothesis that this between-study variance is zero can be evaluated with a Cochran's Q, which is distributed as chi-square with k \u00c0 1 degrees of freedom.", [["The null hypothesis", "PROBLEM", 0, 19], ["a Cochran's Q", "TEST", 83, 96], ["chi-square", "TEST", 122, 132], ["k", "TEST", 138, 139]]], ["Confidence intervals on overall effect sizes are frequently constructed assuming a normal approximation.", [["normal", "OBSERVATION", 83, 89]]], ["However, a number of authors have shown that normal confidence intervals substantially under-estimate the true uncertainty in overall Table 1 Details of studies included in meta-analysis: disease agent, study location, the components of the biodiversity-disease relationship (e.g. species richness, disease seroprevalence, Rosenthal's r, Because of the uneven reporting of test statistics, we also present the published P-values to interpret the statistical strength of the reported relationships between biodiversity and disease risk (Hedges & Olkin 1985) .METHODSWe used a funnel plot, which depicts standardised effect size against the study standard error, to search for any evidence of publication bias (Chaplin-Kramer et al. 2011) .", [["P", "DNA", 420, 421], ["disease agent", "PROBLEM", 188, 201], ["disease relationship", "PROBLEM", 254, 274], ["a funnel plot", "TEST", 573, 586], ["the study", "TEST", 635, 644], ["publication bias", "PROBLEM", 691, 707], ["biodiversity", "OBSERVATION", 241, 253]]], ["If there is no publication bias, effect sizes from studies with larger sample sizes will be near the average, whereas effect sizes from smaller sample sizes will spread on both sides of the average.", [["publication bias", "PROBLEM", 15, 31], ["studies", "TEST", 51, 58], ["larger sample sizes", "PROBLEM", 64, 83], ["smaller sample sizes", "PROBLEM", 136, 156], ["no", "UNCERTAINTY", 12, 14], ["publication bias", "OBSERVATION", 15, 31], ["sizes", "OBSERVATION_MODIFIER", 40, 45], ["larger", "OBSERVATION_MODIFIER", 64, 70], ["sizes", "OBSERVATION_MODIFIER", 78, 83], ["sizes", "OBSERVATION_MODIFIER", 125, 130], ["smaller", "OBSERVATION_MODIFIER", 136, 143], ["sample", "OBSERVATION_MODIFIER", 144, 150], ["sizes", "OBSERVATION_MODIFIER", 151, 156]]], ["That is, unbiased data should be shaped like a funnel, whereas biased data will generate an asymmetric funnel plot (Chaplin-Kramer et al. 2011) .", [["an asymmetric funnel plot", "PROBLEM", 89, 114]]], ["We also tested for the effect of potential publication bias by using the trim-and-fill method (Duval & Tweedie 2000a,b) , implemented in the R package meta.", [["the trim", "TREATMENT", 69, 77]]], ["This intuitively appealing method allows the imputation of possible missing effect-size estimates based on inferred publication bias.", [["missing effect", "PROBLEM", 68, 82], ["size estimates", "PROBLEM", 83, 97], ["size", "OBSERVATION_MODIFIER", 83, 87]]], ["In the case of publication bias, confidence intervals are likely to be systematically under-estimated since the variance of the low-power samples (i.e. the bottom right of our funnel plot) is truncated by the missing samples.", [["right", "ANATOMY_MODIFIER", 163, 168]]], ["In trim-and-fill method, confidence intervals for the overall effect size are recalculated including imputed values.", [["size", "OBSERVATION_MODIFIER", 69, 73]]], ["Confidence intervals for the trim-and-fill method are calculated using a normal approximation.", [["the trim", "TEST", 25, 33], ["normal", "OBSERVATION", 73, 79]]], ["A sample not subject to publication bias should show little change in the estimated confidence intervals from the original sample to the augmented sample.", [["A sample", "TEST", 0, 8], ["publication bias", "TEST", 24, 40], ["little", "OBSERVATION_MODIFIER", 53, 59], ["change", "OBSERVATION_MODIFIER", 60, 66]]], ["The trim-and-fill approach also allows rank-based estimates (R 0 + and L 0 + ) of the probable number of missing studies due to publication bias, rounded to the nearest integer as recommended (Duval & Tweedie 2000a,b) .", [["missing studies", "PROBLEM", 105, 120], ["publication bias", "PROBLEM", 128, 144]]], ["Because this is a question of publication bias, we calculate this value for both our complete sample (which includes three unpublished studies) and the sub-sample of only published papers (n = 13).RESULTSWe analysed 16 biodiversity-disease relationships: eight studies on hantaviruses (including one unpublished data set), three studies on West Nile virus, two studies on Lyme disease risk, two studies on A. phagocytophilum (including one unpublished data set) and one study on plague (from an unpublished data set) (Table 1) .RESULTSAcross all studies, the mean Fisher's Z was \u00c00.138 (95% CI using t-distribution = \u00c00.220 to \u00c00.057; n = 16) from the fixedeffects model.", [["Lyme disease", "DISEASE", 372, 384], ["West Nile virus", "ORGANISM", 340, 355], ["A. phagocytophilum", "ORGANISM", 406, 424], ["Nile virus", "SPECIES", 345, 355], ["A. phagocytophilum", "SPECIES", 406, 424], ["West Nile virus", "SPECIES", 340, 355], ["A. phagocytophilum", "SPECIES", 406, 424], ["publication bias", "PROBLEM", 30, 46], ["unpublished studies", "TEST", 123, 142], ["eight studies", "TEST", 255, 268], ["hantaviruses", "PROBLEM", 272, 284], ["three studies", "TEST", 323, 336], ["Lyme disease risk", "PROBLEM", 372, 389], ["two studies", "TEST", 391, 402], ["one study", "TEST", 466, 475], ["all studies", "TEST", 542, 553], ["the mean Fisher's Z", "TEST", 555, 574], ["t-distribution", "TEST", 600, 614]]], ["However, the test for heterogeneity in the error models of the individual studies was significant at the P < 0.0001 level (Q = 66.66, d.f. = 15), indicating that the random effects model is more appropriate for the overall mean.", [["the test", "TEST", 9, 17], ["the individual studies", "TEST", 59, 81]]], ["The mean effect from the random effects model was \u00c00.2301 (95% CI using t-distribution = \u00c00.470-0.008; n = 16).", [["CI", "TEST", 63, 65], ["t-distribution", "TEST", 72, 86], ["mean effect", "OBSERVATION", 4, 15]]], ["The 95% confidence interval crosses zero, suggesting a non-significant relationship between measures of biodiversity and zoonotic disease risk (Fig. 1) .", [["zoonotic disease", "DISEASE", 121, 137], ["The 95% confidence interval crosses zero", "PROBLEM", 0, 40], ["zoonotic disease risk", "PROBLEM", 121, 142], ["zoonotic disease", "OBSERVATION", 121, 137]]], ["The distribution of P-values was uniform (Fig. 2) , suggesting that the relationship between biodiversity and disease risk fails to contradict the null hypothesis overall.RESULTSThe funnel plot (Fig. 3) provides mixed evidence of publication bias but is nonetheless quite revealing.", [["P", "DNA", 20, 21], ["P-values", "TEST", 20, 28], ["disease risk fails", "PROBLEM", 110, 128], ["the null hypothesis", "PROBLEM", 143, 162], ["funnel plot", "TEST", 182, 193], ["publication bias", "PROBLEM", 230, 246], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["publication bias", "OBSERVATION", 230, 246]]], ["First, all the strongest negative effects (i.e. those supporting the dilution effect hypothesis) are for studies with quite small sample sizes, and therefore large standard errors.", [["studies", "TEST", 105, 112], ["quite small sample sizes", "PROBLEM", 118, 142], ["large standard errors", "PROBLEM", 158, 179], ["sizes", "OBSERVATION_MODIFIER", 137, 142], ["large", "OBSERVATION_MODIFIER", 158, 163], ["standard errors", "OBSERVATION", 164, 179]]], ["Second, while the effect-sizes for the larger studies do indeed cluster near the overall mean effect size, this mean is quite modestly negative.", [["the larger studies", "TEST", 35, 53], ["overall", "OBSERVATION_MODIFIER", 81, 88], ["mean effect", "OBSERVATION", 89, 100], ["size", "OBSERVATION_MODIFIER", 101, 105], ["modestly", "OBSERVATION_MODIFIER", 126, 134], ["negative", "OBSERVATION", 135, 143]]], ["Finally, there is a pronounced asymmetry to the funnel, with more highly negative results at the lowest sample sizes.", [["a pronounced asymmetry to the funnel", "PROBLEM", 18, 54], ["pronounced", "OBSERVATION_MODIFIER", 20, 30], ["asymmetry", "OBSERVATION", 31, 40], ["funnel", "OBSERVATION", 48, 54], ["sizes", "OBSERVATION_MODIFIER", 111, 116]]], ["This is suggestive that either (1) small studies that do not support the dilution effect hypothesis are not published or (2) that there is unmeasured heterogeneity in the studies.", [["small studies", "TEST", 35, 48], ["the dilution effect hypothesis", "PROBLEM", 69, 99], ["unmeasured heterogeneity in the studies", "PROBLEM", 139, 178], ["unmeasured", "OBSERVATION_MODIFIER", 139, 149], ["heterogeneity", "OBSERVATION", 150, 163]]], ["Spearman rank correlations between Fisher's Z and standard error were not statistically significant at the conventional P < 0.05 level: excluding unpublished studies, q = 0.51, P = 0.06; across all studies, q = 0.46, P = 0.11.", [["Fisher's Z", "TEST", 35, 45], ["unpublished studies", "TEST", 146, 165], ["P", "TEST", 177, 178], ["all studies", "TEST", 194, 205], ["P", "TEST", 217, 218]]], ["This last point is suggestive of publication bias favouring negative relationships between biodiversity and disease risk.RESULTSThe trim and fill analysis uses a normal approximation for the confidence interval of the estimated overall effect size (in contrast to the t-distribution CIs we report above): for the full sample, the fixed-effect model yielded a mean Fisher's Z of \u00c00.138 (95% CI using normal distribution = \u00c00.213 to \u00c00.063; n = 16); for the random-effects model, the mean Fisher's Z was \u00c00.230 (95% CI using normal distribution = \u00c00.450 to \u00c00.010; n = 16) with a significant test of heterogeneity in the error models of the individual studies (P < 0.0001, Q = 66.66, d.f. = 15), indicating that the random effects model is more appropriate for the overall mean.", [["publication bias", "PROBLEM", 33, 49], ["disease risk", "PROBLEM", 108, 120], ["fill analysis", "TEST", 141, 154], ["a mean Fisher's Z", "TEST", 357, 374], ["CI", "TEST", 390, 392], ["the mean Fisher's Z", "TEST", 478, 497], ["CI", "TEST", 514, 516], ["P", "TEST", 659, 660], ["Q", "TEST", 671, 672], ["suggestive of", "UNCERTAINTY", 19, 32], ["publication bias", "OBSERVATION", 33, 49], ["effect", "OBSERVATION_MODIFIER", 236, 242], ["size", "OBSERVATION_MODIFIER", 243, 247], ["significant", "OBSERVATION_MODIFIER", 578, 589], ["heterogeneity", "OBSERVATION", 598, 611]]], ["For the sub-sample of published studies, the fixed-effect model yielded a mean Fisher's Z of \u00c00.159 (95% CI using normal distribution = \u00c00.236 to \u00c00.081; n = 13); for the random-effects model, the mean Fisher's Z was \u00c00.331 (95% CI using normal distribution = \u00c00.587-0.075; n = 13) with a significant test of heterogeneity in the error models of the individual studies (P < 0.0001, Q = 62.59, d.f. = 12), indicating that the random effects model is more appropriate for the overall mean.RESULTSImputing the possible missing effect-size estimates using the trim and fill analyses calculates CI intervals that mirror the results found from our analyses of the t-distributions.", [["published studies", "TEST", 22, 39], ["a mean Fisher's Z", "TEST", 72, 89], ["CI", "TEST", 105, 107], ["the mean Fisher's Z", "TEST", 193, 212], ["CI", "TEST", 229, 231], ["P", "TEST", 370, 371], ["Q", "TEST", 382, 383], ["missing effect", "PROBLEM", 516, 530], ["significant", "OBSERVATION_MODIFIER", 289, 300], ["heterogeneity", "OBSERVATION", 309, 322], ["possible", "UNCERTAINTY", 507, 515], ["size", "OBSERVATION_MODIFIER", 531, 535]]], ["For the full sample, the trim and fill imputation added one study to the sample.", [["one study", "TEST", 56, 65]]], ["For the fixed-effect model, mean Fisher's Z was \u00c00.129 (95% CI using normal distribution = \u00c00.204 to \u00c00.054; n = 17); and for the random effects model, mean Fisher's Z was \u00c00.175 (95% CI using normal distribution = \u00c00.416-0.066; n = 17).", [["mean Fisher's Z", "TEST", 28, 43], ["CI", "TEST", 60, 62], ["mean Fisher's Z", "TEST", 152, 167], ["CI", "TEST", 184, 186]]], ["Once again, the test for heterogeneity in the error models of the individual studies was significant at the P < 0.0001 level (Q = 86.21, d.f. = 16), indicating that the random effects model is more appropriate for the overall mean and suggests a non-significant overall effect of biodiversity on disease risk.", [["the test", "TEST", 12, 20], ["the individual studies", "TEST", 62, 84], ["the random effects model", "PROBLEM", 165, 189], ["disease risk", "PROBLEM", 296, 308], ["non-significant", "OBSERVATION_MODIFIER", 246, 261], ["overall", "OBSERVATION_MODIFIER", 262, 269], ["effect", "OBSERVATION_MODIFIER", 270, 276], ["biodiversity", "OBSERVATION", 280, 292]]], ["The rank-based estimates of the probable number of missing studies due to publication bias are R 0 + = 4 and L 0 + = 4, suggesting that four studies are missing from the meta-analysis due to publication bias (Duval & Tweedie 2000a,b) .", [["missing studies", "TEST", 51, 66], ["publication bias", "TEST", 74, 90], ["four studies", "TEST", 136, 148], ["the meta-analysis", "TEST", 166, 183]]], ["This represents 25% of the total sample of studies analysed here and 20% of the hypothetical sample.", [["the total sample of studies", "TEST", 23, 50], ["the hypothetical sample", "TEST", 76, 99]]], ["For the sub-sample of published studies, trim and fill analysis imputation added three studies to this sub-sample, and calculated a mean Fisher's Z for the fixed-effect model of \u00c00.117 (95% CI using normal distribution = \u00c00.193 to \u00c00.040; n = 16); and for the random effects model, mean Fisher's Z was \u00c00.105 (95% CI using normal distribution = \u00c00.388-0.179; n = 16).", [["published studies", "TEST", 22, 39], ["fill analysis imputation", "TEST", 50, 74], ["CI", "TEST", 190, 192], ["mean Fisher's Z", "TEST", 282, 297], ["CI", "TEST", 314, 316]]], ["Once again, the test for heterogeneity in the error models of the individual studies was significant at the P < 0.0001 level (Q = 106.99, d.f. = 15), indicating that the random effects model is more appropriate for the overall mean and suggests a non-significant overall effect of biodiversity on disease risk.", [["the test", "TEST", 12, 20], ["the individual studies", "TEST", 62, 84], ["the random effects model", "PROBLEM", 166, 190], ["disease risk", "PROBLEM", 297, 309], ["non-significant", "OBSERVATION_MODIFIER", 247, 262], ["overall", "OBSERVATION_MODIFIER", 263, 270], ["effect", "OBSERVATION_MODIFIER", 271, 277], ["biodiversity", "OBSERVATION", 281, 293]]], ["The rank-based estimates of the probable number of missing studies due to publication bias are R 0 + = 7 and L 0 + = 5, suggesting that between five and seven studies are missing from the published sub-sample due to publication bias (Duval & Tweedie 2000a,b) , representing 38-54% of the total sample of studies analysed here and 31-44% of the hypothetical sample.RESULTSOur results are not consistent with the claim that biodiversity provides a general service of reducing the risk of infectious disease.", [["infectious disease", "DISEASE", 486, 504], ["missing studies", "TEST", 51, 66], ["publication bias", "TEST", 74, 90], ["seven studies", "TEST", 153, 166], ["publication bias", "TEST", 216, 232], ["the total sample of studies", "TEST", 284, 311], ["the hypothetical sample", "TEST", 340, 363], ["infectious disease", "PROBLEM", 486, 504], ["not consistent with", "UNCERTAINTY", 387, 406], ["infectious", "OBSERVATION", 486, 496]]], ["Considering just hantavirus study systems, the mean Fisher's Z-value was \u00c00.1438 (n = 8, 95% t-distribution CI = \u00c00.231-0.057) from the fixed-effects model, with 3/8 studies reporting a statistically significant relationship at P < 0.05 (Table 1 ).", [["hantavirus study systems", "TEST", 17, 41], ["the mean Fisher's Z", "TEST", 43, 62], ["t-distribution", "TEST", 93, 107], ["CI", "TEST", 108, 110], ["3/8 studies", "TEST", 162, 173]]], ["The hantavirus studies showed significant evidence for heterogeneity (Q = 52.44, d.f. = 7, P < 0.0001).", [["The hantavirus studies", "TEST", 0, 22], ["heterogeneity", "PROBLEM", 55, 68], ["P", "TEST", 91, 92], ["hantavirus", "OBSERVATION", 4, 14], ["significant evidence for", "UNCERTAINTY", 30, 54]]], ["The mean and 95% CI from the random effects model was \u00c00.325 (\u00c00.668-0.019).", [["The mean", "TEST", 0, 8], ["CI", "TEST", 17, 19], ["the random effects model", "TEST", 25, 49], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["Mean Fisher's Z-value s for tick-borne disease agents (A. phagocytophilum and B. burgdorferi combined) was 0.112 (95% t-distribution CI = \u00c00.186-0.410, n = 4; fixed-effects model), with 0/4 studies reporting a statistically significant relationship at P < 0.05 (Table 1) .", [["A. phagocytophilum", "ORGANISM", 55, 73], ["B. burgdorferi", "ORGANISM", 78, 92], ["A. phagocytophilum", "SPECIES", 55, 73], ["B. burgdorferi", "SPECIES", 78, 92], ["A. phagocytophilum", "SPECIES", 55, 73], ["B. burgdorferi", "SPECIES", 78, 92], ["Mean Fisher's Z-value s", "TEST", 0, 23], ["tick-borne disease agents", "PROBLEM", 28, 53], ["CI", "TEST", 133, 135], ["0/4 studies", "TEST", 186, 197]]], ["Mean Fisher's Z-values for West Nile virus was \u00c00.672 (95% t-distribution CI = \u00c01.126-0.272, n = 3), with 1/3 studies reporting a statistically significant relationship at P < 0.05 (Table 1) .DISCUSSIONOur meta-analysis of effect sizes and P-values from the published literature on human disease agents provides very weak support, at best, for the dilution effect, and by extension the assertion that the preservation of endemic biodiversity will reduce the prevalence of zoonotic diseases.", [["zoonotic diseases", "DISEASE", 472, 489], ["West Nile virus", "ORGANISM", 27, 42], ["human", "ORGANISM", 282, 287], ["Nile virus", "SPECIES", 32, 42], ["human", "SPECIES", 282, 287], ["West Nile virus", "SPECIES", 27, 42], ["human", "SPECIES", 282, 287], ["Mean Fisher's Z-values", "TEST", 0, 22], ["West Nile virus", "TEST", 27, 42], ["t-distribution", "TEST", 59, 73], ["CI", "TEST", 74, 76], ["1/3 studies", "TEST", 106, 117], ["effect sizes", "PROBLEM", 223, 235], ["P-values", "TEST", 240, 248], ["human disease agents", "TREATMENT", 282, 302], ["endemic biodiversity", "TREATMENT", 421, 441], ["zoonotic diseases", "PROBLEM", 472, 489], ["sizes", "OBSERVATION_MODIFIER", 230, 235], ["zoonotic diseases", "OBSERVATION", 472, 489]]], ["Although the mean effect size is negative, the confidence interval around the mean crosses zero, so the null hypothesis of no effect cannot be rejected.", [["the mean crosses zero", "TEST", 74, 95], ["the null hypothesis", "PROBLEM", 100, 119], ["size", "OBSERVATION_MODIFIER", 25, 29], ["negative", "OBSERVATION", 33, 41], ["no effect cannot be", "UNCERTAINTY", 123, 142]]], ["Furthermore, there is strong evidence for heterogeneity in the effects, suggesting that different processes are acting on the different studies.", [["heterogeneity in the effects", "PROBLEM", 42, 70], ["the different studies", "TEST", 122, 143], ["strong evidence for", "UNCERTAINTY", 22, 41], ["heterogeneity", "OBSERVATION", 42, 55], ["different", "OBSERVATION_MODIFIER", 88, 97], ["processes", "OBSERVATION", 98, 107]]], ["We conclude that the relationship between biodiversity and zoonotic disease risk is probably idiosyncratic, and that understanding the ecological dynamics of specific disease systems is more important in predicting zoonotic disease risk.DISCUSSIONA challenge in assessing the evidence in support of the dilution effect is the differences between disease systems and/or variable measures of disease risk.", [["zoonotic disease", "DISEASE", 59, 75], ["zoonotic disease", "DISEASE", 215, 231], ["zoonotic disease risk", "PROBLEM", 59, 80], ["idiosyncratic", "PROBLEM", 93, 106], ["specific disease systems", "PROBLEM", 158, 182], ["zoonotic disease risk", "PROBLEM", 215, 236], ["the dilution effect", "TREATMENT", 299, 318], ["the differences between disease systems", "PROBLEM", 322, 361], ["disease risk", "PROBLEM", 390, 402], ["zoonotic disease", "OBSERVATION", 59, 75], ["probably", "UNCERTAINTY", 84, 92], ["idiosyncratic", "OBSERVATION_MODIFIER", 93, 106]]], ["For example, we used two studies examining Lyme disease: LoGiudice et al. (2008) determined risk by nymphal infection prevalence (NIP, i.e. proportion of ticks infected with B. burgdorferi), whereas Prusinski et al. (2006) measured B. burgdorferi infection prevalence in mammalian hosts.", [["Lyme disease", "DISEASE", 43, 55], ["nymphal infection", "DISEASE", 100, 117], ["B. burgdorferi", "DISEASE", 174, 188], ["B. burgdorferi infection", "DISEASE", 232, 256], ["nymphal", "ORGANISM_SUBDIVISION", 100, 107], ["B. burgdorferi", "ORGANISM", 174, 188], ["B. burgdorferi", "ORGANISM", 232, 246], ["B. burgdorferi", "SPECIES", 174, 188], ["B. burgdorferi", "SPECIES", 232, 246], ["B. burgdorferi", "SPECIES", 174, 188], ["B. burgdorferi", "SPECIES", 232, 246], ["two studies", "TEST", 21, 32], ["Lyme disease", "PROBLEM", 43, 55], ["nymphal infection prevalence", "PROBLEM", 100, 128], ["nymphal", "ANATOMY", 100, 107], ["infection", "OBSERVATION", 108, 117]]], ["Lyme disease risk can also be measured as density of infected nymphs (DIN), and the implications of the dilution effect are starkly different depending on the risk measure adopted: for instance, a reduction in nymphal infection prevalence associated with increased host biodiversity may be negated if higher host biodiversity increases vector density (Schmidt & Ostfeld 2001; Salkeld & Lane 2010; Wood & Lafferty 2012) , which is why several studies suggest that DIN is a more direct measure of risk to humans.", [["Lyme disease", "DISEASE", 0, 12], ["infection", "DISEASE", 218, 227], ["DIN", "CHEMICAL", 463, 466], ["humans", "ORGANISM", 503, 509], ["humans", "SPECIES", 503, 509], ["Schmidt & Ostfeld 2001; Salkeld & Lane 2010; Wood & Lafferty 2012", "SPECIES", 352, 417], ["humans", "SPECIES", 503, 509], ["Lyme disease risk", "PROBLEM", 0, 17], ["infected nymphs", "PROBLEM", 53, 68], ["the dilution effect", "TREATMENT", 100, 119], ["a reduction in nymphal infection prevalence", "PROBLEM", 195, 238], ["increased host biodiversity", "PROBLEM", 255, 282], ["infected", "OBSERVATION_MODIFIER", 53, 61], ["nymphs", "OBSERVATION", 62, 68], ["nymphal infection", "OBSERVATION", 210, 227], ["host biodiversity", "OBSERVATION", 265, 282], ["biodiversity", "OBSERVATION_MODIFIER", 313, 325]]], ["Similarly, in Argentina, host species diversity and evenness was not correlated with Andes virus (a hantavirus) antibody seroprevalence in the reservoir hostthe long-tailed colilargo, Oligoryzomys longicaudatusbut there was a correlation between species diversity and the abundance of antibodypositive O. longicaudatus (Piudo et al. 2011) .", [["Andes virus", "ORGANISM", 85, 96], ["Oligoryzomys longicaudatusbut", "ORGANISM", 184, 213], ["O. longicaudatus", "ORGANISM", 302, 318], ["Oligoryzomys longicaudatusbut", "SPECIES", 184, 213], ["O. longicaudatus", "SPECIES", 302, 318], ["Andes virus", "SPECIES", 85, 96], ["hantavirus", "SPECIES", 100, 110], ["hostthe long-tailed colilargo", "SPECIES", 153, 182], ["Oligoryzomys longicaudatusbut", "SPECIES", 184, 213], ["O. longicaudatus", "SPECIES", 302, 318], ["Andes virus", "PROBLEM", 85, 96], ["a hantavirus)", "TREATMENT", 98, 111], ["Oligoryzomys", "TREATMENT", 184, 196], ["species diversity", "PROBLEM", 246, 263], ["host", "OBSERVATION_MODIFIER", 25, 29], ["species diversity", "OBSERVATION", 30, 47]]], ["We recommend reporting data on both prevalence and density of infection (in vectors and/or vertebrate hosts) so that public health agencies can interpret how biodiversity affects these key components of disease risk.", [["infection", "DISEASE", 62, 71], ["reporting data", "TEST", 13, 27], ["infection", "PROBLEM", 62, 71], ["disease risk", "PROBLEM", 203, 215], ["density", "OBSERVATION_MODIFIER", 51, 58], ["infection", "OBSERVATION", 62, 71]]], ["Parallel issues arise when attempting to interpret measures of biodiversity: is species richness, evenness or some index the best indicator of community biodiversity?DISCUSSIONWe only included studies that explicitly measured biodiversity, because proxies may fail to accurately represent local community ecology (Wood & Lafferty 2012) .", [["Parallel issues", "PROBLEM", 0, 15], ["studies", "TEST", 193, 200]]], ["When species richness was explicitly measured, there was little evidence of a significant relationship with Lyme disease risk (Prusinski et al. 2006; LoGiudice et al. 2008) .", [["Lyme disease", "DISEASE", 108, 120], ["species richness", "PROBLEM", 5, 21], ["Lyme disease risk", "PROBLEM", 108, 125], ["little evidence of", "UNCERTAINTY", 57, 75], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["Lyme disease", "OBSERVATION", 108, 120]]], ["Studies that do use substitute measures (e.g. forest fragmentation) provide conflicting results: a negative correlation between forest fragmentation and Lyme disease risk in New York & Connecticut (Allan et al. 2003; Brownstein et al. 2005) ; no relationship across New York, Connecticut and New Jersey (LoGiudice et al. 2008); and lower human incidence of Lyme disease in fragmented contexts in Connecticut (Brownstein et al. 2005) .DISCUSSIONRather than biodiversity, it is more likely that the role of individual host species and their interactions with other hosts, vectors, and the pathogen that are more influential in determining local disease risk (Kilpatrick et al. 2006; LoGiudice et al. 2008; Salkeld & Lane 2010; Hamer et al. 2011) .", [["Lyme disease", "DISEASE", 153, 165], ["Lyme disease", "DISEASE", 357, 369], ["human", "ORGANISM", 338, 343], ["human", "SPECIES", 338, 343], ["human", "SPECIES", 338, 343], ["substitute measures", "TREATMENT", 20, 39], ["forest fragmentation", "PROBLEM", 128, 148], ["Lyme disease risk", "PROBLEM", 153, 170], ["Lyme disease", "PROBLEM", 357, 369], ["individual host species", "PROBLEM", 505, 528], ["the pathogen", "PROBLEM", 583, 595], ["Lyme disease", "OBSERVATION", 153, 165], ["Lyme disease", "OBSERVATION", 357, 369], ["more likely", "UNCERTAINTY", 476, 487]]], ["For example, the reservoir competence and abundance of particular bird species and the mosquito vector's feeding preferences may be better predictors of West Nile virus activity than avian species richness (Kilpatrick et al. 2006; Loss et al. 2009; Hamer et al. 2011) .", [["West Nile virus", "ORGANISM", 153, 168], ["West Nile virus", "SPECIES", 153, 168], ["particular bird species", "PROBLEM", 55, 78], ["the mosquito vector's feeding preferences", "TREATMENT", 83, 124], ["bird species", "OBSERVATION", 66, 78]]], ["In Utah's Great Basin Desert, pinyon mice (Peromyscus truei) appear to reduce hantavirus antibody prevalence, whereas kangaroo rats (Dipodomys ordii) seem to increase hantavirus antibody prevalence (Clay et al. 2009) , and in Montana, estimated Sin Nombre antibody prevalence in deer mice was reduced in the presence of voles (Microtus spp.), although vole abundance was not important (Carver et al. 2011) .DISCUSSIONAt a larger spatial scale, some studies have demonstrated negative correlations between measures of diversity and disease, for example, human WNV incidence at the county level negatively correlated with data from breeding bird atlases or surveys (Ezenwa et al. 2006; Swaddle & Calos 2008; Allan et al. 2009 ).", [["hantavirus antibody prevalence", "DISEASE", 78, 108], ["pinyon mice", "ORGANISM", 30, 41], ["Peromyscus truei", "ORGANISM", 43, 59], ["hantavirus", "ORGANISM", 78, 88], ["kangaroo rats", "ORGANISM", 118, 131], ["Dipodomys ordii", "ORGANISM", 133, 148], ["hantavirus", "ORGANISM", 167, 177], ["Sin", "ORGANISM", 245, 248], ["Nombre", "GENE_OR_GENE_PRODUCT", 249, 255], ["deer mice", "ORGANISM", 279, 288], ["voles", "ORGANISM", 320, 325], ["Microtus spp.", "ORGANISM", 327, 340], ["human", "ORGANISM", 553, 558], ["WNV", "ORGANISM", 559, 562], ["Sin Nombre antibody", "PROTEIN", 245, 264], ["mice", "SPECIES", 37, 41], ["Peromyscus truei", "SPECIES", 43, 59], ["kangaroo", "SPECIES", 118, 126], ["rats", "SPECIES", 127, 131], ["Dipodomys ordii", "SPECIES", 133, 148], ["mice", "SPECIES", 284, 288], ["Microtus spp.", "SPECIES", 327, 340], ["human", "SPECIES", 553, 558], ["mice", "SPECIES", 37, 41], ["Peromyscus truei", "SPECIES", 43, 59], ["hantavirus", "SPECIES", 78, 88], ["kangaroo", "SPECIES", 118, 126], ["Dipodomys ordii", "SPECIES", 133, 148], ["deer", "SPECIES", 279, 283], ["mice", "SPECIES", 284, 288], ["voles", "SPECIES", 320, 325], ["Microtus spp.", "SPECIES", 327, 340], ["human", "SPECIES", 553, 558], ["WNV", "SPECIES", 559, 562], ["pinyon mice (Peromyscus truei)", "TREATMENT", 30, 60], ["hantavirus antibody prevalence", "PROBLEM", 78, 108], ["some studies", "TEST", 444, 456], ["disease", "PROBLEM", 531, 538], ["disease", "OBSERVATION", 531, 538]]], ["In contrast, mammal diversity at a global scale has been linked to increased likelihood of emerging zoonotic pathogens (Jones et al. 2008) .", [["zoonotic pathogens", "DISEASE", 100, 118], ["emerging zoonotic pathogens", "PROBLEM", 91, 118], ["mammal diversity", "OBSERVATION", 13, 29], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["zoonotic", "OBSERVATION_MODIFIER", 100, 108]]], ["We believe that these studies should be interpreted with caution given that vertebrate diversity, incidence of zoonoses, vector feeding ecology and infection rates are often recorded at different times or spatial scales and rely on disparate sources of data.", [["zoonoses", "DISEASE", 111, 119], ["infection", "DISEASE", 148, 157], ["these studies", "TEST", 16, 29], ["vertebrate diversity", "PROBLEM", 76, 96], ["zoonoses", "PROBLEM", 111, 119], ["vector feeding ecology", "TREATMENT", 121, 143], ["infection rates", "PROBLEM", 148, 163], ["spatial scales", "TEST", 205, 219]]], ["That is, disease transmission can operate at fine spatial scales and data at coarse county or region levels may not be indicative of local pathogen transmission patterns (Loss et al. 2009; Hamer et al. 2011) .", [["disease transmission", "PROBLEM", 9, 29], ["local pathogen transmission patterns", "PROBLEM", 133, 169], ["may not be indicative of", "UNCERTAINTY", 108, 132], ["local", "OBSERVATION_MODIFIER", 133, 138], ["pathogen", "OBSERVATION", 139, 147]]], ["We have attempted to avoid this fallacy by not including county-level studies.DISCUSSIONWe did not include studies that examine non-human pathogens in our meta-analysis because our interest was in the possible relationship between wildlife biodiversity and human health.", [["non-human", "ORGANISM", 128, 137], ["human", "ORGANISM", 257, 262], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 257, 262], ["studies", "TEST", 107, 114], ["non-human pathogens", "PROBLEM", 128, 147]]], ["However, we presume that impacts of biodiversity on non-human diseases will also depend on local ecology and the particular host-pathogen relationships (e.g. Hudson et al. 2006; Salkeld et al. 2008; Chasar et al. 2009; Wood et al. 2010) .", [["non-human diseases", "DISEASE", 52, 70], ["non-human", "ORGANISM", 52, 61], ["non-human diseases", "PROBLEM", 52, 70], ["biodiversity", "OBSERVATION_MODIFIER", 36, 48]]], ["For example, a recent meta-analysis, found that relationships between primate parasite prevalence and mammal species richness were idiosyncratic (Young et al. 2013 ).DISCUSSIONIf we are to gain an understanding of causal mechanisms generating diversity-disease relationships, investigations into the relationship between biodiversity and zoonotic disease risk must collect data on biodiversity that is spatially and temporally related to the relevant measures of disease risk.", [["zoonotic disease", "DISEASE", 338, 354], ["primate", "ORGANISM", 70, 77], ["a recent meta-analysis", "TEST", 13, 35], ["mammal species richness", "PROBLEM", 102, 125], ["disease relationships", "PROBLEM", 253, 274], ["zoonotic disease risk", "PROBLEM", 338, 359], ["disease risk", "PROBLEM", 463, 475], ["mammal", "OBSERVATION_MODIFIER", 102, 108], ["species richness", "OBSERVATION", 109, 125], ["zoonotic disease", "OBSERVATION", 338, 354]]], ["For example, WNV infection rates in mosquitoes should be related to the bird community that fed the mosquito population.", [["WNV infection", "DISEASE", 13, 26], ["WNV", "ORGANISM", 13, 16], ["WNV", "SPECIES", 13, 16], ["WNV infection rates in mosquitoes", "PROBLEM", 13, 46], ["WNV", "OBSERVATION_MODIFIER", 13, 16], ["infection", "OBSERVATION", 17, 26]]], ["Investigations must acknowledge variation in vector feeding behaviour (host species preferences), vector and host transmission biology, and the influences of abiotic factors (e.g. temperature, rainfall) and habitat types upon disease dynamics (Randolph & Dobson 2012) .", [["Investigations", "TEST", 0, 14], ["abiotic factors", "PROBLEM", 158, 173], ["temperature", "TEST", 180, 191], ["disease dynamics", "PROBLEM", 226, 242]]], ["Measures of biodiversity should incorporate additional species that may interact with reservoir species, for example, carnivores that might influence rodent host population biology and thereby influence hantavirus or B. burgdorferi transmission dynamics (Ostfeld & Holt 2004) .", [["hantavirus or B. burgdorferi transmission", "DISEASE", 203, 244], ["hantavirus", "ORGANISM", 203, 213], ["B. burgdorferi", "ORGANISM", 217, 231], ["rodent", "SPECIES", 150, 156], ["B. burgdorferi", "SPECIES", 217, 231], ["B. burgdorferi", "SPECIES", 217, 231], ["biodiversity", "TREATMENT", 12, 24], ["additional species", "PROBLEM", 44, 62], ["reservoir species", "TREATMENT", 86, 103]]], ["A promising approach to understanding interactions between disease ecology and epidemiology is to focus on tractable manipulations such as removal of particular host or vector species (e.g. Tsao et al. 2004; Perkins et al. 2006; Suz an et al. 2009 ).", [["tractable manipulations", "TREATMENT", 107, 130], ["removal", "TREATMENT", 139, 146]]], ["Also, analyses must entertain and control for alternate hypotheses that affect both biodiversity and disease risk, such as rainfall gradients, urbanisation, vector abundance, human behaviour, latitude.", [["human", "ORGANISM", 175, 180], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 175, 180], ["analyses", "TEST", 6, 14], ["disease risk", "PROBLEM", 101, 113]]], ["Such study designs, incorporating ecologists, epidemiologists, medical entomologists and public health agencies may facilitate an understanding of exactly what metrics are required to understand the local disease risk, and the mechanisms that allow zoonotic disease to spill over into human cases.DISCUSSIONPublic health initiatives intending to ameliorate disease risk must rely on a comprehensive, empirically based understanding of local disease ecology and epidemiology.", [["zoonotic disease", "DISEASE", 249, 265], ["human", "ORGANISM", 285, 290], ["human", "SPECIES", 285, 290], ["human", "SPECIES", 285, 290], ["the local disease risk", "PROBLEM", 195, 217], ["zoonotic disease", "PROBLEM", 249, 265], ["disease risk", "PROBLEM", 357, 369]]], ["Our analyses suggest that the links between biodiversity and disease prevalence are variable and dependent on the disease system, local ecology and probably human social context.", [["human", "ORGANISM", 157, 162], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["Our analyses", "TEST", 0, 12], ["disease prevalence", "PROBLEM", 61, 79]]], ["Broadly advocating for the preservation of biodiversity and natural ecosystems to reduce disease risk is an oversimplification of disease ecology and epidemiology.", [["the preservation of biodiversity", "TREATMENT", 23, 55], ["natural ecosystems", "TREATMENT", 60, 78], ["disease risk", "PROBLEM", 89, 101]]], ["If the disease dynamics are not well understood, conservation of endemic biodiversity could, in fact, increase human disease risk (e.g. if density of reservoirs or vectors increases), and may simultaneously remove economic and logistical resources from more effective control measures (Randolph & Dobson 2012) .", [["human", "ORGANISM", 111, 116], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["the disease dynamics", "PROBLEM", 3, 23], ["endemic biodiversity", "PROBLEM", 65, 85], ["human disease risk", "PROBLEM", 111, 129], ["economic and logistical resources", "TREATMENT", 214, 247], ["disease", "OBSERVATION", 7, 14], ["endemic", "OBSERVATION_MODIFIER", 65, 72], ["biodiversity", "OBSERVATION", 73, 85]]], ["Certainly, the links between measures of disease risk (e.g. infection rates in reservoir hosts or vectors) and actual human incidence (rates of infection in the local human populations) need to be better established.", [["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 144, 153], ["human", "ORGANISM", 118, 123], ["human", "ORGANISM", 167, 172], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 167, 172], ["disease risk", "PROBLEM", 41, 53], ["infection rates", "PROBLEM", 60, 75], ["infection", "PROBLEM", 144, 153]]], ["Furthermore, how and where humans are exposed has important consequences for the biodiversity-disease buffer hypothesis, that is are the scales at which biodiversity and disease risk are investigated actually relevant to human exposure to disease?DISCUSSIONIt is possible that the hope for a win-win outcomesimultaneous protection of biodiversity and human healthhas led to premature acceptance that the dilution effect is a general ecosystem service associated with biodiversity (Randolph & Dobson 2012) .", [["humans", "ORGANISM", 27, 33], ["human", "ORGANISM", 221, 226], ["human", "ORGANISM", 351, 356], ["humans", "SPECIES", 27, 33], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 351, 356], ["humans", "SPECIES", 27, 33], ["human", "SPECIES", 221, 226], ["human", "SPECIES", 351, 356], ["disease buffer hypothesis", "PROBLEM", 94, 119], ["disease risk", "PROBLEM", 170, 182], ["disease", "PROBLEM", 239, 246]]], ["However, our meta-analysis suggests that the dilution effect is neither general nor strong.", [["our meta-analysis", "TEST", 9, 26], ["the dilution effect", "PROBLEM", 41, 60], ["dilution effect", "OBSERVATION", 45, 60]]], ["The ecology of infectious disease is often too complicated to expect that there will be simple relationships between disease risk and biodiversity.", [["infectious disease", "DISEASE", 15, 33], ["simple relationships between disease risk", "PROBLEM", 88, 129], ["infectious", "OBSERVATION", 15, 25]]], ["A focus on the local ecology and interactions of important hosts and vectors is more likely to reveal insights into how to reduce disease risk and humans.", [["humans", "ORGANISM", 147, 153], ["humans", "SPECIES", 147, 153], ["humans", "SPECIES", 147, 153], ["disease risk", "PROBLEM", 130, 142]]]], "PMC7019308": [], "adb62a03ae3affb63e87e211b00927feb7f6e6c4": [["IntroductionCongenital neutropenia (CN) is a group of rare and inherited hematological disorders characterized by chronic profound neutropenia caused by impaired differentiation of neutrophilic granulocytes.", [["hematological", "ANATOMY", 73, 86], ["neutrophilic granulocytes", "ANATOMY", 181, 206], ["Congenital neutropenia", "DISEASE", 12, 34], ["CN", "DISEASE", 36, 38], ["hematological disorders", "DISEASE", 73, 96], ["neutropenia", "DISEASE", 131, 142], ["neutrophilic granulocytes", "CELL", 181, 206], ["neutrophilic granulocytes", "CELL_TYPE", 181, 206], ["Congenital neutropenia", "PROBLEM", 12, 34], ["inherited hematological disorders", "PROBLEM", 63, 96], ["chronic profound neutropenia", "PROBLEM", 114, 142], ["neutrophilic granulocytes", "PROBLEM", 181, 206], ["Congenital", "OBSERVATION_MODIFIER", 12, 22], ["neutropenia", "OBSERVATION", 23, 34], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["profound", "OBSERVATION_MODIFIER", 122, 130], ["neutropenia", "OBSERVATION", 131, 142], ["impaired", "OBSERVATION_MODIFIER", 153, 161], ["differentiation", "OBSERVATION_MODIFIER", 162, 177], ["neutrophilic granulocytes", "OBSERVATION", 181, 206]]], ["Often diagnosed early in life, CN is defined as recurrent, life-threatening bacterial infections (e.g., skin infections, otitis, gingivitis, abscesses and sepsis) [1] .", [["skin", "ANATOMY", 104, 108], ["abscesses", "ANATOMY", 141, 150], ["bacterial infections", "DISEASE", 76, 96], ["skin infections", "DISEASE", 104, 119], ["otitis", "DISEASE", 121, 127], ["gingivitis", "DISEASE", 129, 139], ["abscesses", "DISEASE", 141, 150], ["sepsis", "DISEASE", 155, 161], ["skin", "ORGAN", 104, 108], ["life-threatening bacterial infections", "PROBLEM", 59, 96], ["skin infections", "PROBLEM", 104, 119], ["otitis", "PROBLEM", 121, 127], ["gingivitis", "PROBLEM", 129, 139], ["abscesses", "PROBLEM", 141, 150], ["sepsis", "PROBLEM", 155, 161], ["bacterial", "OBSERVATION_MODIFIER", 76, 85], ["infections", "OBSERVATION", 86, 96], ["skin", "ANATOMY", 104, 108], ["infections", "OBSERVATION", 109, 119], ["otitis", "OBSERVATION", 121, 127], ["gingivitis", "OBSERVATION", 129, 139], ["abscesses", "OBSERVATION", 141, 150], ["sepsis", "OBSERVATION", 155, 161]]], ["The elastase, neutrophilexpressed (ELANE) gene encodes neutrophil elastase, and is responsible for ELANE neutropenia, which is probably the most frequent and one of the most severe CN forms, based on its infection rate [2] .", [["neutrophil", "ANATOMY", 55, 65], ["neutropenia", "DISEASE", 105, 116], ["infection", "DISEASE", 204, 213], ["elastase", "GENE_OR_GENE_PRODUCT", 4, 12], ["neutrophilexpressed", "GENE_OR_GENE_PRODUCT", 14, 33], ["ELANE", "GENE_OR_GENE_PRODUCT", 35, 40], ["neutrophil elastase", "GENE_OR_GENE_PRODUCT", 55, 74], ["elastase, neutrophilexpressed (ELANE) gene", "DNA", 4, 46], ["neutrophil elastase", "PROTEIN", 55, 74], ["The elastase", "TEST", 0, 12], ["neutrophil elastase", "TEST", 55, 74], ["ELANE neutropenia", "PROBLEM", 99, 116], ["its infection rate", "PROBLEM", 200, 218], ["elastase", "OBSERVATION", 4, 12], ["neutrophil elastase", "OBSERVATION", 55, 74], ["most frequent", "OBSERVATION_MODIFIER", 140, 153]]], ["Two distinct ELANE-related CN phenotypes have been described: cyclic neutropenia (CyN), in which neutrophil counts classically oscillate with 21-day periodicity, and severe congenital neutropenia (SCN), with persistently low blood neutrophil counts [3, 4] .", [["neutrophil", "ANATOMY", 97, 107], ["blood neutrophil", "ANATOMY", 225, 241], ["cyclic neutropenia", "DISEASE", 62, 80], ["CyN", "DISEASE", 82, 85], ["congenital neutropenia", "DISEASE", 173, 195], ["CN", "CANCER", 27, 29], ["neutrophil", "CELL", 97, 107], ["blood", "ORGANISM_SUBSTANCE", 225, 230], ["neutrophil", "CELL", 231, 241], ["CN", "PROTEIN", 27, 29], ["Two distinct ELANE-related CN phenotypes", "PROBLEM", 0, 40], ["cyclic neutropenia", "PROBLEM", 62, 80], ["neutrophil counts", "TEST", 97, 114], ["severe congenital neutropenia", "PROBLEM", 166, 195], ["persistently low blood neutrophil counts", "PROBLEM", 208, 248], ["distinct", "OBSERVATION_MODIFIER", 4, 12], ["ELANE", "OBSERVATION", 13, 18], ["CN phenotypes", "OBSERVATION", 27, 40], ["cyclic neutropenia", "OBSERVATION_MODIFIER", 62, 80], ["neutrophil counts", "OBSERVATION", 97, 114], ["21-day periodicity", "OBSERVATION_MODIFIER", 142, 160], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["congenital", "OBSERVATION_MODIFIER", 173, 183], ["neutropenia", "OBSERVATION", 184, 195]]], ["The standard-of-care for ELANEneutropenia patients consists of granulocytecolony-stimulating factor (GCSF) administration, which increases the numbers of circulating neutrophils, thereby lowering infection-related mortality.", [["neutrophils", "ANATOMY", 166, 177], ["ELANEneutropenia", "DISEASE", 25, 41], ["infection", "DISEASE", 196, 205], ["patients", "ORGANISM", 42, 50], ["granulocytecolony-stimulating factor", "GENE_OR_GENE_PRODUCT", 63, 99], ["GCSF", "GENE_OR_GENE_PRODUCT", 101, 105], ["neutrophils", "CELL", 166, 177], ["granulocytecolony-stimulating factor", "PROTEIN", 63, 99], ["GCSF", "PROTEIN", 101, 105], ["circulating neutrophils", "CELL_TYPE", 154, 177], ["patients", "SPECIES", 42, 50], ["granulocytecolony", "TEST", 63, 80], ["circulating neutrophils", "PROBLEM", 154, 177], ["lowering infection", "PROBLEM", 187, 205], ["circulating neutrophils", "OBSERVATION", 154, 177], ["lowering", "OBSERVATION_MODIFIER", 187, 195], ["infection", "OBSERVATION", 196, 205]]], ["Hematopoietic stemcell transplantation (HSCT) is indicated for the rare patients with GCSF-refractory disease (i.e., no absolute neutrophil count (ANC) increase at \u226550 \u00b5g/kg/day) or those with myelodysplastic syndrome (MDS) [5] [6] [7] .IntroductionPatients with ELANE-related CN are at risk of developing MDS-acute leukemia (MDS-AL).", [["Hematopoietic stemcell", "ANATOMY", 0, 22], ["neutrophil", "ANATOMY", 129, 139], ["MDS-acute leukemia", "ANATOMY", 306, 324], ["GCSF", "CHEMICAL", 86, 90], ["myelodysplastic syndrome", "DISEASE", 193, 217], ["MDS", "DISEASE", 219, 222], ["ELANE", "CHEMICAL", 263, 268], ["MDS-acute leukemia", "DISEASE", 306, 324], ["MDS", "DISEASE", 326, 329], ["AL", "DISEASE", 330, 332], ["Hematopoietic stemcell", "CELL", 0, 22], ["patients", "ORGANISM", 72, 80], ["neutrophil", "CELL", 129, 139], ["MDS-acute leukemia", "CANCER", 306, 324], ["GCSF", "PROTEIN", 86, 90], ["patients", "SPECIES", 72, 80], ["Hematopoietic stemcell transplantation", "TREATMENT", 0, 38], ["GCSF", "TEST", 86, 90], ["refractory disease", "PROBLEM", 91, 109], ["absolute neutrophil count", "TEST", 120, 145], ["ANC", "TEST", 147, 150], ["myelodysplastic syndrome (MDS)", "PROBLEM", 193, 223], ["developing MDS", "PROBLEM", 295, 309], ["acute leukemia", "PROBLEM", 310, 324], ["myelodysplastic syndrome", "OBSERVATION", 193, 217], ["MDS", "OBSERVATION", 306, 309], ["acute", "OBSERVATION_MODIFIER", 310, 315], ["leukemia", "OBSERVATION", 316, 324]]], ["In 2005, our team showed [8] that the CN leukemia risk depends on two major features, the genetic defect and GCSF use, with the latter controlling the patients' infection rates.", [["CN leukemia", "ANATOMY", 38, 49], ["leukemia", "DISEASE", 41, 49], ["infection", "DISEASE", 161, 170], ["CN leukemia", "CANCER", 38, 49], ["GCSF", "GENE_OR_GENE_PRODUCT", 109, 113], ["patients", "ORGANISM", 151, 159], ["GCSF", "PROTEIN", 109, 113], ["patients", "SPECIES", 151, 159], ["the CN leukemia risk", "PROBLEM", 34, 54], ["the genetic defect", "PROBLEM", 86, 104], ["GCSF use", "TREATMENT", 109, 117], ["the patients' infection rates", "PROBLEM", 147, 176], ["leukemia", "OBSERVATION", 41, 49], ["defect", "OBSERVATION", 98, 104], ["GCSF", "OBSERVATION", 109, 113], ["infection", "OBSERVATION", 161, 170]]], ["The relationship between high-dose GCSF exposure and leukemic transformation was confirmed in 2006 by the International Severe Chronic Neutropenia Registry (ISCNR), in which the USA, Canada, UK, the Netherlands, and Germany participate [9] .", [["leukemic", "ANATOMY", 53, 61], ["GCSF", "CHEMICAL", 35, 39], ["leukemic transformation", "DISEASE", 53, 76], ["Chronic Neutropenia", "DISEASE", 127, 146], ["GCSF", "PROTEIN", 35, 39], ["high-dose GCSF exposure", "TREATMENT", 25, 48], ["leukemic transformation", "PROBLEM", 53, 76], ["leukemic transformation", "OBSERVATION", 53, 76], ["Severe", "OBSERVATION_MODIFIER", 120, 126], ["Chronic", "OBSERVATION_MODIFIER", 127, 134], ["Neutropenia", "OBSERVATION", 135, 146]]], ["Based on those results, guidelines were issued in France recommending HSCT for patients receiving high-dose GCSF, while the French Severe Chronic Neutropenia Registry has continued to collect data prospectively.", [["Neutropenia", "DISEASE", 146, 157], ["patients", "ORGANISM", 79, 87], ["GCSF", "PROTEIN", 108, 112], ["patients", "SPECIES", 79, 87], ["high-dose GCSF", "TREATMENT", 98, 112], ["the French Severe Chronic Neutropenia", "PROBLEM", 120, 157], ["Severe", "OBSERVATION_MODIFIER", 131, 137], ["Chronic", "OBSERVATION_MODIFIER", 138, 145], ["Neutropenia", "OBSERVATION", 146, 157]]], ["This practice represents an extension of the validated indication of HSCT for CN.IntroductionThis study was undertaken to analyze the effect of this policy on patients with the ELANE-gene mutation, as they are currently one of the most heavily GCSF-treated.", [["GCSF", "CHEMICAL", 244, 248], ["CN", "CANCER", 78, 80], ["patients", "ORGANISM", 159, 167], ["ELANE", "GENE_OR_GENE_PRODUCT", 177, 182], ["GCSF", "GENE_OR_GENE_PRODUCT", 244, 248], ["CN", "PROTEIN", 78, 80], ["ELANE-gene mutation", "DNA", 177, 196], ["GCSF", "PROTEIN", 244, 248], ["patients", "SPECIES", 159, 167], ["CN", "PROBLEM", 78, 80], ["This study", "TEST", 93, 103], ["the ELANE-gene mutation", "TREATMENT", 173, 196]]], ["In addition, even though HSCT has been proposed for CN since 1980 [10] , it has been reported in only 11 patients with known ELANE status thus far [11] [12] [13] [14] [15] [16] [17] [18] .", [["patients", "ORGANISM", 105, 113], ["[11] [12] [13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 147, 186], ["CN", "PROTEIN", 52, 54], ["patients", "SPECIES", 105, 113], ["known ELANE status", "PROBLEM", 119, 137]]], ["Therefore, a comprehensive review of these cases appeared useful concerning HSCT indication and its impact.Registry organization and data monitoringThe patients included in this study were all entered in the French Severe Chronic Neutropenia Registry (FSCNR).", [["Neutropenia", "DISEASE", 230, 241], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["Registry organization", "TEST", 107, 128], ["data monitoring", "TEST", 133, 148], ["this study", "TEST", 173, 183], ["Severe", "OBSERVATION_MODIFIER", 215, 221], ["Chronic", "OBSERVATION_MODIFIER", 222, 229], ["Neutropenia", "OBSERVATION", 230, 241]]], ["A clinical research associate assured accurate data monitoring, based on annual on-site reviews of medical charts.", [["accurate data monitoring", "TEST", 38, 62]]], ["The following parameters are currently recorded: sex, age at diagnosis, severe bacterial or fungal infections (septicemia, cellulitis, pneumonia, osteitis and liver abscess), complete blood cell counts, differential bone-marrow cell counts (smear method) and all information on HSCTs.", [["liver abscess", "ANATOMY", 159, 172], ["blood cell", "ANATOMY", 184, 194], ["bone-marrow cell", "ANATOMY", 216, 232], ["bacterial or fungal infections", "DISEASE", 79, 109], ["septicemia", "DISEASE", 111, 121], ["cellulitis", "DISEASE", 123, 133], ["pneumonia", "DISEASE", 135, 144], ["osteitis", "DISEASE", 146, 154], ["liver abscess", "DISEASE", 159, 172], ["liver", "ORGAN", 159, 164], ["blood cell", "CELL", 184, 194], ["bone-marrow cell", "CELL", 216, 232], ["severe bacterial or fungal infections", "PROBLEM", 72, 109], ["septicemia", "PROBLEM", 111, 121], ["cellulitis", "PROBLEM", 123, 133], ["pneumonia", "PROBLEM", 135, 144], ["osteitis", "PROBLEM", 146, 154], ["liver abscess", "PROBLEM", 159, 172], ["complete blood cell counts", "TEST", 175, 201], ["marrow cell counts", "TEST", 221, 239], ["smear method", "TEST", 241, 253], ["HSCTs", "TEST", 278, 283], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["bacterial", "OBSERVATION_MODIFIER", 79, 88], ["fungal", "OBSERVATION_MODIFIER", 92, 98], ["infections", "OBSERVATION", 99, 109], ["septicemia", "OBSERVATION", 111, 121], ["cellulitis", "OBSERVATION", 123, 133], ["pneumonia", "OBSERVATION", 135, 144], ["osteitis", "OBSERVATION", 146, 154], ["liver", "ANATOMY", 159, 164], ["abscess", "OBSERVATION", 165, 172], ["bone", "ANATOMY", 216, 220], ["marrow cell counts", "OBSERVATION", 221, 239]]], ["Each patient had to provide written informed consent to be entered in the FSCNR.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["Several reports on the FSCNR are available elsewhere [2, 8, [19] [20] [21] [22] [23] [24] .Study designThis before-after study compared patients divided into two groups according to follow-up period: \"before 2005\", for those born before 2005 and followed until 31/12/2004, and \"after 2005\", for those born after 2005 or before 2005 but still being followed after 2005 until the last update (31/05/ 2019).", [["FSCNR", "SIMPLE_CHEMICAL", 23, 28], ["[2, 8, [19] [20] [21] [22] [23] [24]", "SIMPLE_CHEMICAL", 53, 89], ["patients", "ORGANISM", 136, 144], ["FSCNR", "DNA", 23, 28], ["patients", "SPECIES", 136, 144], ["the FSCNR", "TEST", 19, 28], ["study", "TEST", 121, 126]]], ["The main reason to separate these two periods was the HSCT-indication modification at the end of 2004.", [["the HSCT", "TEST", 50, 58], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Since 2005, patients in France receiving a GCSF dose above the 15-\u03bcg/kg/day threshold become eligible for HSCT, in addition to patients with validated indications, such as MDS-AL or GCSF refractoriness (typically \u226550 \u03bcg/kg/day).ELANE-neutropenia geneticsWe classified variants according to American College of Medical Genetics and Genomics guidelines [25] .", [["GCSF", "CHEMICAL", 43, 47], ["MDS", "DISEASE", 172, 175], ["neutropenia", "DISEASE", 234, 245], ["patients", "ORGANISM", 12, 20], ["GCSF", "GENE_OR_GENE_PRODUCT", 43, 47], ["patients", "ORGANISM", 127, 135], ["GCSF", "SIMPLE_CHEMICAL", 182, 186], ["GCSF", "PROTEIN", 43, 47], ["GCSF", "PROTEIN", 182, 186], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 127, 135], ["a GCSF dose", "TREATMENT", 41, 52], ["HSCT", "TREATMENT", 106, 110], ["MDS-AL or GCSF refractoriness", "TREATMENT", 172, 201], ["neutropenia", "PROBLEM", 234, 245], ["neutropenia", "OBSERVATION", 234, 245]]], ["Only pathogenic (class 5) and probably pathogenic ELANE-gene variants (class 4) were included in this study.", [["ELANE", "GENE_OR_GENE_PRODUCT", 50, 55], ["ELANE-gene variants", "DNA", 50, 69], ["this study", "TEST", 97, 107], ["pathogenic", "OBSERVATION_MODIFIER", 5, 15], ["probably", "UNCERTAINTY", 30, 38], ["pathogenic", "OBSERVATION_MODIFIER", 39, 49], ["gene variants", "OBSERVATION", 56, 69]]], ["The patients or their parents gave written informed consent for genetic testing.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["genetic testing", "TEST", 64, 79]]], ["Standard procedures were used to extract DNA from blood.", [["blood", "ANATOMY", 50, 55], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["Standard procedures", "TREATMENT", 0, 19]]], ["The ELANE-gene coding sequence and exon-intron boundaries were determined either by Sanger sequencing, as described previously [2, 3] , or by targeted sequencing of a gene panel including ELANE.", [["ELANE-gene coding sequence", "DNA", 4, 30], ["ELANE", "DNA", 188, 193], ["exon-intron boundaries", "TEST", 35, 57], ["Sanger sequencing", "TEST", 84, 101], ["a gene panel", "TEST", 165, 177]]], ["Mutations were numbered as recommended by the Human Genome Variation Society (http://www.hgvs.org/), using the reference sequence NM_001972.2.Literature reviewTo identify all publications related to ELANE-associated neutropenia and summarize reported cases, we first screened PubMed using the keywords \"ELANE\" \"ELA2\" \"Severe congenital neutropenia\" \"Congenital neutropenia\".", [["neutropenia", "DISEASE", 216, 227], ["congenital neutropenia", "DISEASE", 325, 347], ["Congenital neutropenia", "DISEASE", 350, 372], ["Human", "ORGANISM", 46, 51], ["Human", "SPECIES", 46, 51], ["neutropenia", "PROBLEM", 216, 227], ["Severe congenital neutropenia", "PROBLEM", 318, 347], ["Congenital neutropenia\"", "PROBLEM", 350, 373], ["neutropenia", "OBSERVATION", 216, 227], ["Severe", "OBSERVATION_MODIFIER", 318, 324], ["congenital", "OBSERVATION_MODIFIER", 325, 335], ["neutropenia", "OBSERVATION", 336, 347], ["Congenital neutropenia", "OBSERVATION", 350, 372]]], ["Then the reference list of each article was checked to identify additional references and avoid duplicates.Hematological eventsAL, either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), was defined using WHO criteria (i.e., at least 20% blast cells in bone-marrow smears).", [["acute myeloid leukemia", "ANATOMY", 138, 160], ["AML", "ANATOMY", 162, 165], ["acute lymphoblastic leukemia", "ANATOMY", 170, 198], ["ALL", "ANATOMY", 200, 203], ["blast cells", "ANATOMY", 257, 268], ["bone", "ANATOMY", 272, 276], ["marrow", "ANATOMY", 277, 283], ["acute myeloid leukemia", "DISEASE", 138, 160], ["AML", "DISEASE", 162, 165], ["acute lymphoblastic leukemia", "DISEASE", 170, 198], ["ALL", "DISEASE", 200, 203], ["acute myeloid leukemia", "CANCER", 138, 160], ["AML", "CANCER", 162, 165], ["acute lymphoblastic leukemia", "CANCER", 170, 198], ["ALL", "CANCER", 200, 203], ["blast cells", "CELL", 257, 268], ["bone-marrow smears", "MULTI-TISSUE_STRUCTURE", 272, 290], ["blast cells", "CELL_TYPE", 257, 268], ["Hematological eventsAL", "TEST", 107, 129], ["acute myeloid leukemia", "PROBLEM", 138, 160], ["AML)", "PROBLEM", 162, 166], ["acute lymphoblastic leukemia", "PROBLEM", 170, 198], ["blast cells", "TEST", 257, 268], ["bone-marrow smears", "TEST", 272, 290], ["acute", "OBSERVATION_MODIFIER", 138, 143], ["myeloid leukemia", "OBSERVATION", 144, 160], ["AML", "OBSERVATION", 162, 165], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["lymphoblastic leukemia", "OBSERVATION", 176, 198], ["blast cells", "OBSERVATION", 257, 268], ["bone", "ANATOMY", 272, 276], ["marrow", "ANATOMY", 277, 283]]], ["Because these patients almost always had dystrophic cytological abnormalities, MDS was diagnosed when cytological abnormalities were associated with central anemia or central thrombocytopenia requiring blood transfusion, and when clonal cytogenetic abnormalities were present.", [["blood", "ANATOMY", 202, 207], ["MDS", "DISEASE", 79, 82], ["anemia", "DISEASE", 157, 163], ["thrombocytopenia", "DISEASE", 175, 191], ["patients", "ORGANISM", 14, 22], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["patients", "SPECIES", 14, 22], ["dystrophic cytological abnormalities", "PROBLEM", 41, 77], ["MDS", "PROBLEM", 79, 82], ["cytological abnormalities", "PROBLEM", 102, 127], ["central anemia", "PROBLEM", 149, 163], ["central thrombocytopenia", "PROBLEM", 167, 191], ["blood transfusion", "TREATMENT", 202, 219], ["clonal cytogenetic abnormalities", "PROBLEM", 230, 262], ["dystrophic", "OBSERVATION_MODIFIER", 41, 51], ["central", "OBSERVATION_MODIFIER", 149, 156], ["anemia", "OBSERVATION", 157, 163], ["central", "OBSERVATION_MODIFIER", 167, 174], ["thrombocytopenia", "OBSERVATION", 175, 191]]], ["Singlestrand conformational polymorphism, as previously described [26] , was used to screen for GCSF-receptor mutations, which were confirmed by sequencing.", [["GCSF-receptor", "GENE_OR_GENE_PRODUCT", 96, 109], ["GCSF", "PROTEIN", 96, 100], ["Singlestrand conformational polymorphism", "PROBLEM", 0, 40], ["GCSF", "TEST", 96, 100], ["receptor mutations", "PROBLEM", 101, 119]]], ["More recently, targeted next-generation sequencing was used.GCSF exposureTo calculate GCSF exposure, we assumed dose equivalence between filgrastim and lenograstim.", [["filgrastim", "CHEMICAL", 137, 147], ["lenograstim", "CHEMICAL", 152, 163], ["filgrastim", "CHEMICAL", 137, 147], ["lenograstim", "CHEMICAL", 152, 163], ["GCSF", "GENE_OR_GENE_PRODUCT", 60, 64], ["GCSF", "GENE_OR_GENE_PRODUCT", 86, 90], ["filgrastim", "SIMPLE_CHEMICAL", 137, 147], ["lenograstim", "SIMPLE_CHEMICAL", 152, 163], ["GCSF", "PROTEIN", 60, 64], ["GCSF", "PROTEIN", 86, 90], ["targeted next-generation sequencing", "TREATMENT", 15, 50], ["GCSF", "TEST", 60, 64], ["GCSF exposure", "PROBLEM", 86, 99], ["filgrastim", "TREATMENT", 137, 147], ["lenograstim", "TREATMENT", 152, 163], ["GCSF exposure", "OBSERVATION", 86, 99]]], ["Because the unit dose and frequency of GCSF injections are individually tailored, each patient's overall treatment was estimated using several parameters calculated for each GCSF therapeutic period during which the dose and frequency of injections were stable: dose delivered per injection (dd i , \u00b5g/kg); number of injections (n i ); cumulative dose, defined as the total dose received during the relevant period (mg/kg) = dd i \u00d7 n i ; and duration of the relevant period in days.", [["GCSF", "GENE_OR_GENE_PRODUCT", 39, 43], ["patient", "ORGANISM", 87, 94], ["GCSF", "PROTEIN", 39, 43], ["GCSF", "PROTEIN", 174, 178], ["patient", "SPECIES", 87, 94], ["the unit dose", "TREATMENT", 8, 21], ["GCSF injections", "TREATMENT", 39, 54], ["frequency of injections", "TREATMENT", 224, 247]]], ["The total cumulative dose (\u00b5g) was calculated as the sum of cumulative doses for each therapeutic period, from day 1 of GCSF to the last day of follow-up.", [["GCSF", "PROTEIN", 120, 124], ["The total cumulative dose (\u00b5g)", "TREATMENT", 0, 30], ["GCSF", "TREATMENT", 120, 124]]], ["The cumulative duration of GCSF use (in years) was calculated as the sum of all therapeutic periods.", [["GCSF", "PROTEIN", 27, 31], ["GCSF use", "TREATMENT", 27, 35]]], ["For each patient, total GCSF-therapy follow-up (in years) since onset was calculated from the first injection to the last day.", [["patient", "ORGANISM", 9, 16], ["GCSF", "PROTEIN", 24, 28], ["patient", "SPECIES", 9, 16], ["total GCSF-therapy", "TREATMENT", 18, 36]]], ["The time-averaged dose (\u00b5g/kg/day) was calculated by dividing the cumulative dose by the cumulative duration of treatment.HSCT and engraftmentThe conditioning regimen, donor, type of graft and number of cells injected were recorded.", [["graft", "ANATOMY", 183, 188], ["cells", "ANATOMY", 203, 208], ["graft", "TISSUE", 183, 188], ["cells", "CELL", 203, 208], ["treatment", "TREATMENT", 112, 121], ["HSCT", "TEST", 122, 126], ["engraftment", "TREATMENT", 131, 142], ["The conditioning regimen", "TREATMENT", 142, 166], ["donor, type of graft", "TREATMENT", 168, 188], ["number of cells", "TREATMENT", 193, 208], ["engraftment", "OBSERVATION", 131, 142], ["graft", "OBSERVATION", 183, 188]]], ["Chimerism analysis was performed by means of cytogenetic or polymerase chain reaction (PCR) amplification of microsatellites on peripheral mononuclear blood cells.Statistical methodsDemographic, clinical, biological and therapeutic data were recorded using an Access database (Microsoft).", [["peripheral mononuclear blood cells", "ANATOMY", 128, 162], ["peripheral mononuclear blood cells", "CELL", 128, 162], ["peripheral mononuclear blood cells", "CELL_TYPE", 128, 162], ["Chimerism analysis", "TEST", 0, 18], ["cytogenetic or polymerase chain reaction", "PROBLEM", 45, 85], ["PCR", "TEST", 87, 90], ["peripheral mononuclear blood cells", "TEST", 128, 162], ["therapeutic data", "TEST", 220, 236], ["peripheral", "ANATOMY_MODIFIER", 128, 138], ["mononuclear blood cells", "OBSERVATION", 139, 162]]], ["The frequencies were calculated by dividing the numbers of events by the person-years observed for before and after periods.", [["person", "SPECIES", 73, 79]]], ["This before-after study compared medical intervention (HSCT) and medical complication (MDS-AL) frequencies between before-and after-2005 groups, using the Mantel-Haensel test [27, 28] .", [["medical intervention", "TREATMENT", 33, 53], ["medical complication", "PROBLEM", 65, 85]]], ["Categorical data were compared with Fisher's exact test and quantitative data with the Mann-Whitney test.", [["Categorical data", "TEST", 0, 16], ["Fisher's exact test", "TEST", 36, 55]]], ["All tests were two-tailed, with P < 0.05 defining significance.", [["All tests", "TEST", 0, 9]]], ["For survival analyses, the endpoints were death, bone-marrow transplantation and MDS-AL onset.", [["bone", "ANATOMY", 49, 53], ["marrow", "ANATOMY", 54, 60], ["death", "DISEASE", 42, 47], ["MDS", "DISEASE", 81, 84], ["bone-marrow", "MULTI-TISSUE_STRUCTURE", 49, 60], ["survival analyses", "TEST", 4, 21], ["death", "PROBLEM", 42, 47], ["bone-marrow transplantation", "TREATMENT", 49, 76], ["MDS", "PROBLEM", 81, 84], ["bone", "ANATOMY", 49, 53], ["marrow", "ANATOMY", 54, 60]]], ["Survival was compared between before and after groups with the log-rank test [29] .", [["the log-rank test", "TEST", 59, 76]]], ["For the entire cohort, 112 patients received GCSF, at a mean dose of 9.8 \u00b5g/kg/day, and 32 patients were not given GCSF.", [["GCSF", "CHEMICAL", 45, 49], ["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 91, 99], ["GCSF", "GENE_OR_GENE_PRODUCT", 115, 119], ["GCSF", "PROTEIN", 45, 49], ["GCSF", "PROTEIN", 115, 119], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 91, 99], ["GCSF", "TREATMENT", 45, 49], ["GCSF", "TREATMENT", 115, 119]]], ["The mean (range) total doses (\u00b5g/kg) were 9837 (0-115 431) for the entire cohort, 12 564 (0-115 431) for SCN patients and 3837 (0-25 038) for those with CyN.", [["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 109, 117], ["CyN.", "SPECIES", 153, 157]]], ["For the 112 treated patients, the time-averaged dose (\u00b5g/kg/day) was 0.1-4.9 for three (2.7%) patients, 5-9.9 for 47 (42%), 10-14.9 for 26 (23.2%), 15-29.9 for 14 (12.5%) or 30-49.9 for nine (8.0%) and >50 \u00b5g/kg/day for 13 (11.6%).", [["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 94, 102]]], ["Maximum doses (\u00b5g/kg/ day) were < 5 for 32 (22.2%) patients, 5-10 for 38 (26.4%), 10-20 for 32 (22.2%), 20-30 for 26 (18%) or >30 for 16 (11.1%).", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59]]], ["Five patients' neutropenias were considered GCSF-refractory (ANC < 0.2 G/L after receiving \u226550 \u00b5g/kg/ day).Cohort descriptionSix leukemic transformations occurred, including one ALL.", [["ALL", "ANATOMY", 178, 181], ["GCSF", "CHEMICAL", 44, 48], ["leukemic transformations", "DISEASE", 129, 153], ["ALL", "DISEASE", 178, 181], ["patients", "ORGANISM", 5, 13], ["neutropenias", "CANCER", 15, 27], ["ALL", "CANCER", 178, 181], ["GCSF", "PROTEIN", 44, 48], ["patients", "SPECIES", 5, 13], ["Five patients' neutropenias", "PROBLEM", 0, 27], ["GCSF", "TEST", 44, 48], ["ANC", "TEST", 61, 64], ["Cohort descriptionSix leukemic transformations", "PROBLEM", 107, 153], ["leukemic transformations", "OBSERVATION", 129, 153]]], ["None of the patients followed after 2005 developed MDS-AL.", [["MDS", "DISEASE", 51, 54], ["AL", "DISEASE", 55, 57], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["MDS", "PROBLEM", 51, 54]]], ["For the entire cohort, the cumulative MDS-AL frequencies (SD) were 4.4% (1.9) at 10 years and 5.5% (2.2) at 20 years.", [["MDS", "DISEASE", 38, 41], ["the cumulative MDS-AL frequencies (SD)", "TREATMENT", 23, 61]]], ["Two patients initially diagnosed with MDS developed AL.", [["MDS", "DISEASE", 38, 41], ["AL", "DISEASE", 52, 54], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["MDS", "PROBLEM", 38, 41]]], ["No CyN patients developed MDS-AL.", [["MDS", "DISEASE", 26, 29], ["AL", "DISEASE", 30, 32], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15], ["MDS", "OBSERVATION", 26, 29]]], ["Diabetes insipidus with pituitary nodules was the first manifestation for two patients.", [["pituitary nodules", "ANATOMY", 24, 41], ["Diabetes insipidus", "DISEASE", 0, 18], ["pituitary nodules", "DISEASE", 24, 41], ["pituitary nodules", "CANCER", 24, 41], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["Diabetes insipidus", "PROBLEM", 0, 18], ["pituitary nodules", "PROBLEM", 24, 41], ["pituitary", "ANATOMY", 24, 33], ["nodules", "OBSERVATION", 34, 41]]], ["Among the six MDS-AL patients, three had monosomy-7, and one a complex caryotype and 2 have no identified cytogenetic clone.", [["clone", "ANATOMY", 118, 123], ["MDS-AL", "DISEASE", 14, 20], ["patients", "ORGANISM", 21, 29], ["clone", "CELL", 118, 123], ["patients", "SPECIES", 21, 29], ["monosomy", "TEST", 41, 49], ["cytogenetic clone", "PROBLEM", 106, 123], ["cytogenetic clone", "OBSERVATION", 106, 123]]], ["A CSF3R mutation was detected at the time of malignant transformation in 2 patients [30] .", [["malignant transformation", "DISEASE", 45, 69], ["CSF3R", "GENE_OR_GENE_PRODUCT", 2, 7], ["patients", "ORGANISM", 75, 83], ["CSF3R", "PROTEIN", 2, 7], ["patients", "SPECIES", 75, 83], ["A CSF3R mutation", "PROBLEM", 0, 16], ["malignant transformation", "PROBLEM", 45, 69], ["malignant", "OBSERVATION_MODIFIER", 45, 54]]], ["The mean GCSF dose before MDS-AL for the six patients was 18.9 \u03bcg/kg/day.", [["MDS", "DISEASE", 26, 29], ["GCSF", "GENE_OR_GENE_PRODUCT", 9, 13], ["patients", "ORGANISM", 45, 53], ["GCSF", "PROTEIN", 9, 13], ["patients", "SPECIES", 45, 53], ["The mean GCSF dose", "TREATMENT", 0, 18], ["MDS", "TEST", 26, 29]]], ["The two patients who did not undergo HSCT died of leukemia, while, among the four transplanted patients (two for AML, one for ALL and one for MDS); patient #3 died of HSCT-related complications, despite complete engraftment.Cohort descriptionSeven of the 144 cohort patients died.", [["leukemia", "ANATOMY", 50, 58], ["AML", "ANATOMY", 113, 116], ["ALL", "ANATOMY", 126, 129], ["leukemia", "DISEASE", 50, 58], ["AML", "DISEASE", 113, 116], ["ALL", "DISEASE", 126, 129], ["MDS", "DISEASE", 142, 145], ["patients", "ORGANISM", 8, 16], ["leukemia", "CANCER", 50, 58], ["patients", "ORGANISM", 95, 103], ["AML", "CANCER", 113, 116], ["ALL", "CANCER", 126, 129], ["patient", "ORGANISM", 148, 155], ["patients", "ORGANISM", 266, 274], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 95, 103], ["patient", "SPECIES", 148, 155], ["patients", "SPECIES", 266, 274], ["leukemia", "PROBLEM", 50, 58], ["AML", "PROBLEM", 113, 116], ["MDS", "PROBLEM", 142, 145], ["HSCT", "PROBLEM", 167, 171], ["related complications", "PROBLEM", 172, 193], ["complete engraftment", "TREATMENT", 203, 223], ["leukemia", "OBSERVATION", 50, 58], ["engraftment", "OBSERVATION", 212, 223]]], ["The 20-and 40year overall survival rates (95% CI) were 95.7% (90-98.2%) and 92.4% (79.1-97.2%), respectively (Fig. 1b) .", [["CI", "TEST", 46, 48]]], ["Five nontransplanted patients died.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["Before 2005, two deaths were attributed to AL complications without HSCT; another died of sepsis.", [["deaths", "DISEASE", 17, 23], ["AL", "DISEASE", 43, 45], ["sepsis", "DISEASE", 90, 96], ["AL complications", "PROBLEM", 43, 59], ["HSCT", "PROBLEM", 68, 72], ["sepsis", "PROBLEM", 90, 96], ["sepsis", "OBSERVATION", 90, 96]]], ["After 2005, one adult died of sepsis during a chemotherapy regimen for colon cancer and another died of septic shock and renal failure.Description of the 16 patients who underwent HSCTSix males and ten females underwent HSCT (Table 1) .", [["colon cancer", "ANATOMY", 71, 83], ["renal", "ANATOMY", 121, 126], ["sepsis", "DISEASE", 30, 36], ["colon cancer", "DISEASE", 71, 83], ["septic shock", "DISEASE", 104, 116], ["renal failure", "DISEASE", 121, 134], ["colon cancer", "CANCER", 71, 83], ["renal", "ORGAN", 121, 126], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["sepsis", "PROBLEM", 30, 36], ["a chemotherapy regimen", "TREATMENT", 44, 66], ["colon cancer", "PROBLEM", 71, 83], ["septic shock", "PROBLEM", 104, 116], ["renal failure", "PROBLEM", 121, 134], ["sepsis", "OBSERVATION", 30, 36], ["colon", "ANATOMY", 71, 76], ["cancer", "OBSERVATION", 77, 83], ["septic shock", "OBSERVATION", 104, 116], ["renal", "ANATOMY", 121, 126], ["failure", "OBSERVATION", 127, 134]]], ["Median age at transplantation was 4.3 (range 0.6-20.4) years.", [["transplantation", "TEST", 14, 29]]], ["All 16 underwent preparatory myeloablation: nine were given a combination of busulfan, cyclophosphamide and anti-thymocyte globulin (ATG); six were given fludarabine and busulfan, combined with ATG alone for four, and melphalan and ATG for one, and thiotepa and ATG for one.", [["busulfan", "CHEMICAL", 77, 85], ["cyclophosphamide", "CHEMICAL", 87, 103], ["anti-thymocyte globulin", "CHEMICAL", 108, 131], ["ATG", "CHEMICAL", 133, 136], ["fludarabine", "CHEMICAL", 154, 165], ["busulfan", "CHEMICAL", 170, 178], ["ATG", "CHEMICAL", 194, 197], ["melphalan", "CHEMICAL", 218, 227], ["ATG", "CHEMICAL", 232, 235], ["thiotepa", "CHEMICAL", 249, 257], ["ATG", "CHEMICAL", 262, 265], ["busulfan", "CHEMICAL", 77, 85], ["cyclophosphamide", "CHEMICAL", 87, 103], ["fludarabine", "CHEMICAL", 154, 165], ["busulfan", "CHEMICAL", 170, 178], ["melphalan", "CHEMICAL", 218, 227], ["thiotepa", "CHEMICAL", 249, 257], ["busulfan", "SIMPLE_CHEMICAL", 77, 85], ["cyclophosphamide", "SIMPLE_CHEMICAL", 87, 103], ["anti-thymocyte globulin", "SIMPLE_CHEMICAL", 108, 131], ["ATG", "SIMPLE_CHEMICAL", 133, 136], ["fludarabine", "SIMPLE_CHEMICAL", 154, 165], ["busulfan", "SIMPLE_CHEMICAL", 170, 178], ["ATG", "SIMPLE_CHEMICAL", 194, 197], ["melphalan", "SIMPLE_CHEMICAL", 218, 227], ["ATG", "SIMPLE_CHEMICAL", 232, 235], ["thiotepa", "SIMPLE_CHEMICAL", 249, 257], ["ATG", "SIMPLE_CHEMICAL", 262, 265], ["anti-thymocyte globulin", "PROTEIN", 108, 131], ["preparatory myeloablation", "TREATMENT", 17, 42], ["busulfan", "TREATMENT", 77, 85], ["cyclophosphamide", "TREATMENT", 87, 103], ["anti-thymocyte globulin", "TREATMENT", 108, 131], ["ATG)", "TREATMENT", 133, 137], ["fludarabine", "TREATMENT", 154, 165], ["busulfan", "TREATMENT", 170, 178], ["ATG", "TREATMENT", 194, 197], ["melphalan", "TREATMENT", 218, 227], ["ATG", "TREATMENT", 232, 235], ["thiotepa", "TREATMENT", 249, 257], ["ATG", "TREATMENT", 262, 265]]], ["One patient underwent TAM12 (total body irradiation, cytarabine and melphalan).", [["body", "ANATOMY", 35, 39], ["TAM12", "CHEMICAL", 22, 27], ["cytarabine", "CHEMICAL", 53, 63], ["melphalan", "CHEMICAL", 68, 77], ["cytarabine", "CHEMICAL", 53, 63], ["melphalan", "CHEMICAL", 68, 77], ["patient", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["cytarabine", "SIMPLE_CHEMICAL", 53, 63], ["melphalan", "SIMPLE_CHEMICAL", 68, 77], ["patient", "SPECIES", 4, 11], ["TAM12", "TREATMENT", 22, 27], ["total body irradiation", "TREATMENT", 29, 51], ["cytarabine", "TREATMENT", 53, 63], ["melphalan", "TREATMENT", 68, 77]]], ["A Gly214Arg mutation was detected in 6/16 (37.5%) HSCT recipients.", [["Gly214", "CHEMICAL", 2, 8], ["Gly214", "CHEMICAL", 2, 8], ["Arg", "CHEMICAL", 8, 11], ["Arg", "AMINO_ACID", 8, 11], ["A Gly", "TEST", 0, 5], ["Arg mutation", "TEST", 8, 20]]], ["HSCTs were done in 4/89 before-2005 patients and 12/139 after-2005 patients ( Table 2) .Description of the 16 patients who underwent HSCTAll 16 patients achieved complete hematological recovery with full engraftment, and have a normal neutrophil count after HSCT.", [["neutrophil", "ANATOMY", 235, 245], ["HSCTs", "CANCER", 0, 5], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 144, 152], ["neutrophil", "CELL", 235, 245], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 144, 152], ["HSCTs", "TEST", 0, 5], ["full engraftment", "TREATMENT", 199, 215], ["neutrophil count", "OBSERVATION", 235, 251]]], ["The median time required for ANCs to reach 0.5 \u00d7 10 9 /L was 21 (range 14-77) days; the longest engraftment time refers to an unrelated cord blood (UCB) HSCT in patient #3.", [["ANCs", "ANATOMY", 29, 33], ["cord blood", "ANATOMY", 136, 146], ["UCB", "ANATOMY", 148, 151], ["cord blood", "MULTI-TISSUE_STRUCTURE", 136, 146], ["UCB", "TISSUE", 148, 151], ["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["ANCs", "TEST", 29, 33]]], ["After 9-42 (median 27) days, platelet counts reached 50 \u00d7 10 9 /L, without further transfusion.", [["platelet", "ANATOMY", 29, 37], ["platelet", "CELL", 29, 37], ["platelet counts", "TEST", 29, 44], ["further transfusion", "TREATMENT", 75, 94]]], ["Despite successful engraftment, patient #13 developed autoimmunity (antinuclear factor (ANF) titer > 1/640), lost his graft at 18 months, and was not amenable to immunosuppression.", [["graft", "ANATOMY", 118, 123], ["autoimmunity", "DISEASE", 54, 66], ["patient", "ORGANISM", 32, 39], ["antinuclear factor", "GENE_OR_GENE_PRODUCT", 68, 86], ["ANF", "GENE_OR_GENE_PRODUCT", 88, 91], ["graft", "TISSUE", 118, 123], ["antinuclear factor", "PROTEIN", 68, 86], ["ANF", "PROTEIN", 88, 91], ["patient", "SPECIES", 32, 39], ["successful engraftment", "TREATMENT", 8, 30], ["autoimmunity (antinuclear factor", "PROBLEM", 54, 86], ["ANF) titer", "TEST", 88, 98], ["his graft", "TREATMENT", 114, 123], ["immunosuppression", "TREATMENT", 162, 179], ["engraftment", "OBSERVATION", 19, 30], ["graft", "OBSERVATION", 118, 123], ["not amenable to", "UNCERTAINTY", 146, 161], ["immunosuppression", "OBSERVATION", 162, 179]]], ["She underwent retransplantation complicated by severe varicella zoster but nonetheless achieved good and stable engraftment and is in good health, without sequelae, 4 years later.Description of the 16 patients who underwent HSCTAll surviving patients are disease-free and no longer require erythrocyte and platelet transfusions, with normalized ANCs.", [["erythrocyte", "ANATOMY", 290, 301], ["platelet", "ANATOMY", 306, 314], ["varicella zoster", "DISEASE", 54, 70], ["ANCs", "DISEASE", 345, 349], ["patients", "ORGANISM", 201, 209], ["patients", "ORGANISM", 242, 250], ["erythrocyte", "CELL", 290, 301], ["platelet", "CELL", 306, 314], ["ANCs", "CELL_TYPE", 345, 349], ["patients", "SPECIES", 201, 209], ["patients", "SPECIES", 242, 250], ["retransplantation", "TREATMENT", 14, 31], ["severe varicella zoster", "PROBLEM", 47, 70], ["sequelae", "PROBLEM", 155, 163], ["disease", "PROBLEM", 255, 262], ["erythrocyte", "TREATMENT", 290, 301], ["platelet transfusions", "TREATMENT", 306, 327], ["retransplantation", "OBSERVATION", 14, 31], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["varicella zoster", "OBSERVATION", 54, 70], ["stable", "OBSERVATION_MODIFIER", 105, 111], ["engraftment", "OBSERVATION", 112, 123], ["without", "UNCERTAINTY", 147, 154], ["no longer", "UNCERTAINTY", 272, 281], ["platelet transfusions", "OBSERVATION", 306, 327]]], ["Complete chimerism was found in all patients.Description of the 16 patients who underwent HSCTMedian follow-up post-transplantation was 5.7 years and 5-year survival rate was 87.5% [95% confidence intervals (CI) 58.7-96.7%] (Fig. 1c) .", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 67, 75], ["Complete chimerism", "PROBLEM", 0, 18], ["transplantation", "TREATMENT", 116, 131], ["survival rate", "TEST", 157, 170], ["CI", "TEST", 208, 210], ["chimerism", "OBSERVATION", 9, 18]]], ["Two patients died after HSCT: patient #3 with ALL for which HSCT was indicated, died of sepsis before 2005 and patient #11 with GCSF-refractory ELANE neutropenia, for which HSCT was indicated, died after 2005 of refractory grade-IV GVHD with transplantassociated thrombotic microangiopathy.", [["ALL", "ANATOMY", 46, 49], ["ALL", "DISEASE", 46, 49], ["sepsis", "DISEASE", 88, 94], ["GCSF", "CHEMICAL", 128, 132], ["neutropenia", "DISEASE", 150, 161], ["GVHD", "DISEASE", 232, 236], ["thrombotic microangiopathy", "DISEASE", 263, 289], ["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 30, 37], ["ALL", "CANCER", 46, 49], ["patient", "ORGANISM", 111, 118], ["GCSF", "PROTEIN", 128, 132], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 111, 118], ["ALL", "PROBLEM", 46, 49], ["sepsis", "PROBLEM", 88, 94], ["GCSF", "TEST", 128, 132], ["refractory ELANE neutropenia", "PROBLEM", 133, 161], ["HSCT", "TEST", 173, 177], ["refractory grade-IV GVHD", "PROBLEM", 212, 236], ["transplantassociated thrombotic microangiopathy", "PROBLEM", 242, 289], ["sepsis", "OBSERVATION", 88, 94], ["neutropenia", "OBSERVATION", 150, 161], ["GVHD", "OBSERVATION", 232, 236], ["thrombotic microangiopathy", "OBSERVATION", 263, 289]]], ["In addition, six patients had grade-II GVHDs, including one with chronic skin GVHD and persistent livedo.Comparison of HSCT rates and leukemia rates before vs. after 2005Comparing before 2005 to after 2005, respectively, median ages were 0.44 years and 0.15 years (nonsignificant difference) at diagnosis, and 6.9 (range, 1.", [["skin", "ANATOMY", 73, 77], ["leukemia", "ANATOMY", 134, 142], ["GVHDs", "DISEASE", 39, 44], ["GVHD", "DISEASE", 78, 82], ["leukemia", "DISEASE", 134, 142], ["patients", "ORGANISM", 17, 25], ["skin", "ORGAN", 73, 77], ["leukemia", "CANCER", 134, 142], ["patients", "SPECIES", 17, 25], ["grade-II GVHDs", "PROBLEM", 30, 44], ["chronic skin GVHD", "PROBLEM", 65, 82], ["persistent livedo", "PROBLEM", 87, 104], ["HSCT rates", "TEST", 119, 129], ["leukemia rates", "PROBLEM", 134, 148], ["-II", "OBSERVATION_MODIFIER", 35, 38], ["GVHDs", "OBSERVATION", 39, 44], ["chronic", "OBSERVATION_MODIFIER", 65, 72], ["skin", "ANATOMY", 73, 77], ["GVHD", "OBSERVATION", 78, 82], ["persistent", "OBSERVATION_MODIFIER", 87, 97], ["livedo", "OBSERVATION", 98, 104], ["leukemia", "OBSERVATION", 134, 142]]], ["GCSF doses (15-30 \u03bcg/kg/day) and one with MDS (P < 0.03).", [["GCSF", "CHEMICAL", 0, 4], ["MDS", "DISEASE", 42, 45], ["GCSF", "GENE_OR_GENE_PRODUCT", 0, 4], ["GCSF", "PROTEIN", 0, 4], ["GCSF doses", "TEST", 0, 10]]], ["Neither the mean before-and after-2005 GCSF doses (8.5 vs. 11.6 \u03bcg/kg/day, respectively; P < 0.09) nor the maximum doses (respectively, 14.4 vs. 13.6 \u03bcg/kg/day; P < 0.15) received by these patients changed significantly with time.", [["patients", "ORGANISM", 189, 197], ["GCSF", "PROTEIN", 39, 43], ["patients", "SPECIES", 189, 197], ["GCSF doses", "TREATMENT", 39, 49]]], ["Finally, the major change between before and after 2005 was not the dose prescribed initially to treat the patients needing GCSF but the medical decision with regards to the indication of HSCT.DiscussionThe main finding issued from this population-based study on 144 patients with ELANE mutations was that slightly extending the HSCT indication to patients currently taking high-dose GCSF may lessen the risk of leukemia.", [["leukemia", "ANATOMY", 412, 420], ["GCSF", "CHEMICAL", 384, 388], ["leukemia", "DISEASE", 412, 420], ["patients", "ORGANISM", 107, 115], ["GCSF", "GENE_OR_GENE_PRODUCT", 124, 128], ["patients", "ORGANISM", 267, 275], ["patients", "ORGANISM", 348, 356], ["GCSF", "SIMPLE_CHEMICAL", 384, 388], ["leukemia", "CANCER", 412, 420], ["GCSF", "PROTEIN", 124, 128], ["GCSF", "PROTEIN", 384, 388], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 267, 275], ["patients", "SPECIES", 348, 356], ["GCSF", "TREATMENT", 124, 128], ["this population", "TEST", 232, 247], ["based study", "TEST", 248, 259], ["ELANE mutations", "PROBLEM", 281, 296], ["high-dose GCSF", "TREATMENT", 374, 388], ["leukemia", "PROBLEM", 412, 420], ["major", "OBSERVATION_MODIFIER", 13, 18], ["change", "OBSERVATION_MODIFIER", 19, 25], ["leukemia", "OBSERVATION", 412, 420]]], ["In our FSCNR experience, leukemia has not been diagnosed in ELANE-neutropenia patients since 2005, when we extended the HSCT indication to patients receiving >15 \u00b5g/kg/day of GCSF.", [["leukemia", "ANATOMY", 25, 33], ["leukemia", "DISEASE", 25, 33], ["neutropenia", "DISEASE", 66, 77], ["leukemia", "CANCER", 25, 33], ["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 139, 147], ["GCSF", "GENE_OR_GENE_PRODUCT", 175, 179], ["GCSF", "PROTEIN", 175, 179], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 139, 147], ["leukemia", "PROBLEM", 25, 33], ["neutropenia", "PROBLEM", 66, 77], ["GCSF", "TREATMENT", 175, 179], ["leukemia", "OBSERVATION", 25, 33], ["neutropenia", "OBSERVATION", 66, 77]]], ["Analysis of administered GCSF doses showed no differences between before-2005 and after-2005 mean doses, maximum doses or total doses for transplantation candidates.", [["GCSF", "PROTEIN", 25, 29], ["Analysis", "TEST", 0, 8], ["GCSF doses", "TEST", 25, 35], ["maximum doses", "TREATMENT", 105, 118], ["total doses", "TREATMENT", 122, 133], ["transplantation candidates", "TREATMENT", 138, 164]]], ["However, after 2005, the number of HSCTs increased significantly and patients were transplanted at a significantly younger mean age.DiscussionELANE neutropenia was identified first in CyN [31] , and then shortly thereafter in chronic neutropenia [32] .", [["neutropenia", "DISEASE", 148, 159], ["neutropenia", "DISEASE", 234, 245], ["HSCTs", "PATHOLOGICAL_FORMATION", 35, 40], ["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77], ["HSCTs", "TEST", 35, 40], ["neutropenia", "PROBLEM", 148, 159], ["chronic neutropenia", "PROBLEM", 226, 245], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["chronic", "OBSERVATION_MODIFIER", 226, 233], ["neutropenia", "OBSERVATION", 234, 245]]], ["Infections and hematological malignancies are the main life-threatening complications of ELANE neutropenia.", [["hematological malignancies", "ANATOMY", 15, 41], ["Infections", "DISEASE", 0, 10], ["hematological malignancies", "DISEASE", 15, 41], ["neutropenia", "DISEASE", 95, 106], ["hematological malignancies", "CANCER", 15, 41], ["Infections", "PROBLEM", 0, 10], ["hematological malignancies", "PROBLEM", 15, 41], ["ELANE neutropenia", "PROBLEM", 89, 106], ["hematological malignancies", "OBSERVATION", 15, 41], ["neutropenia", "OBSERVATION", 95, 106]]], ["Long-term use of GCSF to treat CN, which started in 1988, markedly limits the infectious risk, dramatically improving these patients' quality of life.", [["GCSF", "CHEMICAL", 17, 21], ["CN", "DISEASE", 31, 33], ["GCSF", "GENE_OR_GENE_PRODUCT", 17, 21], ["patients", "ORGANISM", 124, 132], ["GCSF", "PROTEIN", 17, 21], ["patients", "SPECIES", 124, 132], ["GCSF", "TREATMENT", 17, 21], ["CN", "PROBLEM", 31, 33], ["infectious", "OBSERVATION_MODIFIER", 78, 88]]], ["However, it has also raised questions regarding the balance between the natural risk of severe infections and that of iatrogenic leukemic transformation [8, 9] .DiscussionPatients carrying an ELANE mutation can develop MDS, AML or, more rarely, ALL.", [["leukemic", "ANATOMY", 129, 137], ["AML", "ANATOMY", 224, 227], ["ALL", "ANATOMY", 245, 248], ["infections", "DISEASE", 95, 105], ["leukemic transformation", "DISEASE", 129, 152], ["MDS", "DISEASE", 219, 222], ["AML", "DISEASE", 224, 227], ["ALL", "DISEASE", 245, 248], ["AML", "CANCER", 224, 227], ["ALL", "CANCER", 245, 248], ["severe infections", "PROBLEM", 88, 105], ["iatrogenic leukemic transformation", "PROBLEM", 118, 152], ["an ELANE mutation", "PROBLEM", 189, 206], ["MDS", "PROBLEM", 219, 222], ["AML", "PROBLEM", 224, 227], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["infections", "OBSERVATION", 95, 105], ["iatrogenic", "OBSERVATION_MODIFIER", 118, 128], ["leukemic transformation", "OBSERVATION", 129, 152], ["AML", "OBSERVATION", 224, 227]]], ["The leukemic transformation rate reported in the literature for ELANE-neutropenia patients is 15-25% by 20 years of age [2, 3, 33] .", [["leukemic", "ANATOMY", 4, 12], ["leukemic transformation", "DISEASE", 4, 27], ["neutropenia", "DISEASE", 70, 81], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["The leukemic transformation rate", "PROBLEM", 0, 32], ["ELANE", "TEST", 64, 69], ["neutropenia", "PROBLEM", 70, 81], ["leukemic transformation", "OBSERVATION", 4, 27], ["neutropenia", "OBSERVATION", 70, 81]]], ["That risk is considered to be stable over time, affecting 25% of the 52 patients in a series from the NIH and US SCN registry [33] .", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["considered to be", "UNCERTAINTY", 13, 29], ["stable", "OBSERVATION_MODIFIER", 30, 36]]], ["During the last 20 years, two large case series were reported; one from the ISCNR on 307 patients [4] and the other from the Hannover genetic laboratory on 213 patients [3] .", [["patients", "ORGANISM", 89, 97], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 89, 97], ["patients", "SPECIES", 160, 168]]], ["Those reports mentioned that 40 HSCTs had been performed but no information was provided about the indications or outcomes.", [["HSCTs", "CANCER", 32, 37], ["40 HSCTs", "TEST", 29, 37]]], ["Among the largest series of HSCTs (136 including 39 ELANE-neutropenia patients) indicated for SCN [6] , which includes our patients, the HSCT indication was not analyzed, and that series was not population-based.", [["HSCTs", "DISEASE", 28, 33], ["neutropenia", "DISEASE", 58, 69], ["HSCTs", "CANCER", 28, 33], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 123, 131], ["HSCTs", "TEST", 28, 33], ["ELANE", "TEST", 52, 57], ["SCN", "PROBLEM", 94, 97], ["largest", "OBSERVATION_MODIFIER", 10, 17]]], ["An exhaustive literature review of HSCT for CN identified only 11 cases with a known ELANE mutation (Table 3) and sufficient details about transplantation indications and outcomes) [11] [12] [13] [14] [15] [16] [17] [18] .", [["CN", "CANCER", 44, 46], ["[11] [12] [13] [14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 181, 220], ["CN", "PROTEIN", 44, 46], ["a known ELANE mutation", "PROBLEM", 77, 99]]], ["All the reported HSCT indications were 'classical' in the literature reviewed: three for MDS-AL and eight for GCSF refractoriness.", [["MDS", "DISEASE", 89, 92], ["AL", "DISEASE", 93, 95], ["GCSF", "DISEASE", 110, 114], ["GCSF", "PROTEIN", 110, 114], ["MDS", "PROBLEM", 89, 92], ["GCSF refractoriness", "TREATMENT", 110, 129]]], ["None of those papers can be used to study the HSCT impact on the risk of developing MDS-AL, because only the numbers of HSCTs during follow-up of all ELANE-neutropenia patients are known but not the entire population.DiscussionBecause our study was an exhaustive examination of a national cohort, with the participation of all French centers, we think that it could be representative of a nonbiased sample of ELANE-neutropenia patients.", [["MDS", "DISEASE", 84, 87], ["AL", "DISEASE", 88, 90], ["neutropenia", "DISEASE", 156, 167], ["neutropenia", "DISEASE", 415, 426], ["HSCTs", "CANCER", 120, 125], ["patients", "ORGANISM", 168, 176], ["ELANE", "CANCER", 409, 414], ["patients", "ORGANISM", 427, 435], ["patients", "SPECIES", 168, 176], ["patients", "SPECIES", 427, 435], ["developing MDS", "PROBLEM", 73, 87], ["HSCTs", "TEST", 120, 125], ["neutropenia", "PROBLEM", 156, 167], ["our study", "TEST", 235, 244], ["an exhaustive examination", "TEST", 249, 274], ["neutropenia", "PROBLEM", 415, 426], ["MDS", "OBSERVATION", 84, 87], ["neutropenia", "OBSERVATION", 156, 167], ["neutropenia", "OBSERVATION", 415, 426]]], ["Our first important observation is that the HSCT outcome for ELANE-neutropenia patients was good, with overall 95% engraftment survival and 90% long-term survival.", [["neutropenia", "DISEASE", 67, 78], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["ELANE", "TEST", 61, 66], ["neutropenia", "PROBLEM", 67, 78], ["90% long-term survival", "TREATMENT", 140, 162]]], ["Extending HSCT to a small number of patients requiring high-dose GCSF proved beneficial and may lower their risk of AL.DiscussionMany data have been collected on ELANE-neutropenia patients regarding clonal evolution.", [["GCSF", "CHEMICAL", 65, 69], ["AL", "DISEASE", 116, 118], ["neutropenia", "DISEASE", 168, 179], ["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 180, 188], ["clonal", "CELL", 199, 205], ["GCSF", "PROTEIN", 65, 69], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 180, 188], ["high-dose GCSF", "TREATMENT", 55, 69], ["neutropenia", "PROBLEM", 168, 179], ["clonal evolution", "PROBLEM", 199, 215], ["small", "OBSERVATION_MODIFIER", 20, 25], ["number", "OBSERVATION_MODIFIER", 26, 32]]], ["The first clonal event was shown to occur in the colony-stimulating factor-3 (CSF3R) clone [34] , but the ultimate clonal evolution involved a broader panel of mutations at the time of leukemic transformation [35, 36] .", [["leukemic", "ANATOMY", 185, 193], ["leukemic transformation", "DISEASE", 185, 208], ["colony-stimulating factor-3", "GENE_OR_GENE_PRODUCT", 49, 76], ["CSF3R", "GENE_OR_GENE_PRODUCT", 78, 83], ["colony-stimulating factor-3 (CSF3R) clone", "DNA", 49, 90], ["stimulating factor", "TEST", 56, 74], ["mutations", "PROBLEM", 160, 169], ["leukemic transformation", "PROBLEM", 185, 208], ["leukemic transformation", "OBSERVATION", 185, 208]]], ["Although such information is crucial to following patients with ELANE-germline mutations, the initial step of leukemogenesis in ELANEneutropenia patients involved CSF3R mutations, which appear to be induced by GCSF therapy, and is sufficient to trigger MDS-AL.", [["leukemogenesis", "DISEASE", 110, 124], ["ELANEneutropenia", "DISEASE", 128, 144], ["GCSF", "CHEMICAL", 210, 214], ["MDS", "DISEASE", 253, 256], ["patients", "ORGANISM", 50, 58], ["ELANE", "GENE_OR_GENE_PRODUCT", 64, 69], ["ELANEneutropenia", "ORGANISM", 128, 144], ["patients", "ORGANISM", 145, 153], ["CSF3R", "GENE_OR_GENE_PRODUCT", 163, 168], ["GCSF", "GENE_OR_GENE_PRODUCT", 210, 214], ["germline", "DNA", 70, 78], ["CSF3R", "PROTEIN", 163, 168], ["GCSF", "PROTEIN", 210, 214], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 145, 153], ["germline mutations", "PROBLEM", 70, 88], ["leukemogenesis", "PROBLEM", 110, 124], ["CSF3R mutations", "PROBLEM", 163, 178], ["GCSF therapy", "TREATMENT", 210, 222], ["leukemogenesis", "OBSERVATION", 110, 124], ["GCSF", "OBSERVATION", 210, 214]]], ["Taking into consideration the GCSF 'load', key information on early patient management may potentially help make the clinical decision about the HSCT indication.DiscussionOur results are limited by the small sample size.", [["GCSF", "GENE_OR_GENE_PRODUCT", 30, 34], ["patient", "ORGANISM", 68, 75], ["GCSF", "PROTEIN", 30, 34], ["patient", "SPECIES", 68, 75], ["the GCSF 'load'", "TREATMENT", 26, 41], ["early patient management", "TREATMENT", 62, 86], ["the small sample size", "PROBLEM", 198, 219], ["small", "OBSERVATION_MODIFIER", 202, 207], ["sample", "OBSERVATION_MODIFIER", 208, 214], ["size", "OBSERVATION_MODIFIER", 215, 219]]], ["Further studies on larger populations could help improve our understanding the GCSF role and what dose can reasonably be considered low risk for leukemic transformation.", [["leukemic", "ANATOMY", 145, 153], ["leukemic transformation", "DISEASE", 145, 168], ["GCSF", "GENE_OR_GENE_PRODUCT", 79, 83], ["GCSF", "PROTEIN", 79, 83], ["Further studies", "TEST", 0, 15], ["larger populations", "TREATMENT", 19, 37], ["leukemic transformation", "PROBLEM", 145, 168], ["leukemic transformation", "OBSERVATION", 145, 168]]], ["However, HSCT remains a viable therapeutic option for patients who are difficult to manage and at high risk of severe infections.", [["infections", "DISEASE", 118, 128], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["severe infections", "PROBLEM", 111, 128], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["infections", "OBSERVATION", 118, 128]]]], "7bf651a906a21f0c84f8b726d2f6822aded2748e": [["CORRESPONDENCEThere was excellent agreement between cardiologists on whether recordings were acceptable for QTc measurements (\u03ba=0.92).", [["recordings", "TEST", 77, 87], ["QTc measurements", "TEST", 108, 124]]], ["Interobserver agreement for QTc measurements was similarly high with a median absolute error of 9 milliseconds (interquartile range, 5-15 milliseconds) and an intraclass correlation coefficient of 0.92 (95% CI, 0.85-0.95).", [["QTc measurements", "TEST", 28, 44], ["an intraclass correlation coefficient", "TEST", 156, 193], ["CI", "TEST", 207, 209]]], ["Compared with the 12-lead ECG, the median absolute error in QTc was 18 milliseconds for AW-I (interquartile range, 9-35 milliseconds), 20 milliseconds for AW-II (interquartile range, 8-33 milliseconds), and 16 milliseconds for AW-LAT (interquartile range, 8-27 milliseconds).", [["LAT", "PROTEIN", 230, 233], ["lead ECG", "TEST", 21, 29], ["QTc", "TEST", 60, 63], ["AW", "TEST", 88, 90], ["AW", "TEST", 155, 157], ["AW", "TEST", 227, 229]]], ["There were no significant differences in absolute offset between smartwatch positions.", [["significant differences in absolute offset between smartwatch positions", "PROBLEM", 14, 85], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["differences", "OBSERVATION_MODIFIER", 26, 37], ["absolute offset", "OBSERVATION", 41, 56]]], ["Bland-Altman analyses revealed a bias of \u22125 milliseconds (95% limits of agreement, \u221265 to 54) with AW-I, \u22129 milliseconds with AW-II (95% limits of agreement, \u221267 to 50), and \u221211 milliseconds (95% limits of agreement, \u221260 to 37) with AW-LAT.", [["LAT", "PROTEIN", 236, 239], ["Altman analyses", "TEST", 6, 21], ["AW", "TEST", 99, 101], ["AW", "TEST", 126, 128], ["agreement", "TEST", 147, 156], ["agreement", "TEST", 206, 215]]], ["The negative bias suggests that using the smartwatch slightly overestimated the QTc interval.", [["the smartwatch slightly overestimated the QTc interval", "PROBLEM", 38, 92], ["negative bias", "OBSERVATION", 4, 17]]], ["T waves were significantly higher in AW-LAT than in AW-I and AW-II (0.28 mV versus 0.20 mV and 0.19 mV, respectively; P<0.001, ANOVA).", [["AW-LAT", "GENE_OR_GENE_PRODUCT", 37, 43], ["AW-II", "CELL", 61, 66], ["LAT", "PROTEIN", 40, 43], ["T waves", "TEST", 0, 7], ["AW", "TEST", 52, 54], ["AW", "TEST", 61, 63], ["mV", "TEST", 73, 75], ["mV", "TEST", 88, 90], ["mV", "TEST", 100, 102], ["P", "TEST", 118, 119], ["significantly", "OBSERVATION_MODIFIER", 13, 26], ["higher", "OBSERVATION_MODIFIER", 27, 33]]], ["Tracings with T-wave amplitudes >1 mV demonstrated lower absolute errors in AW-I (21\u00b116 milliseconds versus 30\u00b125 milliseconds; P=0.03, unpaired t test).CORRESPONDENCEIn our study, Apple Watch electrocardiographic tracings allowed adequate QT measurements when the smartwatch was worn on the left wrist in 85% of patients.", [["left wrist", "ANATOMY", 292, 302], ["wrist", "ORGANISM_SUBDIVISION", 297, 302], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 313, 321], ["Tracings", "TEST", 0, 8], ["T-wave amplitudes", "TEST", 14, 31], ["lower absolute errors", "PROBLEM", 51, 72], ["AW", "TEST", 76, 78], ["P", "TEST", 128, 129], ["unpaired t test", "TEST", 136, 151], ["our study", "TEST", 170, 179], ["electrocardiographic tracings", "TEST", 193, 222], ["lower", "OBSERVATION_MODIFIER", 51, 56], ["absolute errors", "OBSERVATION", 57, 72], ["left", "ANATOMY_MODIFIER", 292, 296], ["wrist", "ANATOMY", 297, 302]]], ["This figure increased to 94% when the smartwatch was moved to alternative positions.", [["increased", "OBSERVATION_MODIFIER", 12, 21]]], ["Performance depends on factors such as electrocardiographic tracing quality and T-wave amplitude.", [["electrocardiographic tracing quality", "TEST", 39, 75]]], ["Therefore, identifying the best smartwatch position (ie, T-wave mapping) at baseline may improve accuracy.", [["T-wave mapping", "TREATMENT", 57, 71], ["accuracy", "TEST", 97, 105]]], ["Other electrocardiographic systems were not evaluated but may be similarly valuable 4,5 such as the Kardia 6 L system (AliveCor, Mountain View, CA), which has received US Food and Drug Administration clearance for QT measurement.", [["Other electrocardiographic systems", "TEST", 0, 34], ["QT measurement", "TEST", 214, 228]]], ["Overall, this technology has the potential to facilitate remote QT monitoring, including among quarantined outpatients on QT-prolonging treatments.ARTICLE INFORMATIONThe data from this study are available from the corresponding author on reasonable request.", [["remote QT monitoring", "TEST", 57, 77], ["QT-prolonging treatments", "TREATMENT", 122, 146], ["this study", "TEST", 180, 190]]]], "58a5803650f73bfd15e2e6b2f63fbc530ca59933": [["Rosko and Mutter (2011) point out that while costs can be reduced by socially undesirable ways such as reducing quality or reducing quantity of services (which reduces access), improvements in efficiency allow an increase in quality or quantity of services for the same outlay.", [["increase", "OBSERVATION_MODIFIER", 213, 221]]], ["However, increasing efficiency allows a reduction of costs without affecting quality or access and the attention to efficiency in the literature has been substantial.", [["increasing efficiency", "PROBLEM", 9, 30], ["a reduction of costs", "TREATMENT", 38, 58], ["increasing", "OBSERVATION_MODIFIER", 9, 19], ["efficiency", "OBSERVATION", 20, 30], ["reduction", "OBSERVATION_MODIFIER", 40, 49], ["substantial", "OBSERVATION_MODIFIER", 154, 165]]], ["As a result of the provisions of the Affordable Care Act of (2010), Medicare has implemented the Value-Based Purchasing (VBP) Program which rewards hospitals for the provision of efficient and good quality and patient centered care (Turner et al. 2015) .IntroductionThis study focuses on the relationship between efficiency and profit in 1317 not-forprofit (NFP) hospitals in 2015.", [["patient", "ORGANISM", 210, 217], ["patient", "SPECIES", 210, 217], ["This study", "TEST", 266, 276]]], ["It is likely that the COVID-19 pandemic has had a substantial negative effect on hospital profitability.", [["the COVID", "TEST", 18, 27], ["is likely", "UNCERTAINTY", 3, 12], ["substantial", "OBSERVATION_MODIFIER", 50, 61], ["negative effect", "OBSERVATION", 62, 77]]], ["Financial difficulties can deter hospital efforts to acquire new technology (Huang 2016) , attract well-trained and gifted healthcare professionals, and make structural changes needed to deliver patient care in today's value-based purchasing environment (Bazzoli et al. 2014; Singh and Wheeler 2012) .", [["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 195, 202], ["Financial difficulties", "PROBLEM", 0, 22]]], ["Therefore, profitability is important for both for-profit and not-for-profit hospitals.IntroductionThere has been much interest in measuring health care efficiency and identifying sources of inefficiency.", [["measuring health care efficiency", "TREATMENT", 131, 163]]], ["Hussey et al. (2009) point out that the term efficiency is used by different stakeholders to connote various constructs.", [["the term efficiency", "PROBLEM", 36, 55]]], ["Further, the definition of efficiency may have an output (e.g., the maximization of outputs, quality of care, and outcomes given the resources committed (Davis et al. 2014) ) or an input orientation (e, g., the minimization of inputs needed to produce a target output).", [["an output", "TEST", 47, 56], ["output", "OBSERVATION_MODIFIER", 50, 56]]], ["In this study, we use stochastic frontier analysis (SFA) to estimate cost-inefficiency (i.e., the difference between observed costs and the costs that would occur on the Best Practice Cost Frontier, given the hospital's output mix and the input prices it faces) because it reflects most sources of measurable inefficiency.", [["this study", "TEST", 3, 13], ["stochastic frontier analysis", "TEST", 22, 50], ["the hospital's output mix", "TREATMENT", 205, 230], ["measurable inefficiency", "PROBLEM", 298, 321], ["SFA", "ANATOMY", 52, 55], ["measurable", "OBSERVATION_MODIFIER", 298, 308], ["inefficiency", "OBSERVATION", 309, 321]]], ["SFA cost-inefficiency is very similar to X-Inefficiency (i.e., the difference between optimal performance and actual performance) (Leibenstein 1987) .IntroductionCost-inefficiency may be due to any of the following types of inefficiency: technical, allocative, scale, or scope.", [["SFA", "CHEMICAL", 0, 3], ["SFA", "CHEMICAL", 0, 3], ["SFA", "SIMPLE_CHEMICAL", 0, 3], ["SFA cost-inefficiency", "PROBLEM", 0, 21], ["X-Inefficiency", "PROBLEM", 41, 55], ["cost-inefficiency", "OBSERVATION", 4, 21]]], ["For example, if a hospital that employed a combination of inputs that was capable of producing 1000 units of output, but only produced 600 units of output, it would be considered 40 percent inefficient or 60 percent efficient.", [["output", "TREATMENT", 109, 115], ["output", "TREATMENT", 148, 154]]], ["Allocative inefficiencies occur when hospitals do not use the least costly combination of inputs in producing output.", [["Allocative inefficiencies", "PROBLEM", 0, 25]]], ["Scale inefficiencies occur when the hospital fails to produce at the minimum point of its long-run average cost curve because it is either too small (i.e., experiencing increasing returns to scale) or too large (i.e., experiencing decreasing returns to scale).", [["Scale inefficiencies", "PROBLEM", 0, 20], ["too small", "OBSERVATION_MODIFIER", 139, 148], ["large", "OBSERVATION_MODIFIER", 205, 210]]], ["Scope inefficiencies are due to the hospital's inability to reap the advantages that sometimes occur in the joint production of outputs that require similar inputs (e.g., providing adult and pediatric care in the same general hospital).", [["Scope inefficiencies", "PROBLEM", 0, 20], ["joint", "ANATOMY", 108, 113]]], ["This is the first article that uses a measure of efficiency based on stochastic frontier analysis (SFA) to examine the association between efficiency and hospital profitability with a focus on NFP hospitals.", [["stochastic frontier analysis", "TEST", 69, 97], ["SFA", "ANATOMY", 99, 102]]], ["1 Although the conventional wisdom argues that increases in efficiency should increase profitability, Kaplan and Norton (1992) argued that the linkage between operating performance and financial success is actually tenuous and uncertain.", [["increases", "OBSERVATION_MODIFIER", 47, 56]]], ["For example, Newhouse (1970) postulated that administrators at NFP hospitals attempt to maximize their utility from quality and quantity subject to a break-even constraint.", [["a break-even constraint", "PROBLEM", 148, 171]]], ["Pauly (1987) agreed that NFPs act differently than FPs but mentioned that it is impossible to directly identify which objective NFP hospitals pursue because it is impossible to observe a hospital's utility function.", [["NFPs", "SIMPLE_CHEMICAL", 25, 29]]], ["We checked for this using a Hausman test which could not support the existence of endogeneity.Conceptual frameworkThe association between efficiency and firm profitability is well established and an important area of research given the impact profitability has on organizational survival and growth.", [["a Hausman test", "TEST", 26, 40], ["firm profitability", "PROBLEM", 153, 171], ["organizational survival", "TREATMENT", 264, 287], ["efficiency", "OBSERVATION_MODIFIER", 138, 148], ["firm", "OBSERVATION_MODIFIER", 153, 157], ["profitability", "OBSERVATION", 158, 171]]], ["Organizations need to generate profits to ensure the availability of resources needed for the continuity, adaptability, and growth of the firm.", [["firm", "OBSERVATION", 138, 142]]], ["In this section, we focus on the relationship between efficiency and profitability and present other organizational and market determinants of profitability.Conceptual frameworkProfit is the difference between revenue and expense.", [["expense", "OBSERVATION_MODIFIER", 222, 229]]], ["Increased profitability is the result, among other factors, of organizations efficiently transforming their inputs (resources) to increase their output (Baik et al. 2013 ).", [["Increased profitability", "PROBLEM", 0, 23], ["profitability", "OBSERVATION", 10, 23]]], ["Findings from different industries support the proposition that organizational efficiency is associated with profitability.", [["organizational efficiency", "PROBLEM", 64, 89], ["organizational efficiency", "OBSERVATION", 64, 89]]], ["For example, Greene and Segal (2004) found a negative association between inefficiency and organizational profitability in the life insurance industry.", [["negative", "OBSERVATION", 45, 53], ["organizational", "OBSERVATION_MODIFIER", 91, 105], ["profitability", "OBSERVATION_MODIFIER", 106, 119]]], ["Berger (1995) identified a positive impact of efficiency on the profitability of banks.", [["positive impact", "OBSERVATION_MODIFIER", 27, 42]]], ["In a descriptive study, Rosko et al. (2018) found that hospitals in the highest quartile of efficiency were substantially more profitable than hospitals in the lowest quartile of efficiency.", [["a descriptive study", "TEST", 3, 22]]], ["However, two frontier studies in the banking industry could not find a relationship between efficiency and profitability (Goddard et al. 2004; Papadopoulos 2004) .Conceptual frameworkNFP hospitals are private charitable institutions that are owned by religious or private secular entities.", [["two frontier studies", "TEST", 9, 29]]], ["While many things might yield utility, NFPs are likely to attempt to provide high quality and prestigious services and graduate medical education, as well as community benefits and charity care, as long as this does not threaten their financial solvency.", [["graduate medical education", "TREATMENT", 119, 145]]], ["However, Leibenstein's (1987) X-Efficiency theory predicts that external pressures that threaten solvency would cause managers of NFP hospitals to adopt strategies and tactics (including actions to increase efficiency) similar to their FP counterparts to improve their financial position.", [["Leibenstein's", "PROBLEM", 9, 22], ["external pressures", "TREATMENT", 64, 82], ["NFP hospitals", "TREATMENT", 130, 143], ["tactics", "TREATMENT", 168, 175]]], ["It has been argued that firm size is probably one of the most important structural dimensions that influences a firm's performance (Damanpour 1992; Hannan and Freeman 1984; Smith et al. 1986 ).", [["firm", "OBSERVATION_MODIFIER", 24, 28], ["size", "OBSERVATION_MODIFIER", 29, 33], ["probably", "UNCERTAINTY", 37, 45], ["one of the most important structural dimensions", "OBSERVATION_MODIFIER", 46, 93], ["firm", "OBSERVATION_MODIFIER", 112, 116]]], ["Previous research found a positive relationship between organizational size and profitability (Hall and Weiss 1967) .", [["positive", "OBSERVATION", 26, 34], ["size", "OBSERVATION_MODIFIER", 71, 75]]], ["Lee (2009) studied 70,000 publicly traded firms over a 9-year period and found a significant positive relationship between organizational size and profits.", [["a significant positive relationship between organizational size and profits", "PROBLEM", 79, 154], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["positive", "OBSERVATION", 93, 101], ["size", "OBSERVATION_MODIFIER", 138, 142]]], ["Porter (1998) argues that larger organizations build on brand recognition and economies of scale in their strategies.", [["larger", "OBSERVATION_MODIFIER", 26, 32]]], ["Related to size are also the effects of system membership, which can convey the benefits of market power and firmlevel scale effects (Rosko et al. 2007; Melnick and Keeler 2007) .Conceptual frameworkLarger organizations possess an array of attributes that allows them to achieve higher levels of profitability.", [["Conceptual frameworkLarger organizations", "TREATMENT", 179, 219], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["Larger hospitals, like larger firms, are expected to have the financial, human and technology resources and capabilities needed to capitalize on opportunities in the environment to generate more profits.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["larger", "OBSERVATION_MODIFIER", 23, 29], ["firms", "OBSERVATION", 30, 35]]], ["Industry attractiveness influences firm profitability (Grant 1996) .", [["firm", "OBSERVATION_MODIFIER", 35, 39]]], ["This is particularly true in the hospital industry whereby in addition to size, market share strengthens a hospital's position in negotiation with insurance companies (Gaynor and Town 2012) .", [["size", "OBSERVATION_MODIFIER", 74, 78]]], ["Similarly, we expect profitability to be positively associated with market concentration.Conceptual frameworkAnother external factor that can affect hospital profitability is regulatory and public payment policy.", [["Another external factor", "PROBLEM", 109, 132]]], ["The relative generosity of these payments can have an important impact on hospital profits.", [["generosity", "OBSERVATION_MODIFIER", 13, 23]]], ["However, in recent years most hospitals have tended to lose money when serving Medicare patients (Medpac 2006; MedPac 2018) .", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["Medicaid, a joint federalstate program for the categorically needy, has underpaid most hospitals since its inception (Cunningham, et al. 2016) .", [["a joint federalstate program", "TREATMENT", 10, 38], ["joint", "ANATOMY", 12, 17]]], ["Therefore, we expect increases in the share of patients covered by Medicare or Medicaid would adversely affect hospital profits.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["increases", "OBSERVATION_MODIFIER", 21, 30]]], ["Hospitals in states that expanded Medicaid eligibility, pursuant to the provisions of the Affordable Care Act of 2010, should have less uncompensated care expense (Dranove et al. 2016 ) and this should lead to increased profitability.Conceptual frameworkConsistent with other hospital studies (Bai and Anderson 2016; Bazzoli et al. 2014; Blavin 2016; Rosko et al. 2018; Schneider et al. 2007; Turner et al. 2015) , we also included variables for academic medical center, average length of stay, and occupancy rate.", [["increased profitability", "PROBLEM", 210, 233], ["occupancy rate", "TEST", 499, 513], ["increased", "OBSERVATION_MODIFIER", 210, 219], ["profitability", "OBSERVATION", 220, 233]]], ["We first describe how hospital efficiency is estimated and follow that with a discussion of our hospital profitability model.SFA cost-efficiency modelWe use an SFA model developed by Jondrow et al. (1982) to estimate hospital cost-efficiency.", [["SFA", "CHEMICAL", 125, 128], ["SFA", "SIMPLE_CHEMICAL", 125, 128], ["SFA", "ANATOMY", 160, 163]]], ["Early techniques to measure hospital efficiency included ratio analysis and OLS regression (Rosko 1990b) .", [["ratio analysis", "TEST", 57, 71], ["OLS regression", "PROBLEM", 76, 90]]], ["Ratio analysis does not work well for multi-product firms (too may ratios to consider), relies on arbitrary inefficiency criteria, such as a median or percentile cutoff point, and there is an information loss caused by the averaging out effects of OLS.", [["Ratio analysis", "TEST", 0, 14], ["multi-product firms", "PROBLEM", 38, 57], ["an information loss", "PROBLEM", 189, 208]]], ["Frontier techniques such as data envelopment analysis (DEA) and stochastic frontier analysis (SFA) were developed to overcome these problems.", [["data envelopment analysis", "TEST", 28, 53], ["stochastic frontier analysis", "TEST", 64, 92], ["these problems", "PROBLEM", 126, 140], ["SFA", "ANATOMY", 94, 97]]], ["A particularly useful feature of SFA is that it allows for the inclusion of many product descriptor variables which helps account for output heterogeneity.SFA cost-efficiency modelThe first health care application of SFA was published by Wagstaff (1989) , who examined 49 Spanish hospitals.", [["SFA", "CHEMICAL", 155, 158], ["SFA", "CHEMICAL", 217, 220], ["SFA", "CHEMICAL", 33, 36], ["SFA", "CHEMICAL", 155, 158], ["SFA", "CHEMICAL", 217, 220], ["SFA", "SIMPLE_CHEMICAL", 33, 36], ["SFA", "SIMPLE_CHEMICAL", 155, 158], ["output heterogeneity", "PROBLEM", 134, 154], ["SFA", "ANATOMY", 33, 36], ["SFA", "ANATOMY", 217, 220]]], ["Zuckerman et al. (1994) published the first SFA-based study of US hospitals.", [["SFA", "ANATOMY", 44, 47]]], ["Rosko and Mutter (2011) reviewed the results from 27 U.S. hospital SFA studies.", [["SFA studies", "TEST", 67, 78]]], ["The non-parametric alternative to SFA is DEA.", [["SFA", "CHEMICAL", 34, 37], ["DEA", "CHEMICAL", 41, 44], ["SFA", "CHEMICAL", 34, 37], ["SFA", "SIMPLE_CHEMICAL", 34, 37], ["SFA", "ANATOMY", 34, 37], ["DEA", "OBSERVATION", 41, 44]]], ["A preference for SFA or DEA has not been established in the hospital efficiency estimation literature, and it is unlikely that such a consensus will occur.", [["SFA", "CHEMICAL", 17, 20], ["DEA", "CHEMICAL", 24, 27], ["SFA", "CHEMICAL", 17, 20], ["DEA", "CHEMICAL", 24, 27], ["SFA", "SIMPLE_CHEMICAL", 17, 20], ["SFA", "ANATOMY", 17, 20]]], ["Frontier experts suggest that the choice of technique should be context specific (i.e., based on the goals of the analysis and the availability of data; Coelli et al. 2005) .", [["the analysis", "TEST", 110, 122]]], ["We choose SFA because it estimates cost-efficiency which is a broader measure (i.e,. is based on a best practice cost frontier rather than a best practice production frontier) than technical efficiency which is usually estimated by DEA.", [["SFA", "CHEMICAL", 10, 13], ["DEA", "CHEMICAL", 232, 235], ["SFA", "CHEMICAL", 10, 13], ["SFA", "ANATOMY", 10, 13]]], ["Therefore, it is likely to reflect more factors that affect profitability than would a DEA-based measure of technical efficiency.Model specificationSFA decomposes variations from the best practice frontier (BPF) into a random or classical error and a deterministic error, which is assumed to represent cost-inefficiency.", [["technical efficiency", "PROBLEM", 108, 128], ["Model specificationSFA decomposes variations", "PROBLEM", 129, 173], ["a random or classical error", "PROBLEM", 217, 244], ["cost-inefficiency", "PROBLEM", 302, 319], ["likely to reflect", "UNCERTAINTY", 17, 34], ["technical efficiency", "OBSERVATION", 108, 128], ["assumed to represent", "UNCERTAINTY", 281, 301], ["cost-inefficiency", "OBSERVATION", 302, 319]]], ["Our framework for the estimation of the BPF is the neoclassical cost function which assumes that total expenses depend upon input prices and output volumes.", [["total expenses", "PROBLEM", 97, 111], ["output volumes", "TEST", 141, 155]]], ["Recognizing that outputs, such as admissions, are heterogeneous, it is important to control variations in input requirements for different types of admissions by including product descriptor variables that reflect differences in services, patient case mix, and hospital quality.", [["patient", "ORGANISM", 239, 246], ["patient", "SPECIES", 239, 246], ["outputs", "OBSERVATION_MODIFIER", 17, 24], ["heterogeneous", "OBSERVATION_MODIFIER", 50, 63]]], ["Following theory (Kumbhakar and Lovell 2000) and the hospital literature (Grannemann et al. 1986; Rosko et al. 2018 ), we use the following hybrid cost function:Model specificationwhere TC represents total costs; Y is a vector of outputs; W is a vector of input prices; PD is a vector of product descriptors; i indexes the hospital being observed, and e is the error term, which can be decomposed as follows:Model specificationwhere v is statistical noise (i.e., assumed to be distributed as N(0, \u03c3 2 )), and u consists of positive departures from the cost-frontier and represents cost-inefficiency (i.e., the percentage by which observed costs exceed minimum costs predicted for the best practice cost frontier) (Lovell 1993) .Model specificationAlthough u is frequently assumed to follow a half-normal distribution, there is no theoretical reason for the selection of this or other distributional forms for u.", [["PD", "DISEASE", 270, 272], ["statistical noise", "PROBLEM", 438, 455], ["positive departures", "PROBLEM", 523, 542], ["cost-inefficiency", "PROBLEM", 581, 598], ["positive departures", "OBSERVATION", 523, 542], ["cost-inefficiency", "OBSERVATION", 581, 598], ["no", "UNCERTAINTY", 827, 829]]], ["Coelli et al. (2005) indicate that the specification of a more general distribution such as the truncated-normal has partially alleviated concerns about the arbitrary choice of a distribution.", [["normal", "OBSERVATION", 106, 112]]], ["However, concerns about this issue may be overstated as reviews of both the general literature (Coelli et al. 2005 ) and the health services research literature have consistently reported that varying assumptions about the distribution of the deterministic error has had little impact on estimated inefficiencies.Model specificationWe used a hybrid form of the Cobb-Douglas cost function model to estimate the stochastic cost frontier for a sample of U.S. hospitals.", [["the Cobb-Douglas cost function model", "TREATMENT", 357, 393]]], ["It can be expressed as follows:Model specificationwhere TC, Y, W, and PD are the same as defined above; and \u03b1, \u03b2, and \u03c6 are parameters to be estimated; and v i and u i are random variables described above.", [["\u03b1", "GENE_OR_GENE_PRODUCT", 108, 109], ["\u03b2", "GENE_OR_GENE_PRODUCT", 111, 112], ["\u03b1", "PROTEIN", 108, 109], ["\u03b2", "PROTEIN", 111, 112], ["\u03c6", "PROTEIN", 118, 119], ["PD", "PROBLEM", 70, 72]]], ["Due to data constraints, we used only prices for capital and labor inputs.", [["capital and labor inputs", "TREATMENT", 49, 73]]], ["A more complete specification would be desirable, but we follow the practices of most SFA hospital studies.Model specification(1)Model specificationWe imposed the standard assumption of linear homogeneity in input prices by normalizing the equation by the Medicare Wage Index.", [["SFA", "CHEMICAL", 86, 89], ["linear", "OBSERVATION_MODIFIER", 186, 192], ["homogeneity", "OBSERVATION_MODIFIER", 193, 204], ["input prices", "OBSERVATION", 208, 220]]], ["Thus, the dependent variable is the logarithm of total expenses divided by the wage index.", [["dependent", "OBSERVATION_MODIFIER", 10, 19], ["variable", "OBSERVATION_MODIFIER", 20, 28]]], ["The continuous output and input price variables also were also log-transformed.", [["The continuous output", "TEST", 0, 21], ["output", "OBSERVATION_MODIFIER", 15, 21]]], ["The price of two inputs, capital and labor, are recognized by the cost-function.", [["capital", "OBSERVATION_MODIFIER", 25, 32], ["labor", "OBSERVATION", 37, 42]]], ["The Medicare Wage Index was used for the price of labor.", [["The Medicare Wage Index", "TREATMENT", 0, 23], ["labor", "PROBLEM", 50, 55]]], ["Following past practices (Rosko et al. 2018; Zuckerman et al. 1994) , the price of capital was approximated by the area (i.e., core-based statistical area) average depreciation and interest expenses per bed.", [["capital", "OBSERVATION", 83, 90]]], ["The input price variables were also normalized by the price of labor.", [["labor", "PROBLEM", 63, 68]]], ["Since the price of labor (i.e., Medicare Wage Index) was divided by itself, it is removed from the equation.Model specificationThe outputs in the cost function included inpatient admissions, outpatient visits, and post-admission patient days (i.e., total inpatient days minus total admissions).", [["patient", "ORGANISM", 229, 236], ["patient", "SPECIES", 229, 236], ["Medicare Wage Index", "TREATMENT", 32, 51], ["outputs", "OBSERVATION_MODIFIER", 131, 138]]], ["The results of a Hausman specification test (p < 0.05) suggest that hospital outputs can be treated as exogenous, an assumption common to hospital cost studies (Grannemann et al. 1986) .Model specificationA key concern in hospital SFA studies is hospital quality and patient burden of illness might masquerade as inefficiency .", [["illness", "DISEASE", 285, 292], ["patient", "ORGANISM", 267, 274], ["patient", "SPECIES", 267, 274], ["a Hausman specification test", "TEST", 15, 43], ["SFA studies", "TEST", 231, 242], ["illness", "PROBLEM", 285, 292]]], ["This could cause a downward bias in the efficiency estimates for hospitals (e.g., academic medical centers) that tend to attract patients that present more severe problems.", [["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 129, 137], ["a downward bias", "PROBLEM", 17, 32], ["more severe problems", "PROBLEM", 151, 171], ["downward", "OBSERVATION_MODIFIER", 19, 27], ["bias", "OBSERVATION", 28, 32], ["more severe", "OBSERVATION_MODIFIER", 151, 162]]], ["Therefore, we used a variety of product descriptor variables to control for the heterogeneity of output in hospitals.", [["a variety of product descriptor variables", "TREATMENT", 19, 60], ["the heterogeneity of output", "PROBLEM", 76, 103]]], ["Following the methods of Rosko et al. (2018) we included: the Medicare Case-Mix Index, the ratio of outpatient surgeries to total outpatient visits, the ratio of emergency department visits to total outpatient visits, and the ratio of beds classified as acute care to total hospital beds and the ratio of births to total admissions.", [["outpatient surgeries", "TREATMENT", 100, 120], ["total hospital beds", "TREATMENT", 268, 287]]], ["All of these reflect case mix severity and the first four are expected to have positive coefficients.", [["positive coefficients", "PROBLEM", 79, 100]]], ["The absence of publicly available case-mix indices for outpatient care necessitated the use of proxies for this measure.", [["outpatient care", "TREATMENT", 55, 70]]], ["Since some hospitals serve a mixture of acute care and nonacute care patients, we included the proportion of total hospital beds classified as acute care to reflect patients who would not be included in the DRG-based Medicare Case-Mix Index.", [["patients", "ORGANISM", 69, 77], ["patients", "ORGANISM", 165, 173], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 165, 173], ["acute care", "TREATMENT", 40, 50], ["total hospital beds", "TREATMENT", 109, 128]]], ["The teaching variables reflect monotonically increasing levels of teaching activity.", [["teaching activity", "TREATMENT", 66, 83]]], ["Teaching status reflects not only post-graduate medical education output but also it is a structural measure of quality (Taylor et al. 1999) .Model specificationWe also included a measure of reservation quality in the cost function.", [["cost function", "OBSERVATION", 218, 231]]], ["The use of reservation quality is consistent with the premise that some empty beds are not waste (Folland and Hofler 2001) .", [["consistent with", "UNCERTAINTY", 34, 49]]], ["We followed Joskow's (1980) method of calculating reservation quality by dividing the difference between total beds and average daily census by the square root of average daily census.Model specificationIn addition to the above, variations in quality were controlled by the inclusion of variables for the clinical process of care and patient and caregiver centered experience of care.", [["patient", "ORGANISM", 334, 341], ["patient", "SPECIES", 334, 341], ["total beds", "TREATMENT", 105, 115]]], ["2 This data has become available to the public only recently and this is the first time these variables have been used in an SFA study.", [["an SFA study", "TEST", 122, 134], ["SFA", "ANATOMY", 125, 128]]], ["The Centers for Medicare and Medicaid Services (CMS) Value Based Purchasing (VBP) program rewards or penalizes hospitals based on their performance on key domains of performance which include clinical processes, patient safety, patient outcomes, patient experiences and efficiency (cost per Medicare beneficiary) (Turner et al. 2015) .", [["patient", "ORGANISM", 212, 219], ["patient", "ORGANISM", 228, 235], ["patient", "ORGANISM", 246, 253], ["patient", "SPECIES", 212, 219], ["patient", "SPECIES", 228, 235], ["patient", "SPECIES", 246, 253]]], ["The domains and measures have changed over time; some measures have been dropped and new measures have been added.", [["domains", "OBSERVATION_MODIFIER", 4, 11], ["dropped", "OBSERVATION_MODIFIER", 73, 80], ["new", "OBSERVATION_MODIFIER", 85, 88]]], ["For example, the patient safety and efficiency domains were added in recent years.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24]]], ["Descriptive statistics for the variables in the SFA model are provided in the Appendix in Table 4 .Model specificationThe parameters of the cost frontier and cost-efficiency were estimated by a maximum likelihood method using the FRONTIER 4.1 program (Coelli 1996) .", [["SFA", "ANATOMY", 48, 51], ["Appendix", "ANATOMY", 78, 86]]], ["The cost efficiency of the ith hospital is defined as the ratio of the stochastic frontier total costs to observed total costs.", [["cost", "OBSERVATION_MODIFIER", 4, 8], ["efficiency", "OBSERVATION_MODIFIER", 9, 19]]], ["The stochastic total cost frontier is defined by the value total costs would be if u i (i.e., the cost-inefficiency effect) were zero (i.e., full efficiency).Model specificationOur SFA model assumed a Cobb-Douglas production technology and that the composed error that represents inefficiency followed a truncated-normal distribution.", [["Douglas production technology", "TREATMENT", 206, 235], ["stochastic", "OBSERVATION_MODIFIER", 4, 14], ["total", "OBSERVATION_MODIFIER", 15, 20], ["SFA", "ANATOMY", 181, 184], ["normal", "OBSERVATION", 314, 320], ["distribution", "OBSERVATION_MODIFIER", 321, 333]]], ["Although the translog cost function is often used in hospital-based SFA studies because of its flexibility (Rosko and Mutter 2011), we estimated a Cobb-Douglas function which restricts the higher-order terms (i.e., squared and cross-products which are very highly correlated) of the output and input price variables to equal 0.", [["SFA studies", "TEST", 68, 79], ["a Cobb-Douglas function", "TEST", 145, 168], ["the output", "TEST", 279, 289], ["SFA", "ANATOMY", 68, 71]]], ["The parameter estimates for the SFA model are presented in Table 5 in the Appendix.", [["the SFA model", "TEST", 28, 41], ["SFA", "ANATOMY", 32, 35], ["Appendix", "ANATOMY", 74, 82]]], ["The cost-inefficiency estimates were slightly larger (i.e., mean of 0.1048 vs. 0.0766) when the Cobb-Douglas form was assumed rather than the translog.", [["Cobb", "PROTEIN", 96, 100], ["The cost-inefficiency estimates", "TEST", 0, 31], ["slightly larger", "PROBLEM", 37, 52], ["mean", "TEST", 60, 64], ["slightly", "OBSERVATION_MODIFIER", 37, 45], ["larger", "OBSERVATION_MODIFIER", 46, 52]]], ["As expected with these high correlations, the parameter estimates in the profit equations were very similar when the efficiency scores based on either of the two models were used.Model specificationIn specifying the model, we also had to make an assumption about the distribution of the composed error that represents efficiency.", [["the parameter estimates", "TEST", 42, 65], ["the composed error", "PROBLEM", 283, 301], ["efficiency", "OBSERVATION_MODIFIER", 318, 328]]], ["Although the half-normal distribution has been used the most, there is no a priori justification for the use of any particular distribution for the cost inefficiency effects, u i .", [["the cost inefficiency effects", "PROBLEM", 144, 173], ["normal", "OBSERVATION", 18, 24], ["cost inefficiency", "OBSERVATION", 148, 165]]], ["Stevenson (1980) addressed this issue by specifying a truncated-normal distribution, which is a generalization of the half-normal distribution.", [["normal", "OBSERVATION", 64, 70], ["distribution", "OBSERVATION_MODIFIER", 71, 83], ["normal", "OBSERVATION", 123, 129], ["distribution", "OBSERVATION_MODIFIER", 130, 142]]], ["Since the half-normal distribution is a special case of the truncated-normal distribution where the mode (designated by \u03bc) equals 0, the appropriateness of using the half-normal distribution was assessed by testing H 0 : \u03bc = 0.", [["normal", "OBSERVATION", 15, 21], ["distribution", "OBSERVATION_MODIFIER", 22, 34], ["normal", "OBSERVATION", 70, 76], ["normal", "OBSERVATION", 171, 177]]], ["Based on the results (p < 0.01) of a log-likelihood restriction test we rejected the null hypothesis and chose the truncated-normal distribution.", [["a log-likelihood restriction test", "TEST", 35, 68], ["the null hypothesis", "PROBLEM", 81, 100], ["normal", "OBSERVATION", 125, 131], ["distribution", "OBSERVATION_MODIFIER", 132, 144]]], ["However, the efficiency scores were not sensitive to our choice of error term as the scores obtained when using the two distributions were very highly correlated-i.e., r = 0.959.Model specificationThe mean estimated cost-inefficiency was 10.48%.", [["the efficiency scores", "PROBLEM", 9, 30], ["the scores", "TEST", 81, 91], ["The mean estimated cost-inefficiency", "TEST", 197, 233]]], ["This yields a mean efficiency score of 89.52%.", [["a mean efficiency score", "TEST", 12, 35], ["mean efficiency", "OBSERVATION", 14, 29]]], ["Our mean efficiency estimate is within the range (albeit towards the upper limit) of past SFA studies.", [["SFA", "CHEMICAL", 90, 93], ["Our mean efficiency", "TEST", 0, 19], ["past SFA studies", "TEST", 85, 101], ["mean efficiency", "OBSERVATION", 4, 19], ["upper limit", "OBSERVATION_MODIFIER", 69, 80], ["SFA", "ANATOMY", 90, 93]]], ["For example, in Rosko and Mutter's (2008) review of U.S. hospital studies, the mean estimated efficiency score ranged from 62.9 to 92.5%.", [["the mean estimated efficiency score", "TEST", 75, 110]]], ["Hollingsworth (2008) reviewed 59 frontier studies (i.e., SFA and DEA) of US hospitals and found that the mean of all efficiency scores was 82.6%.", [["frontier studies", "TEST", 33, 49], ["SFA", "ANATOMY", 57, 60]]], ["Looking at other industries, Vitaliano and Toren's (1994) study of US nursing homes estimated that cost efficiency was 71.0% and Greene and Segal's (2004) study of US insurance companies had efficiency estimates that ranged from 62.1 to 65.2%.", [["cost efficiency", "TEST", 99, 114]]], ["Greene's (2008) study of the electricity industry had estimates ranging from 92.1 to 93.5%.Model specificationHigher efficiency scores tend to be found in studies of industries where the output is more homogenous (e.g., electricity) or when more elaborate controls for product mix variations are used.", [["Higher efficiency scores", "PROBLEM", 110, 134], ["the output", "TEST", 183, 193], ["output", "OBSERVATION_MODIFIER", 187, 193], ["more homogenous", "OBSERVATION_MODIFIER", 197, 212]]], ["For example, Zuckerman et al. (1994) reported that the mean efficiency score increased from 81.2% in an equation where just a basic cost function was used to 86.6% when variety of variables representing hospital characteristics and output were used.", [["the mean efficiency score", "TEST", 51, 76]]], ["Rosko and Chilingerian (1999) reported similar results (i.e., means increased from 82.0 to 92.5% when a basic model was replaced by a model with control variables for severity and complexity of illness.DataThe dependent variables in the profitability analysis are operating margin (i.e., [(net operating revenue \u2212 total operating expenses)/net operating revenue)] and total margin (i.e., [(total net revenue \u2212 total expenses)/(total net revenue)].", [["illness", "DISEASE", 194, 201], ["a model with control variables", "TREATMENT", 132, 162], ["severity", "PROBLEM", 167, 175], ["illness", "PROBLEM", 194, 201], ["total operating expenses", "TREATMENT", 314, 338], ["total net revenue \u2212 total expenses", "TREATMENT", 390, 424], ["dependent", "OBSERVATION_MODIFIER", 210, 219], ["variables", "OBSERVATION_MODIFIER", 220, 229], ["margin", "OBSERVATION_MODIFIER", 274, 280], ["total", "OBSERVATION_MODIFIER", 368, 373], ["margin", "OBSERVATION_MODIFIER", 374, 380]]], ["The former more closely reflects the effect of payment pressures on hospital financial performance while the latter more closely reflects the solvency of the hospital.DataWe started with 1439 metropolitan, 3 NFP, general, acute care hospitals.", [["payment pressures", "TREATMENT", 47, 64], ["acute", "OBSERVATION_MODIFIER", 222, 227]]], ["Following past practices (Goddard et al. 2009; Bazzoli et al. 2014) , we excluded an additional 26 hospitals that fell outside the 1st through 99th percentiles of operating margin or total margin to avoid outliers and/or implausible values for these margins.", [["margin", "OBSERVATION_MODIFIER", 173, 179]]], ["This resulted in a final file with 1317 hospitals located in the contiguous United States (except for those located in Maryland which were excluded because they did not report two key quality variables pertaining to process of care and patient experience as well as the Medicare Case-Mix Index that were used in the SFA efficiency estimation) and the District of Columbia.", [["patient", "ORGANISM", 236, 243], ["patient", "SPECIES", 236, 243], ["SFA", "ANATOMY", 316, 319]]], ["The mean values of the variables in the trimmed and untrimmed files were almost identical.", [["The mean values", "TEST", 0, 15], ["mean", "OBSERVATION_MODIFIER", 4, 8]]], ["We found the regression results for the data set that was untrimmed were very similar (in terms of sign and level of significance) to those obtained with the smaller data set.DataWe used data for 2015 for all variables.", [["the data", "TEST", 36, 44]]], ["The Area Health Resources File was used for market-level (i.e., county) data for the unemployment rate.", [["the unemployment rate", "TEST", 81, 102]]], ["We expect the last two variables to be positively associated with profits as Medicaid expansion should reduce uncompensated care expenses (Dranove et al. 2016) and system membership should confer the advantages of firm-level scale effects to the hospital.", [["Medicaid expansion", "PROBLEM", 77, 95], ["uncompensated care expenses", "PROBLEM", 110, 137], ["firm-level scale effects", "TREATMENT", 214, 238]]], ["While these hospitals receive extra payments from public and private payers, it is unclear whether these extra payments accurately reflect the extra costs that academic medical centers incur.DataWe used Medicare and Medicaid share of admissions (i.e., Medicaid or Medicare admissions divided by total admissions) to reflect financial pressures associated with serving patients funded by the two dominant public payers in the United States.", [["patients", "ORGANISM", 368, 376], ["patients", "SPECIES", 368, 376], ["financial pressures", "PROBLEM", 324, 343]]], ["Medicare payments were less than expenses in the average hospital in 2015 (MedPac 2017).", [["Medicare payments", "TREATMENT", 0, 17]]], ["Medicaid is a joint federal/state program for the categorically needy.", [["joint", "ANATOMY", 14, 19]]], ["Medicaid payments to hospitals tend to be less than the costs incurred in treating Medicaid patients in most states (Cunningham et al. 2016) .DataWe also included variables for average length of stay (i.e., total patient days divided by total admissions) and occupancy rate (total patient days divided by total bed days available).", [["patients", "ORGANISM", 92, 100], ["patient", "ORGANISM", 213, 220], ["patient", "ORGANISM", 281, 288], ["patients", "SPECIES", 92, 100], ["patient", "SPECIES", 213, 220], ["patient", "SPECIES", 281, 288]]], ["The former variable might reflect the effectiveness of care processes or unobserved variations in the patient burden of illness.", [["illness", "DISEASE", 120, 127], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["care processes", "TREATMENT", 55, 69], ["unobserved variations", "PROBLEM", 73, 94], ["illness", "PROBLEM", 120, 127]]], ["We expect this variable to be inversely associated with profitability, a proposition supported by Rauscher and Wheeler (2012) .DataWe used the number of beds to reflect size.", [["Rauscher", "ORGANISM", 98, 106], ["size", "OBSERVATION_MODIFIER", 169, 173]]], ["Larger hospitals might be able to negotiate higher payment rates from private health plans, and this should contribute to enhanced profitability.", [["enhanced profitability", "PROBLEM", 122, 144]]], ["However, to the extent that diseconomies of scale exist, larger hospitals will have greater increased average costs.", [["greater increased average costs", "PROBLEM", 84, 115], ["larger", "OBSERVATION_MODIFIER", 57, 63], ["greater", "OBSERVATION_MODIFIER", 84, 91], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["average", "OBSERVATION_MODIFIER", 102, 109]]], ["We expect that larger hospitals would be more profitable.", [["larger", "OBSERVATION_MODIFIER", 15, 21]]], ["5 We included two market-level variables; market concentration and unemployment rate.", [["unemployment rate", "TEST", 67, 84]]], ["6 Hospitals in 5 We included beds-squared in preliminary analysis to reflect possible scale effects.", [["preliminary analysis", "TEST", 45, 65], ["scale effects", "PROBLEM", 86, 99]]], ["However, its coefficient was not significantly different from 0 (p < 0.05), so we did not include it in the final model.", [["significantly different", "OBSERVATION_MODIFIER", 33, 56]]], ["6 We included the hospital's market share in preliminary analysis.", [["preliminary analysis", "TEST", 45, 65]]], ["However, because of its strong correlation with HHI we removed it to avoid multi-collinearity problems.", [["multi-collinearity problems", "PROBLEM", 75, 102]]], ["4 We also estimated an HHI at core-based statistical area (CBSA) level.", [["an HHI at core", "PROBLEM", 20, 34]]], ["CBSAs are geographic areas defined by the federal Office of Management and Budget (OMB).", [["CBSAs", "SIMPLE_CHEMICAL", 0, 5], ["Budget (OMB)", "TREATMENT", 75, 87], ["geographic", "OBSERVATION_MODIFIER", 10, 20], ["areas", "OBSERVATION_MODIFIER", 21, 26]]], ["The OMB categorizes counties within a CBSA as metropolitan statistical areas and micropolitan areas (i.e., areas containing between 10,000 and 50,000 people).", [["people", "SPECIES", 150, 156], ["micropolitan areas", "PROBLEM", 81, 99], ["areas", "OBSERVATION_MODIFIER", 71, 76], ["micropolitan", "OBSERVATION_MODIFIER", 81, 93], ["areas", "OBSERVATION_MODIFIER", 94, 99]]], ["Counties defined as micropolitan are not included in this study.", [["this study", "TEST", 53, 63]]], ["The two HHIs were highly correlated (r = 0.63) and regression results were very similar when either of the HHIs were used. the same system in the same market area were treated as one firm in the calculation of the HHI.", [["HHI", "DISEASE", 214, 217], ["the HHIs", "PROBLEM", 103, 111], ["the HHI", "PROBLEM", 210, 217], ["market", "OBSERVATION_MODIFIER", 151, 157], ["area", "OBSERVATION_MODIFIER", 158, 162], ["firm", "OBSERVATION_MODIFIER", 183, 187]]], ["7 We expect profits to be positively associated with concentration of output.", [["concentration of output", "PROBLEM", 53, 76]]], ["The unemployment rate is used to reflect the level of demand for health services and ability to pay and we expect it to be inversely related with profits.", [["The unemployment rate", "TREATMENT", 0, 21]]], ["Table 1 Descriptive statistics for variables in the profit models (n = 1317) a To facilitate interpretation, we reverse coded (1-inefficiency score) cost-inefficiency.", [["cost-inefficiency", "PROBLEM", 149, 166]]], ["To provide a \"truer\" benchmark for the efficiency estimate, the SFA analysis included all (n = 1823) metropolitan, NFP and FP, general, acute care hospitals for which complete data were available b Based on all competing hospitals (includes acute, general, local government hospitals but not federal hospitals) for which admissions data were available c County-level variableResultsAs Table 2 shows the mean value of operating margin was significantly higher (p < 0.01) in system member hospitals and significantly lower (p < 0.01) in academic medical centers (AMCs) and in hospitals located in states that expanded their Medicaid programs.", [["the SFA analysis", "TEST", 60, 76], ["SFA", "ANATOMY", 64, 67]]], ["Similar results were found for the total margin except that the mean difference for AMCs was no longer significant.", [["no longer", "UNCERTAINTY", 93, 102]]], ["Preliminary analysis of the regression equations, using a Breusch-Pagan test for heteroskedasticity, rejected the null hypothesis of constant variance against the number of inpatient beds, a proxy for size.", [["Preliminary analysis", "TEST", 0, 20], ["the regression equations", "TEST", 24, 48], ["a Breusch-Pagan test", "TEST", 56, 76], ["heteroskedasticity", "PROBLEM", 81, 99], ["constant variance", "OBSERVATION", 133, 150], ["size", "OBSERVATION_MODIFIER", 201, 205]]], ["However, the results of a Hausman test (p < 0.05) could not support the existence of endogeneity.ResultsThe OLS parameter estimates, corrected for heteroskedacity, when operating margin and total margin were used as dependent variables, are reported in Table 3 .", [["a Hausman test", "TEST", 24, 38], ["The OLS parameter estimates", "TEST", 104, 131], ["heteroskedacity", "PROBLEM", 147, 162], ["total margin", "TREATMENT", 190, 202], ["total", "OBSERVATION_MODIFIER", 190, 195], ["margin", "OBSERVATION_MODIFIER", 196, 202]]], ["The estimated coefficient of efficiency was significant in both equations with a slightly larger value in the operating margin equation.", [["The estimated coefficient of efficiency", "PROBLEM", 0, 39], ["a slightly larger value", "PROBLEM", 79, 102], ["coefficient", "OBSERVATION_MODIFIER", 14, 25], ["significant", "OBSERVATION_MODIFIER", 44, 55], ["both equations", "OBSERVATION", 59, 73], ["slightly", "OBSERVATION_MODIFIER", 81, 89], ["larger", "OBSERVATION_MODIFIER", 90, 96]]], ["Hence, we reject the null hypothesis that efficiency is not associated with profitability.", [["the null hypothesis", "PROBLEM", 17, 36], ["not associated with", "UNCERTAINTY", 56, 75]]], ["The results suggest that operating margin would increase by 0.02204 if efficiency increased by 10 percent and all other factors remained the same.", [["margin", "OBSERVATION_MODIFIER", 35, 41]]], ["Regarding the control variables, consistent with our expectations we found that operating margin was positively associated with number of beds, Hirschman-Herfindahl Index (an inverse measure of competition), occupancy rate, and system membership.", [["Herfindahl Index", "PROBLEM", 154, 170], ["consistent with", "UNCERTAINTY", 33, 48]]], ["The results for the total margin were similar to those for the operating margin equation with the exception of the estimate for the coefficient of academic medical center which was no longer significant.DiscussionA major assumption of federal hospital payment policy in the United States is that hospital managers will respond to the incentives to cut expenses.", [["the operating margin equation", "TEST", 59, 88], ["no longer", "UNCERTAINTY", 181, 190]]], ["Expenses could be cut by reducing the volume or quality of services or by increasing efficiency.", [["increasing efficiency", "PROBLEM", 74, 95]]], ["Increased surplus can be used to fund future capital projects to expand services to the community.", [["Increased surplus", "TREATMENT", 0, 17]]], ["Increased efficiency is important as it is the only way to increase services without increasing costs or compromising quality.", [["Increased efficiency", "PROBLEM", 0, 20], ["efficiency", "OBSERVATION", 10, 20]]], ["From another perspective, increased efficiency allows hospitals to cut expenses without compromising the quality or quantity of services provided.DiscussionWhen we examine the results for the other variables, for simplicity we will use the term profitability since the results are similar in the operating margin and total margin equations for all variables, except academic medical center.", [["increased efficiency", "PROBLEM", 26, 46], ["total margin equations", "TEST", 317, 339], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["efficiency", "OBSERVATION_MODIFIER", 36, 46]]], ["AMCs tend to be much more expensive than other types of general acute care hospitals because they are tertiary care centers that attract patients who are more expensive to treat.", [["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145]]], ["Besides the direct expenses of graduate medical education programs and the more severely ill patients they attract, AMCs are more expensive because medical students, interns and residents tend to have an adverse impact on the productivity of other staff.", [["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["graduate medical education programs", "TREATMENT", 31, 66]]], ["The lack of significance in the total margin equation reflects the additional sources of non-operating revenue that AMCs are able to attract.DiscussionMedicare and other payers have long recognized the value and cost of graduate medical education and have reimbursed these hospitals at a much higher rate than other hospitals.", [["AMCs", "SIMPLE_CHEMICAL", 116, 120], ["AMCs", "CELL_TYPE", 116, 120], ["graduate medical education", "TREATMENT", 220, 246], ["total margin", "OBSERVATION_MODIFIER", 32, 44]]], ["MedPac (2017) reported that \"Major teaching hospitals have higher overall Medicare margins than the average IPPS (inpatient prospective payment system) hospital in large part because of the extra payments they receive through the IME (indirect medical education) and DSH (disproportionate share hospital) adjustments and uncompensated care payments.\"", [["DSH", "DISEASE", 267, 270], ["the extra payments", "TREATMENT", 186, 204], ["uncompensated care payments", "TREATMENT", 321, 348]]], ["However, in recent years Medicare has cut back on the generosity of its payments to AMCs.", [["AMCs", "DISEASE", 84, 88], ["AMCs", "CANCER", 84, 88]]], ["In 2015, mean Medicare margins were negative for all types of hospitals with values of \u2212 5.2%, \u2212 5.8% and \u2212 9.6% for major-, other-and non-teaching hospitals respectively (MedPac 2017).", [["mean Medicare margins", "TEST", 9, 30], ["values", "TEST", 77, 83], ["\u2212", "TEST", 87, 88], ["\u2212", "TEST", 95, 96], ["\u2212", "TEST", 106, 107]]], ["Accordingly, the mean profitability (i.e., all-payer total margin) of AMCs has been less than that for other types of hospitals each year from 2006 to 2015 (MedPac 2018).", [["all-payer total margin", "TREATMENT", 43, 65]]], ["The coefficient of system-member was positive and significant.", [["significant", "OBSERVATION_MODIFIER", 50, 61]]], ["This probably reflects firm-level scale economies which should reduce costs and enhance the bargaining power of systems which should increase revenue.", [["firm-level scale economies", "TREATMENT", 23, 49], ["probably reflects", "UNCERTAINTY", 5, 22], ["firm", "OBSERVATION", 23, 27], ["level scale", "OBSERVATION_MODIFIER", 28, 39]]], ["Size, represented by beds, had a positive coefficient.", [["a positive coefficient", "PROBLEM", 31, 53], ["positive coefficient", "OBSERVATION_MODIFIER", 33, 53]]], ["The former would reduce expenses and the latter would increase revenue.DiscussionAverage length of stay, Medicaid share of admissions, Medicare share of admissions and unemployment rate had negative coefficients.", [["unemployment rate", "TEST", 168, 185]]], ["The Medicare and Medicaid variables have negative signs because public payers tend to underpay hospitals.", [["Medicaid variables", "TEST", 17, 35]]], ["For example, the mean overall Medicare margin ranged from \u2212 4.9% in 2010 to \u2212 7.1% in 2015 (MedPac 2017).", [["Medicare margin", "TEST", 30, 45], ["\u2212", "TEST", 58, 59], ["margin", "OBSERVATION_MODIFIER", 39, 45]]], ["Unemployment is associated with charity care and bad debt expense (Diehr et al. 1991; Rosko 1990a) .", [["Unemployment", "DISEASE", 0, 12]]], ["While this is less important in the wake of the implementation of the Affordable Care Act, in 2015 there were over 30 million persons without health insurance in the United States (Kaiser Family Foundation (2017) accessed online, December 2018).", [["persons", "SPECIES", 126, 133], ["less important", "OBSERVATION_MODIFIER", 14, 28]]], ["Thus, the gains associated with fewer uninsured patients are tempered by the low payments by Medicaid programs.DiscussionThe Herfindahl-Hirschman Index (HHI) and occupancy rate had positive coefficients.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["occupancy rate", "TEST", 162, 176], ["positive coefficients", "PROBLEM", 181, 202]]], ["The positive coefficient for the HHI suggests that profits are larger in areas in which output is more concentrated, in other words in areas where there is less competition.", [["positive coefficient", "OBSERVATION_MODIFIER", 4, 24], ["larger", "OBSERVATION_MODIFIER", 63, 69], ["output", "OBSERVATION_MODIFIER", 88, 94], ["more concentrated", "OBSERVATION_MODIFIER", 98, 115], ["less competition", "OBSERVATION", 156, 172]]], ["There is a substantial body of evidence (Dranove 2012; Gaynor and Town 2012) that market power allows hospitals to increase prices.DiscussionThe coefficient for location in a Medicaid expansion state was negative in both equations.", [["a Medicaid expansion state", "TEST", 173, 199], ["substantial", "OBSERVATION_MODIFIER", 11, 22], ["body", "OBSERVATION_MODIFIER", 23, 27]]], ["This is consistent with the comparison of means shown in Table 3 .", [["consistent with", "UNCERTAINTY", 8, 23]]], ["However, in a cross-sectional study, it is impossible to attribute causality.", [["a cross-sectional study", "TEST", 12, 35]]], ["Rosko et al. (2018) reported that mean hospital profit margins in expansion states were lower than those in non-expansion states during the entire period 2000-2015.", [["expansion", "OBSERVATION_MODIFIER", 66, 75], ["lower", "OBSERVATION_MODIFIER", 88, 93]]], ["This is the first study to use an SFA-based measure of efficiency to examine the relationship between efficiency and profitability in NFP hospitals.", [["an SFA", "TEST", 31, 37], ["SFA", "ANATOMY", 34, 37], ["profitability", "OBSERVATION_MODIFIER", 117, 130]]], ["There has been some controversy over the application of SFA in hospital studies.", [["SFA", "CHEMICAL", 56, 59], ["SFA", "CHEMICAL", 56, 59], ["SFA", "SIMPLE_CHEMICAL", 56, 59], ["hospital studies", "TEST", 63, 79], ["some", "OBSERVATION_MODIFIER", 15, 19], ["controversy", "OBSERVATION_MODIFIER", 20, 31], ["SFA", "ANATOMY", 56, 59]]], ["Newhouse (1994) has been one of the most vocal critics and has expressed concerns about the strong assumptions pertaining to the structure of production and the probability distribution of the composed error that is used to reflect inefficiency.", [["the composed error", "PROBLEM", 189, 207]]], ["However, studies in both the general literature (Greene 2008 ) and the hospital literature have found that cost-inefficiency estimates are robust over different cost functions and distributions for the error terms.", [["studies", "TEST", 9, 16], ["cost-inefficiency estimates", "PROBLEM", 107, 134]]], ["The advantage of SFA lies on its use of a regression technique that allows it to represent the multi-product nature of hospitals with a variety of output variables and product descriptors.", [["SFA", "CHEMICAL", 17, 20], ["SFA", "CHEMICAL", 17, 20], ["SFA", "SIMPLE_CHEMICAL", 17, 20], ["a regression technique", "TREATMENT", 40, 62], ["SFA", "ANATOMY", 17, 20]]], ["SFA estimates efficiency as a departure from the Best Practice Frontier (BPF).", [["SFA", "CHEMICAL", 0, 3], ["efficiency", "OBSERVATION", 14, 24]]], ["However, the BPF is not observable.", [["BPF", "OBSERVATION", 13, 16], ["not observable", "UNCERTAINTY", 20, 34]]], ["Rather it is estimated by data from a sample.", [["a sample", "TEST", 36, 44]]], ["As mentioned earlier, we followed a standard procedure (i.e., a Hausman test) to try to ascertain if there was a simultaneity issue.", [["a standard procedure", "TREATMENT", 34, 54], ["a Hausman test", "TEST", 62, 76]]], ["However, we must point out that there is no simple test to prove that a right-hand side variable is exogenous.", [["right-hand", "ANATOMY", 72, 82], ["simple test", "TEST", 44, 55], ["right", "ANATOMY_MODIFIER", 72, 77], ["exogenous", "OBSERVATION", 100, 109]]], ["So, our test cannot be considered definitive.", [["our test", "TEST", 4, 12]]], ["We also note that there is no technique available to deal with a potential simultaneity issue within an SFA framework.", [["SFA", "ANATOMY", 104, 107]]], ["Finally, this is the first hospital SFA study to use data (i.e., clinical processes and patient experiences) from the CMS Value Based Purchasing Program.", [["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95]]], ["While this approach is novel and consistent with CMS measures of quality, it has not been tested in other studies.", [["other studies", "TEST", 100, 113], ["consistent with", "UNCERTAINTY", 33, 48], ["CMS", "OBSERVATION", 49, 52]]], ["Further, this data is new and does not allow us to construct a panel study that will cover previous years.ConclusionsAs discussed above, improving efficiency may be the best way to decrease or contain hospital costs.", [["a panel study", "TEST", 61, 74]]], ["Our study finds a strong link between efficiency and profit in NFP hospitals.", [["Our study", "TEST", 0, 9]]], ["Therefore, hospital mangers should be motivated to use techniques such as Lean or Six Sigma to improve processes that will lead to efficiency enhancements.", [["techniques", "TREATMENT", 55, 65], ["efficiency enhancements", "PROBLEM", 131, 154]]], ["X-efficiency theory posits that increased financial pressures will motivate managers to improve organization performance (Leibenstein 1987) , including efficiency.", [["increased financial pressures", "PROBLEM", 32, 61], ["increased", "OBSERVATION_MODIFIER", 32, 41]]], ["Hospitals that increase efficiency (defined as Medicare spending per beneficiary) will receive bonus payments.", [["bonus payments", "TREATMENT", 95, 109]]], ["However, the incentives for reduced spending embedded in the Medicare VBP are small (Werner and Dudley 2012) .", [["small", "OBSERVATION_MODIFIER", 78, 83]]], ["Stronger incentives would improve the linkage between efficiency and profitability and would create a stronger motivation for hospital managers to increase efficiency.ConclusionsThis study also found a positive association between hospital size, system membership, industry concentration of output and profitability.", [["increase efficiency", "PROBLEM", 147, 166], ["This study", "TEST", 178, 188], ["positive", "OBSERVATION", 202, 210], ["output", "OBSERVATION_MODIFIER", 291, 297]]], ["Reviews by Dranove (2012) and Gaynor and Town (2012) found that industry concentration is associated with increased prices.", [["increased prices", "PROBLEM", 106, 122], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["prices", "OBSERVATION", 116, 122]]], ["552).ConclusionsWe found that AMC status and dependence on a larger share of Medicare or Medicaid patients was negatively associated with operating margin.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["AMC status", "PROBLEM", 30, 40], ["margin", "OBSERVATION_MODIFIER", 148, 154]]], ["Indeed, AMCs in this study had a mean operating margin of \u2212 0.0120 in 2015, while the other hospitals in the study had an operating margin of 0.0124.", [["AMCs", "PATHOLOGICAL_FORMATION", 8, 12], ["this study", "TEST", 16, 26], ["the study", "TEST", 105, 114]]], ["However, since 2000 the IME payments have been reduced substantially to reflect the \"true cost\" of medical education and the provision of free care to the indigent patients that these hospitals tend to attract (MedPac 2017).", [["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["medical education", "TREATMENT", 99, 116]]], ["Further, the implementation of the ACA led to reductions of Medicare DSH payments but provided for increases in uncompensated care payments sources of revenue that academic medical centers depend upon more than other-teaching or non-teaching hospitals.", [["DSH", "DISEASE", 69, 72], ["Medicare DSH payments", "TREATMENT", 60, 81]]], ["However, the sum of these two DSH and uncompensated care payments to all hospitals fell from $12.2 billion in 2014 to $10.9 million in 2015 (MedPac 2018).", [["DSH", "DISEASE", 30, 33]]], ["It is not clear that the reduction in uncompensated care expenses associated with the implementation the Affordable Care Act, offset all of these reductions.", [["these reductions", "TREATMENT", 140, 156], ["not", "UNCERTAINTY", 6, 9], ["clear", "OBSERVATION", 10, 15], ["reduction", "OBSERVATION_MODIFIER", 25, 34], ["uncompensated", "OBSERVATION_MODIFIER", 38, 51]]], ["While our results for the total margin suggest that AMCs have been able to obtain non-operating revenue to make up for short falls in Medicare and other payments, the anticipated future cutbacks in Medicare payments raise some concerns for the financial stability of AMCS (Chokshi et al. 2016 ).Table 4Descriptive statistics for variables in SFA equation", [["AMCS", "DISEASE", 267, 271], ["Medicare payments", "TREATMENT", 198, 215], ["SFA", "ANATOMY", 342, 345]]]], "f9bf8f8e752efc523e6c11431a563bc8a262067e": [["The explosion of coronavirus disease (COVID-19), the illness related to the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had worldwide health implications, but it is a particular challenge to those of us who practice Pulmonary and Critical Care Medicine (PCCM) because of the high rate of respiratory tract involvement, the frequent presence of pneumonia in these patients, and the high mortality rate for those with respiratory failure, particularly in the ICU (1, 2) .", [["respiratory tract", "ANATOMY", 316, 333], ["respiratory", "ANATOMY", 444, 455], ["coronavirus disease", "DISEASE", 17, 36], ["COVID-19", "CHEMICAL", 38, 46], ["illness", "DISEASE", 53, 60], ["acute respiratory syndrome coronavirus", "DISEASE", 89, 127], ["respiratory tract involvement", "DISEASE", 316, 345], ["pneumonia", "DISEASE", 372, 381], ["respiratory failure", "DISEASE", 444, 463], ["coronavirus", "ORGANISM", 17, 28], ["SARS-CoV-2", "ORGANISM", 131, 141], ["respiratory tract", "ORGANISM_SUBDIVISION", 316, 333], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 391, 399], ["severe acute respiratory syndrome coronavirus", "SPECIES", 82, 127], ["SARS-CoV-2", "SPECIES", 131, 141], ["coronavirus disease", "PROBLEM", 17, 36], ["COVID", "TEST", 38, 43], ["the illness", "PROBLEM", 49, 60], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 72, 127], ["respiratory tract involvement", "PROBLEM", 316, 345], ["pneumonia", "PROBLEM", 372, 381], ["respiratory failure", "PROBLEM", 444, 463], ["coronavirus disease", "OBSERVATION", 17, 36], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["respiratory syndrome", "OBSERVATION", 95, 115], ["Pulmonary", "ANATOMY", 244, 253], ["respiratory tract", "ANATOMY", 316, 333], ["pneumonia", "OBSERVATION", 372, 381], ["respiratory failure", "OBSERVATION", 444, 463]]], ["In China, although 80% had mild illness, approximately one quarter of those who were hospitalized for COVID-19 needed ICU care.", [["mild illness", "PROBLEM", 27, 39], ["ICU care", "TREATMENT", 118, 126], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["illness", "OBSERVATION", 32, 39]]], ["For those in the ICU, mortality was 49%, whereas those with Acute Respiratory Distress Syndrome (ARDS) had a mortality of 52.4% (1, 3) .", [["Acute Respiratory Distress Syndrome", "DISEASE", 60, 95], ["ARDS", "DISEASE", 97, 101], ["Acute Respiratory Distress Syndrome", "PROBLEM", 60, 95], ["ARDS", "PROBLEM", 97, 101], ["a mortality", "TEST", 107, 118], ["Acute", "OBSERVATION_MODIFIER", 60, 65], ["Respiratory Distress", "OBSERVATION", 66, 86]]], ["As has become clear, many countries have not been able to contain COVID-19 spread because of unavailability of early widespread testing, undertesting of those at risk, failing to trace all contacts of infected patients, and in some overcrowded settings, nosocomial spread of the infection.", [["infection", "DISEASE", 279, 288], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 210, 218], ["COVID", "TEST", 66, 71], ["nosocomial spread", "PROBLEM", 254, 271], ["the infection", "PROBLEM", 275, 288], ["clear", "OBSERVATION", 14, 19], ["infected", "OBSERVATION_MODIFIER", 201, 209], ["infection", "OBSERVATION", 279, 288]]], ["There is concern about a shortage of ICU beds and ventilators, trained medical staff, adequate personal protective equipment (PPE), and everchanging recommendations about management and supportive care, at a time when no definitive therapy for COVID-19 is available.", [["COVID-19", "CHEMICAL", 244, 252], ["ventilators", "TREATMENT", 50, 61], ["management", "TREATMENT", 171, 181], ["supportive care", "TREATMENT", 186, 201], ["definitive therapy", "TREATMENT", 221, 239], ["COVID", "TEST", 244, 249]]]], "f1637681ab79731269862cb7ac3c6aaae32c03d1": [["Although a series of amino acids have been associated with spatial memory formation there is limited information on brain levels of beta-alanine and citrulline in rodents.", [["brain", "ANATOMY", 116, 121], ["amino acids", "CHEMICAL", 21, 32], ["beta-alanine", "CHEMICAL", 132, 144], ["citrulline", "CHEMICAL", 149, 159], ["amino acids", "CHEMICAL", 21, 32], ["beta-alanine", "CHEMICAL", 132, 144], ["citrulline", "CHEMICAL", 149, 159], ["amino acids", "AMINO_ACID", 21, 32], ["brain", "ORGAN", 116, 121], ["beta-alanine", "SIMPLE_CHEMICAL", 132, 144], ["citrulline", "SIMPLE_CHEMICAL", 149, 159], ["amino acids", "TREATMENT", 21, 32], ["beta-alanine", "TREATMENT", 132, 144], ["citrulline in rodents", "TREATMENT", 149, 170]]], ["Given the importance of amino acid metabolism in cognitive functions it was the aim of the study to determine hippocampal levels of beta-alanine and the arginine metabolite citrulline in mice during two different phases of memory retrieval in a spatial memory paradigm.", [["hippocampal", "ANATOMY", 110, 121], ["amino acid", "CHEMICAL", 24, 34], ["beta-alanine", "CHEMICAL", 132, 144], ["arginine", "CHEMICAL", 153, 161], ["citrulline", "CHEMICAL", 173, 183], ["amino acid", "CHEMICAL", 24, 34], ["beta-alanine", "CHEMICAL", 132, 144], ["arginine", "CHEMICAL", 153, 161], ["citrulline", "CHEMICAL", 173, 183], ["amino acid", "AMINO_ACID", 24, 34], ["hippocampal", "MULTI-TISSUE_STRUCTURE", 110, 121], ["beta-alanine", "SIMPLE_CHEMICAL", 132, 144], ["arginine", "SIMPLE_CHEMICAL", 153, 161], ["citrulline", "SIMPLE_CHEMICAL", 173, 183], ["mice", "ORGANISM", 187, 191], ["mice", "SPECIES", 187, 191], ["amino acid metabolism in cognitive functions", "PROBLEM", 24, 68], ["the study", "TEST", 87, 96], ["beta-alanine", "TREATMENT", 132, 144], ["the arginine metabolite citrulline", "TREATMENT", 149, 183], ["memory retrieval", "TREATMENT", 223, 239]]], ["Ten mice were used per group and the first group was trained and sacrificed 5 min, the second 6 h following retrieval in the Morris Water Maze (MWM) and the third and fourth group were untrained, yoked controls that swam the same time in the MWM as their trained counterparts.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["retrieval in the Morris Water Maze", "TREATMENT", 108, 142]]], ["Hippocampi were taken and free amino acids were determined using a well-established HPLC protocol. b-Alanine levels were higher in trained mouse hippocampi, during both, early and late phase of memory retrieval.", [["hippocampi", "ANATOMY", 145, 155], ["amino acids", "CHEMICAL", 31, 42], ["Alanine", "CHEMICAL", 101, 108], ["amino acids", "CHEMICAL", 31, 42], ["Alanine", "CHEMICAL", 101, 108], ["Hippocampi", "SIMPLE_CHEMICAL", 0, 10], ["amino acids", "AMINO_ACID", 31, 42], ["b-", "SIMPLE_CHEMICAL", 99, 101], ["Alanine", "AMINO_ACID", 101, 108], ["mouse", "ORGANISM", 139, 144], ["hippocampi", "ORGAN", 145, 155], ["mouse", "SPECIES", 139, 144], ["mouse", "SPECIES", 139, 144], ["Hippocampi", "TEST", 0, 10], ["free amino acids", "TEST", 26, 42], ["a well-established HPLC protocol", "TREATMENT", 65, 97], ["b-Alanine levels", "TEST", 99, 115], ["memory retrieval", "TREATMENT", 194, 210]]], ["Citrulline levels were lower in trained mouse hippocampi, during both, early and late phase of memory retrieval.", [["hippocampi", "ANATOMY", 46, 56], ["Citrulline", "CHEMICAL", 0, 10], ["Citrulline", "CHEMICAL", 0, 10], ["Citrulline", "SIMPLE_CHEMICAL", 0, 10], ["mouse", "ORGANISM", 40, 45], ["hippocampi", "ORGAN", 46, 56], ["mouse", "SPECIES", 40, 45], ["mouse", "SPECIES", 40, 45], ["Citrulline levels", "TEST", 0, 17], ["memory retrieval", "TREATMENT", 95, 111]]], ["Taurine, methionine, cysteine, lysine and ornithine levels were higher in yoked mice at the late phase while tyrosine was higher in yoked mice during the early phase.", [["Taurine", "CHEMICAL", 0, 7], ["methionine", "CHEMICAL", 9, 19], ["cysteine", "CHEMICAL", 21, 29], ["lysine", "CHEMICAL", 31, 37], ["ornithine", "CHEMICAL", 42, 51], ["tyrosine", "CHEMICAL", 109, 117], ["Taurine", "CHEMICAL", 0, 7], ["methionine", "CHEMICAL", 9, 19], ["cysteine", "CHEMICAL", 21, 29], ["lysine", "CHEMICAL", 31, 37], ["ornithine", "CHEMICAL", 42, 51], ["tyrosine", "CHEMICAL", 109, 117], ["Taurine", "SIMPLE_CHEMICAL", 0, 7], ["methionine", "SIMPLE_CHEMICAL", 9, 19], ["cysteine", "AMINO_ACID", 21, 29], ["lysine", "AMINO_ACID", 31, 37], ["ornithine", "SIMPLE_CHEMICAL", 42, 51], ["mice", "ORGANISM", 80, 84], ["tyrosine", "AMINO_ACID", 109, 117], ["mice", "ORGANISM", 138, 142], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 138, 142], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 138, 142], ["Taurine", "TREATMENT", 0, 7], ["methionine", "TREATMENT", 9, 19], ["cysteine", "TREATMENT", 21, 29], ["lysine", "TREATMENT", 31, 37], ["ornithine levels", "TEST", 42, 58], ["late phase", "OBSERVATION_MODIFIER", 92, 102]]], ["There were no significant correlations between time spent in the target quadrant, the key parameter for spatial memory and any of the amino acid levels.", [["amino acid", "CHEMICAL", 134, 144], ["amino acid", "CHEMICAL", 134, 144], ["amino acid", "AMINO_ACID", 134, 144], ["the amino acid levels", "TEST", 130, 151], ["no", "UNCERTAINTY", 11, 13], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["Herein, an amino acid pattern different between yoked and trained animals at early and late phase of animal retrieval is shown indicating probable involvement of different amino acid pathways in animals trained and untrained in the MWM.", [["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 172, 182], ["amino acid", "CHEMICAL", 11, 21], ["amino acid", "CHEMICAL", 172, 182], ["amino acid", "AMINO_ACID", 11, 21], ["amino acid", "AMINO_ACID", 172, 182], ["an amino acid pattern", "TEST", 8, 29], ["animal retrieval", "TREATMENT", 101, 117], ["different amino acid pathways", "PROBLEM", 162, 191], ["indicating probable", "UNCERTAINTY", 127, 146], ["amino acid", "OBSERVATION", 172, 182]]], ["The results may be useful for the interpretation of previous studies and the design of future research to identify amino acids as possible targets for modulating spatial memory.", [["amino acids", "CHEMICAL", 115, 126], ["amino acids", "CHEMICAL", 115, 126], ["amino acids", "AMINO_ACID", 115, 126], ["previous studies", "TEST", 52, 68], ["amino acids", "TREATMENT", 115, 126], ["modulating spatial memory", "PROBLEM", 151, 176]]]]}